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STRUCTURE OF THE DISSERTATION 
This dissertation is structured using UHM manuscript option. The research proposal is introduced first in 
Chapter I, followed by review of the literature in Chapter II.  The research proposal was successfully 
submitted to OlaHAWAII Team Pilot Grant for funding. A portion of the literature review was submitted for 
publication as a review article to a peer review journal. A series of manuscripts on the microbial 
associations with cancer pathogenesis are presented in Chapter III. Subsequently, a summary of the 
results, overall conclusion and future research are discussed in Chapters IV. Work completed during the 






Background: There is growing evidence that microbial variation can influence cancer development, 
progression, response to therapy, and outcomes.  We wanted to examine the microbial composition of 
paired tumor and adjacent normal tissue across various cancer types in order to provide an improved 
understanding of microbial diversity and abundance patterns of the tumor microenvironment and their 
influence on clinical presentation and survival.  Methods: Using raw whole exome sequencing data from 
22 cancer types from the The Cancer Genome Atlas (TCGA) network, we examined differential relative 
abundance and diversity data in primary tumor and adjacent solid tissue normal (adjacent normal), nine of 
which are presented in this work.  Data were processed through a bioinformatics pipeline designed to 
extract microbial profiles from human sequencing data based on PathoScope 2.0.  Differential abundance 
and diversity metrics were calculated using R-package tools to compare primary tumor and adjacent 
normal within cancer types and across cancer cohorts correlating to clinical features including histologic 
and pathologic features and survival data.  Analyses were controlled for demographic, exposures and 
batch effects.  Findings were then validated by qPCR for selected cancer types with tissue from the 
Hawaii Tumor Registry RTR.  Results: As part of a pilot project we have created microbial composition 
and diversity profiles for a subset of solid tumors within TCGA cancers building a platform for ongoing and 
future studies.  We screened over 10,000 files encompassing a total of 1,838 paired cases from which 
813 are discussed here.  From those, 767 tumors and 753 adjacent normal samples had positive 
microbial (viral and bacterial) sequence reads detection.  Microbial composition and diversity (richness, 
within sample alpha diversity, evenness and beta diversity) varied across cohorts with similar patterns at 
the phylum level in compositional structures.  Bacterial shifts were evident in tumor compared to adjacent 
normal.  Proteobacteria phyla was observed to be increased in tumors of all cohorts except for STAD, 
where Proteobacteria species were reduced and Firmicutes levels increased. Differences between patient 
samples were evident at the higher taxonomic levels.  Differential abundance analyses revealed 
significant differences in stomach adenocarcinoma (STAD) and colon adenocarcinoma (COAD). 
Compared to adjacent normal, tumor samples were found to have lower number of species present 
overall and lower diversity indices.  We found significant association between microbial relative 
abundance and diversity to clinicopathological presentation and survival dependent on race in some 
cancers, particularly those of infectious origin like STAD and LIHC.  Conclusion. This project 
demonstrates the feasibility of the utilization of exome sequencing data to derive complex microbial data 
with easy to interpret results.  This project facilitates the understanding of the role of bacteria play in 
cancer pathogenesis across different race groups as demonstrated in LIHC and STAD cancer cohorts.  In 
these cancers, relative abundance was associated with tumor stage and overall survival days and within 






TABLE OF CONTENTS 
STRUCTURE OF THE DISSERTATION ....................................................................................... iv 
PROJECT SUMMARY ....................................................................................................................v 
LIST OF FIGURES ......................................................................................................................... xi 
TABLE OF ACRONYMS ............................................................................................................... xii 
CHAPTER I. RESEARCH PROPOSAL......................................................................................... 1 
1.1 Objectives ............................................................................................................................ 1 
1.2 Specific Aims ....................................................................................................................... 1 
1.2.1 Primary Aims .................................................................................................................. 1 
1.2.2 Assumptions ................................................................................................................... 1 
1.2.3 Hypotheses ..................................................................................................................... 1 
1.2.4 Secondary aims .............................................................................................................. 2 
1.3 Significance ......................................................................................................................... 2 
1.4 Experimental Approach ...................................................................................................... 2 
1.5 Research Design ................................................................................................................. 3 
1.5.1 Study population ............................................................................................................. 3 
1.5.2 Methods and Planned Statistical Analyses .................................................................... 4 
1.5.3 Strengths of the research proposal ................................................................................ 7 
1.5.4 Limitations and Alternative Strategies ........................................................................... 7 
1.5.5 Changes to planned analyses ........................................................................................ 8 
1.6 Impact ................................................................................................................................... 8 
1.7 Literature cited .................................................................................................................... 8 
CHAPTER II. REVIEW OF THE LITERATURE............................................................................. 9 
2.1 The Role of Tumor Microbiota in Cancer Pathogenesis and the Impact on                           
Racial-Related Disparities ...................................................................................................... 10 
2.1.1 Abstract ....................................................................................................................... 10 
2.1.2 Introduction ................................................................................................................. 10 
2.1.3 Microbiota in Cancer Pathogenesis ......................................................................... 11 
2.1.4 Commensals and Pathobionts ................................................................................. 16 
2.1.5 Cancer Racial Related Disparities ............................................................................ 18 
2.1.6 Summary ..................................................................................................................... 31 
vii 
 
2.2 Identification of Racial-Related Microbial Differences across                                                        
Cancers Derived from Human Sequencing Data................................................................. 32 
2.2.1 Abstract ....................................................................................................................... 32 
2.2.2 Introduction ................................................................................................................. 32 
2.2.3 Infectious disease burden and cancer disparities ................................................. 33 
2.3.4 Microbial detection in high throughput sequencing data ..................................... 34 
2.2.5 Racial disparities in high throughput sequencing data ........................................ 35 
2.2.6 Computational frameworks and microbial detection in cancer ........................... 40 
2.2.6.1 Reference-Based ...................................................................................................... 41 
2.2.6.2 Reference-Free ......................................................................................................... 46 
2.2.6.3 Mixed-method approaches:....................................................................................... 46 
2.2.7 Computational pipelines and functional prediction of microbial differences .... 47 
2.2.8 Summary ..................................................................................................................... 47 
2.2.9 Literature Cited ........................................................................................................... 48 
CHAPTER III. RESULTS .............................................................................................................. 49 
3.1 The landscape of bacterial presence in tumor and adjacent normal tissue across 
tumor types using raw exome sequencing data from The Cancer Genome Atlas (TCGA) 
cohorts ..................................................................................................................................... 50 
3.1.2 Abstract ....................................................................................................................... 50 
3.1.3 Introduction ................................................................................................................. 51 
3.1.4 Results ......................................................................................................................... 53 
3.1.4.1 Identification of microbial sequences in TCGA WXS data ....................................... 53 
3.1.4.2 Population Characteristics ........................................................................................ 55 
3.1.4.3 Taxonomic Composition across Cancer Types ........................................................ 55 
3.1.4.4 Core taxa characterization ........................................................................................ 57 
3.1.4.5 Diversity Metrics, Alpha and Beta diversity .............................................................. 63 
3.1.4.6 Cancer Specific Findings .......................................................................................... 63 
3.1.4.6.1 Stomach ................................................................................................................. 64 
3.1.4.6.2 Liver ........................................................................................................................ 66 
3.1.4.6.3 Colorectal cancers.................................................................................................. 68 
3.1.4.6.4 Cancers of the lung ................................................................................................ 72 
3.1.4.6.5 HPV associated cancers of the head & neck and cervical cancer ........................ 76 
3.1.4.6.6 Bladder ................................................................................................................... 79 
3.1.5 Validation of bacterial species in gastric and lung cancers ................................. 81 
viii 
 
3.1.6 Discussion .................................................................................................................. 83 
3.1.7 Materials and Methods............................................................................................... 84 
3.1.7 Acknowledgements .................................................................................................... 86 
3.1.8 Literature Cited ........................................................................................................... 87 
3.2 Bacterial diversity correlates with survival in infection-associated cancers of                                      
the head & neck, liver and stomach...................................................................................... 88 
3.2.1 Abstract ....................................................................................................................... 88 
3.2.2 Introduction ................................................................................................................. 89 
3.2.3 Material and Methods................................................................................................. 90 
3.2.4 Statistical Analyses .................................................................................................... 90 
3.2.5 Results ......................................................................................................................... 90 
3.2.5.1 Microbial diversity profiles. ........................................................................................ 90 
3.2.5.2 Relative abundance differs by race .......................................................................... 92 
3.2.5.3 Microbial diversity differs by race .............................................................................. 95 
3.2.5.4 Microbial within sample diversity is associated with overall survival. ..................... 100 
3.2.6 Discussion ................................................................................................................ 107 
3.2.8 Literature Cited ............................................................................................................. 109 
CHAPTER IV CONCLUSIONS & FUTURE DIRECTIONS ....................................................... 110 
4.1 Summary of conclusions ............................................................................................... 110 
4.2 Future Directions ............................................................................................................ 111 
CHAPTER V APPENDICES ...................................................................................................... 113 
A. Supplemental data ............................................................................................................ 114 
A.1 Core taxonomy across cancer types ............................................................................ 114 
A.2 Diversity in cancers of the head & neck, liver and stomach......................................... 116 
A.3 Hazards Ratio supplemental plots ................................................................................ 118 
B. Data Management ............................................................................................................. 123 
B.1 Data Management Plan ................................................................................................ 123 
B.2 dbGaP Data Access Request (DAR) ............................................................................ 129 
C. IRB ...................................................................................................................................... 133 
C.1 IRB approval letter ........................................................................................................ 133 
D. R-Package tools ................................................................................................................ 134 
D.1 R script (Microbial differential abundance-main) .......................................................... 134 
D.2 Complete list and session info of R-packages used for this project ............................ 142 
ix 
 






LIST OF TABLES 
Table 1 Racial and ethnic distribution in TCGA cases .................................................................. 4 
Table 2 Available paired cases by cancer cohort in The Cancer Genome Atlas .......................... 6 
Table 3 Microbes associated with cancer pathogenesis and potential role in racial related 
disparities ...................................................................................................................................... 26 
Table 4 Summary of microbial detection in high throughput sequencing data ........................... 36 
Table 5 Computational frameworks designed to detect microbiota from human sequences by 
subtractive, filtration or mixed methods ........................................................................................ 43 
Table 6 Total sample sequencing files screened and processed per TCGA cancer cohort for 
microbial composition characterization ........................................................................................ 53 
Table 7 Sequence comparison of aligned reads in 9 TCGA cancer cohorts .............................. 54 
Table 8 Proportion of samples with microbial reads at any detection level ................................ 54 
Table 9 Demographics and clinical characteristics summary...................................................... 56 
Table 10 Taxonomy classification counts distribution across cancer cohorts per sample type . 62 
Table 11 Fraction of taxa with presence at any detection level for each cancer type ................ 64 
Table 12 Richness and Diversity in Liver hepatocellular carcinoma ........................................... 68 
Table 13 Richness and Diversity in rectal adenocarcinoma........................................................ 72 
Table 14 Richness and Diversity in lung squamous cell carcinoma and lung adenocarcinoma 75 
Table 15 Diversity measures in HNSC anatomical sites and tumor stage by sample type and 
sex ................................................................................................................................................. 78 
Table 16 Diversity measures in BLCA anatomical sites, age at diagnosis and tumor stage 
stratified by sample type and sex ................................................................................................. 80 
Table 17 Proportions tables predicted versus observed in gastric cancer.................................. 82 
Table 18 Microbial diversity profiles among infection associated cancers.................................. 91 




LIST OF FIGURES 
Figure 1 Bioinformatics Pipeline .................................................................................................... 5 
Figure 2 Global Distribution of cancers attributable to infectious agents .................................... 11 
Figure 3 Proposed mechanisms by which bacteria contribute to the alterations and the 
carcinogenic process .................................................................................................................... 13 
Figure 4 Potential impact of the microbiota in racial related disparities ...................................... 20 
Figure 5 Proportion of infectious agents responsible for cancer incidence in both cases 
worldwide ...................................................................................................................................... 34 
Figure 6 Generic pipeline of computational frameworks designed to identify microbial reads 
from human derived sequences ................................................................................................... 41 
Figure 7 Core taxa composition detected across cancer types .................................................. 58 
Figure 8 Core taxa shared species across cancer types ............................................................ 59 
Figure 9-A Landscape of bacterial shift changes in tumor and adjacent normal tissue across 
tumor types ................................................................................................................................... 60 
Figure 10 Microbial composition differences in tumor and adjacent normal paired samples for 
STAD ............................................................................................................................................. 65 
Figure 11 Log 2 Fold Change (l2fc) of top taxa in STAD cohort ................................................. 66 
Figure 12 Microbial composition in tumor and adjacent normal paired samples for LIHC ......... 67 
Figure 13 Microbial composition in tumor and adjacent normal paired samples for COAD ....... 69 
Figure 14 COAD Log 2 fold change of significant taxa ............................................................... 70 
Figure 15 Fusobacteria abundance in COAD cohort .................................................................. 71 
Figure 16 LUSC Log 2 fold change of significant taxa ................................................................ 73 
Figure 17 Log Fold Change (l2fc) of top taxa in LUAD cohort .................................................... 74 
Figure 18 Microbial composition in HNSC and CESC ................................................................ 76 
Figure 19 Microbial presence correlation matrix in HNSC and CESC cohorts ........................... 77 
Figure 20 BLCA overall microbial composition ............................................................................ 79 
Figure 21 Relative abundance in HNSC cohort in tumor and adjacent normal by racial groups 92 
Figure 22 Relative abundance in LIHC cohort in tumor and adjacent normal by racial groups . 93 
Figure 23 Relative abundance in STAD cohort in tumor and adjacent normal by racial groups 93 
Figure 24 Bacterial within sample diversity across cohorts comparing tumor to its paired 
adjacent normal tissue .................................................................................................................. 98 
Figure 25 Microbial profiles of infection-associated cancers of the head& neck, liver and 
stomach ......................................................................................................................................... 99 
Figure 26 Racial diversity differences by cohort in tumor and adjacent normal samples ........ 100 
Figure 27 Bacterial Diversity relationship with survival in HNSC and LIHC is dependent on sex
..................................................................................................................................................... 101 
Figure 28 HNSC Hazard Ratios based on Cox proportional hazards ...................................... 102 
Figure 29 LIHC overall survival is associated with microbial within sample diversity .............. 103 
Figure 30  LIHC Hazard Ratios based on Cox proportional hazards ....................................... 104 
Figure 31 STAD overall survival is associated with microbial within sample diversity ............. 105 




TABLE OF ACRONYMS 
16S rRNA: 16S ribosomal RNA gene ....................................................................................................... 46 
ANOVA: analyses of variance ..................................................................................................................... 6 
anti-PD-L1: Anti-programmed cell death-ligand 1 ..................................................................................... 18 
APC: Annual percent change .................................................................................................................... 30 
BAM: Binary version Sequence Alignment-Map file ................................................................................ 2, 4 
BLAST: Basic local alignment search tool................................................................................................. 82 
BLCA: Bladder carcinoma ..................................................................................................................... 3, 52 
BRAF: B-Raf protein oncogene ................................................................................................................. 23 
BRCA: Breast carcinoma ............................................................................................................................ 3 
Cag-A: Cytotoxin-associated gene A ........................................................................................................ 24 
CaPSID: Computational pathogen sequence identification ................................................................. 41, 46 
CDC: Center for Disease Control .............................................................................................................. 23 
cDNA: Complementary DNA ..................................................................................................................... 39 
CESC: Cervival squamous carcinoma .................................................................................................. 3, 51 
CHOL: Cholangiocarcinoma ....................................................................................................................... 3 
CI: Confidence Interval ............................................................................................................................. 30 
CIM: Complementay and Integrative Medicine ......................................................................................... 87 
COAD: Colon adenocarcinoma ............................................................................................................... v, 3 
COGs: Cluster of Orthologs ...................................................................................................................... 46 
ConStrains: Conspecific strain workflow ............................................................................................. 45, 46 
DAR: Data Access Request .................................................................................................................. iii, 83 
DESeq: Computational program for count sequencing data differential analyses................................. 8, 63 
DNA: Deoxyribonucleic acid........................................................................................................ 5, 7, 21, 28 
E: Enterotoxigenic ..................................................................................................................................... 26 
EBV: Epstein Barr- virus (HHV-4) ................................................................................. 5, 12, 15, 20, 22, 41 
edgeR: computational program for count sequencing data differential analyses ........................................ 5 
EGFR: Epidermal growth factor receptor .................................................................................................. 21 
ESCA: Esophageal carcinoma .................................................................................................................... 3 
FDR: False discovery rate..................................................................................................................... 5, 63 
FFPE: Formalin-fixed, paraffin-embedded .............................................................................................. 2, 7 
GLOBOCAN: Global Cancer Incidendence, Mortality and Prevalence ..................................................... 24 
GRAMMy: Genome relative abundance estimation framework........................................................... 45, 46 
HBV: Human herpes virus-B ................................................................................................................. 5, 12 
HBx: Hepatitis B viral protein .................................................................................................................... 15 
HCV core: Hepatitis C core protein ........................................................................................................... 15 
HCV: Human herpes virus-C................................................................................................................. 5, 12 
HER2-type: Human epidermal growth factor receptor 2-type.................................................................... 21 
hg38: Human reference genome version 38 ............................................................................................... 4 
HIV-1: Human inmmunodeficiency virus ............................................................................................. 12, 41 
HNSC: Head and neck squamous cell carcinomas ..................................................................................... 3 
HPV: Human papilloma virus .................................................................................................... 5, 22, 29, 30 
HR: Hazards Ratio ...................................................................................................................... 30, 85, 105 
Hsp70: Heat shock protein 70 ................................................................................................................... 81 
HTLV-1: Human T-cell cirus-1 ................................................................................................................... 12 
IARC: International Agency for Research on Cancer ................................................................................ 10 
ID: Identification .......................................................................................................................................... iii 
IRB: Institutional Review Board ........................................................................................................... iii, 3, 4 
KICH: Kidney chromophobe carcinoma ...................................................................................................... 3 
KIRP: Kidney papillary carcinoma ............................................................................................................... 3 
xiii 
 
k-mers: Substring of length (k) possible subsequence .............................................................................. 45 
KSV: Kaposi sarcoma virus or Human herpes virus-8 .............................................................................. 12 
LAB: Lacticacid bacteria............................................................................................................................ 17 
LFC: Log fold change ................................................................................................................................ 67 
LIHC: Liver hepathocellular carcinoma ..............................................................................................v, 3, 41 
log2 P/B: Protoebacteria to Bacteroidetes Ratio (log 2 transformed) ........................................................ 66 
log2fc: Log 2 fold change .......................................................................................................................... 62 
LOP: Lip, oral and pharynx overlap ........................................................................................................... 75 
LPS: Lipopolysaccharides ......................................................................................................................... 18 
LUAD: Lung adenocarcinoma ..................................................................................................................... 3 
LUSC: Lung squamous cell carcinoma ....................................................................................................... 3 
MALT: Mucosa-associated lymphoid tissue .............................................................................................. 12 
MCPyV: Merkel cell polyoma virus ...................................................................................................... 12, 24 
MetaShot: Metagenomics taxon classification workflow...................................................................... 41, 46 
MS: Microsoft .............................................................................................................................................. 7 
NA/AN: Native American or Alaskan Native .............................................................................................. 30 
NCI: National Cancer Institute ..................................................................................................................... iii 
NGS: Next Generation Sequencing .......................................................................................................... 34 
NHGRI: National Human Genome Research Institute ................................................................................ iii 
NIH: National Institute of Health .................................................................................................................. 4 
NIMHD: National Institute on Minority Health and Health Disparities ........................................................ 83 
NR: Not-reported ....................................................................................................................................... 90 
NS5a:Non-structural protein 5a ................................................................................................................. 15 
OlaHAWAII: Health And Wellness Achieved by Impacting Inequalities ................................................. iii, iv 
OR: Odds Ratio ......................................................................................................................................... 62 
OTU: Operational taxonomic unit .............................................................................................................. 60 
OV: Ovarian carcinoma ............................................................................................................................... 3 
PAAD: Pancreatic adenomacrinoma ........................................................................................................... 3 
PathoScope: Pathogen identification and quantitation modular workflow ................................................. 46 
PathSeq: Pathogen sequnce .............................................................................................................. 41, 46 
PCR: Polymerase chain reaction ...................................................................................................... iii, 7, 50 
PI: Principal Investigator ............................................................................................................................. iii 
PICRUSt: Phylogenic investigation of communities by reconstruction of unobserved states .............. 46, 47 
PRAD: Prostate adenocarcinoma ............................................................................................................... 3 
READ: Rectal adenocarcinoma ............................................................................................................ 3, 50 
rho: Correlation coefficient ........................................................................................................................ 62 
RINS: Rapid identification of non-human sequences workflow ........................................................... 45, 46 
RNA: Ribonucleic acid ................................................................................................................................ 5 
RNOS: Reactive nitrogen oxyde species .................................................................................................. 13 
ROS: Reactive oxygen speies .................................................................................................................. 13 
RTR: Residual Tissue Repository ......................................................................................... iii, v, 2, 4, 7, 83 
SAMtools: Sequence Alignment Map tools ............................................................................................... 50 
SARC: Sarcoma .......................................................................................................................................... 3 
SCFA: Short chain fatty acids ................................................................................................................... 17 
SD: Standard deviation ............................................................................................................................. 52 
SEER: Surveillance, Epidemiology and End Results Program ............................................. iii, 4, 23, 24, 29 
ShortBRED: Short, Better Representative Extract Dataset ................................................................. 46, 47 
SNP: SIngle nucleotide polymorphism ...................................................................................................... 45 
SRA: Short read archives............................................................................................................................ 7 
SRSA: Short-RNA subtraction and assembly ..................................................................................... 40, 46 
xiv 
 
STAD: Stomach adenocarcinoma ..........................................................................................................v, 41 
SURPI: Sequence based ultra rapid pathogen identification .............................................................. 41, 46 
Tax4Fun: Taxonomy Functional Community Profiling ............................................................................... 46 
TCGA: The Cancer Genome Atlas ............................................................................ iii, v, 1, 3, 7, 20, 35, 41 
THCA: Thyroid carcinoma ........................................................................................................................... 3 
THYM: Thyoma ........................................................................................................................................... 3 
TLR5: Toll-like receptor 5 .......................................................................................................................... 22 
TNBC: Triple negative breast cancer .................................................................................................. 21, 22 
UHM: University of Hawaii Manoa .............................................................................................................. iv 
Vac-A: Vacuolating cytotoxin gene A ........................................................................................................ 24 
VirusScan: Viral sequence scanner .................................................................................................... 41, 46 
WHO: World Health Organization ....................................................................................................... 32, 33 



























CHAPTER I. RESEARCH PROPOSAL 
 
1.1 Objectives 
The goal of this research was to profile the microbial composition of human tumors and to evaluate their 
role in disease progression and survival. Comparisons were made by race and other characteristics. 
Utilizing a comprehensive approach, we compared human derived microbial data between primary tumor, 
henceforth “tumor” and adjacent solid tissue normal, henceforth “adjacent normal” sequencing samples 
from The Cancer Genome Atlas (TCGA) cancer cohorts. 
1.2 Specific Aims 
1.2.1 Primary Aims  
 Determine the microbial relative abundance in tumor and adjacent normal samples across 
cancer types using sequencing data and bioinformatics tools. 
 To determine cancer associations by correlating abundance and diversity metrics to clinical 
features and survival data. 
1.2.2 Assumptions  
 Infected tissue contains both human and microbial nucleic acids 
 Pathogen-derived sequences can be detected after subtraction of human sequences  (Weber 
et al. 2002, Xu et al. 2003, Kostic et al. 2011) 
1.2.3 Hypotheses 
 Microbial relative abundance in cancer tissue can be derived from human whole exome 
sequencing data similar to that derived from whole transcriptome and whole genome 
sequencing methods.  
 Consistent with the literature, it was further hypothesized that  
(a) Adjacent tissue would be associated with greater microbial species diversity  
and 
(b) That location of the colonization and patterns of co-occurrence would be associated with 




This is because microbial composition between and within each body organ is distinct which 
can help drive functional inter-individual variations and determinants of disease (Schwabe and 
Jobin 2013). Prevailing infectious disease exposures differences, and burden of infection-
associated cancers vary among racial and ethnic groups. Taking these together, microbial 
abundance and diversity patterns could contribute to racial disparities.  
 
1.2.4 Secondary aims 
 Experimentally validate bioinformatics microbial composition findings from TCGA cohort against 
formalin-fixed paraffin-embedded (FFPE) tissue blocks  
1.3 Significance  
Identification of co-factors involved in widening racial-related cancer disparities is essential to precise 
diagnostic and treatment strategies. It is accepted that microbiota can influence carcinogenesis and tumor 
progression through inflammatory and immune response (Zitvogel et al. 2017). Recent studies point out 
substantial differences in the gut microbiota composition in healthy individuals and cancer patients from 
different racial and ethnic groups (Brooks et al. 2018, Farhana et al. 2018). Bacteria and bacterial 
metabolites interactions within the tumor microenvironment may have important diagnostic and 
therapeutic implications in the reduction and elimination or racial differences. An important component of 
this project was to evaluate perturbations in microbial diversity of the tumor tissue across different cancer 
types while correlating to clinical features and overall survival. This study provides much-needed 
information on differential bacterial associations with cancer, especially given their potential use in 
microbe-based prevention strategies and possible new targeted therapies.  
1.4 Experimental Approach 
Using TCGA data in a Pan-cancer approach, we proposed to retrospectively examine the relationship 
between bacteria and cancer pathogenesis to cancer survival among racial and ethnic groups. To do this, 
we derived bacterial and viral species relative abundances from human whole exome sequencing data 
using a bioinformatics pipeline designed to generate microbial profiles from binary version of Sequence 
Alignment/Map (BAM) files from solid tissue TCGA cancer cohorts. We used relative abundance for each 
microbe and diversity metrics to correlate clinical features including basic demographics (age at 
diagnosis, sex, vital status, race and ethnicity), exposures (alcohol and smoke), tumor stage, tumor 
grade, treatment type (whenever available), histopathology and survival (days to death and vital status). 
This will help determine if a relationship exists between bacteria and cancer pathogenesis. Findings from 
bioinformatics filtering of TCGA data were validated in a cross-sectional fashion using FFPE tissue from a 
racially diverse sample from the Hawaii Tumor Registry Residual Tumor Repository (Hawaii’s RTR). We 
performed quantitative-polymerase chain reaction (qPCR) using commercially available primers and de-
3 
 
identified archival tissue from selected cancers. Authorization for use of archival tissue was obtained from 
UH IRB (Exempt Protocol 2018-00174).  
1.5 Research Design 
This study used secondary data analyses and cross-sectional design to retrospectively examine the 
relationship between bacteria and cancer pathogenesis.  
1.5.1 Study population 
This project is part of an OlaHAWAII Team Pilot Grant (2U54MD007601-32). The data used in this study 
was derived from The Cancer Genome Atlas (TCGA) consortium (phs000178 versions v9.p8 and v10.p8, 
downloaded October 2017 through November 2018). TCGA is a harmonized cancer data infrastructure 
that is continuously being updated. As of June 2017 (data release 7.0) there were 274,724 files 
constituting 11,160 unique cases across 33 cancer types including bladder carcinoma (BLCA), breast 
carcinoma (BRCA), cervical squamous carcinoma (CESC), cholangiocarcinoma (CHOL), colon 
adenocarcinoma (COAD), esophageal carcinoma (ESCA), cancers of the head & neck (HNSC), kidney 
chromophobe (KICH), kidney renal cell (KIRC), kidney papillary carcinoma (KIRP), liver hepatocellular 
carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell (LUSC), ovarian carcinoma (OV), 
pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), rectal adenocarcinoma (READ), 
sarcoma (SARC), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), thyoma (THYM) and 
uterine corpus and endometrial carcinoma (UCEC). TCGA is a collaborative effort between the National 
Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) which effectively 
combine sample and clinical data from multiple platforms with the goal of developing better strategies for 
diagnosing, treating and preventing cancer.  Datasets are available in different access tiers, open-access 
(level-3 including de-identified clinical data and demographics, gene expression, copy number alterations, 
epigenetic data, compiled data summaries, and anonymized amplicon DNA data) and controlled-access 
(levels 1 and 2 including single nucleotide, variant call, microsatellite instability, whole exome, whole 
genome, tumor miRNA, tumor mRNA and raw data) (http://tcga-data-nih.gov).  Although not part of TCGA 
primary goals, these efforts and availability of cross-platform data enable detection of microbial 
commonalities in tumor types and examination of bacterial effects on cancer modulation processes 
across different sample populations. TCGA samples originate from a diverse populations across the 
United States, while the majority of samples were from Whites (73%, regardless of Hispanic origin), there 
is a representative sample from major racial and ethnic groups (Table 1). We requested access to level 1, 
raw whole exome sequencing data and corresponding de-identified clinical and overall survival data 
(Project # 14778). We anticipate there are approximately 8,000 solid tumor and adjacent normal raw 
sequencing files with available clinical data that can be examined for bacterial composition (Table 2). In a 
comprehensive approach we expect to compare the microbial (bacterial and viral) profiles of available 
solid tissue cancers contained within the TCGA consortium and correlate differences and commonalities 
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with clinical data meeting selection criteria.  For this study, 22 solid tumors were selected on the basis of 
whole exome sequencing data availability for tumor and adjacent normal specimens with at least 13 total 
samples. We elected to examine solid tumors to directly extract microbial content related to tumor 
microenvironment and to reduce introduction of bias by examining blood normal derived sequences. All 
sequencing case pairs meeting selection criteria were downloaded and screened form microbial content. 
Cases were defined as solid tumor cancer types within TCGA that had human aligned sequencing reads, 
paired primary tumor and adjacent normal raw exome sequences in BAM file format, plus available 
clinical data. Paired cases were selected at 1:1 ratio for the bioinformatics interrogation. Each of the 
selected cancer types had a minimum of 13 samples. 
Table 1 Racial and ethnic distribution in TCGA cases  
Race or ethnic group Cases % 
 
White, Caucasian 8186 73.4 
Black or African American 934 8.4 
Asian 675 6.0 
Native Hawaiian,  
Other Pacific Islander 13 0.1 
Native American, 
Alaskan Native 27 0.2 
Not Reported 1325 11.9 
Not Hispanic or Latino 8173 63.9 
Hispanic or Latino 377 2.9 
Not reported  2610 20.3 
   
Table displays racial and ethnic group breakdown in TCGA datasets as of data release 7.0 (June 2017). 
 
A separate IRB Protocol submission was made for the validation of findings and use of archival tissue 
from the Hawaii’s RTR. The RTR and Hawaii’s Tumor Registry are part of the NIH, Surveillance 
Epidemiology and End Results Program (SEER). RTR comprises of a uniquely racially diverse collection 
of FFPE tumor specimens from cancer patients diagnosed within the catchment area of Hawaii’s Tumor 
Registry. Validation with archival tissue from a racially diverse population is vital to the understanding of 
racial and ethnic variation in cancer incidence and survival. Archival tissue was requested for selected 
cancer types for which microbial profiles showed significant results. Tissue was requested at similar 1:1 
ratio tumor and adjacent normal. 
1.5.2 Methods and Planned Statistical Analyses 
Specific Aim 1. To determine the microbial relative abundance in tumors and adjacent normal paired 
samples across cancer types using exome sequencing data and bioinformatics tools 
We determined microbial relative abundance from unmapped to human reads using PathoScope 2.0 and 
R shiny app package PathoStat (Hong et al. 2014, Manimaran S 2017) (Figure 1). PathoScope is a well 
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described bioinformatics tool developed to detect microbial reads present in clinical or environmental 
samples’ sequencing data (Hong et al. 2014). PathoStat is designed to work with PathoScope generated 
reports (Manimaran S 2017). In brief, selected sequencing reads were quality filtered, trimmed and 
compiled for data analysis using SAMtools and Picard. Additional filtering was completed by 
computational subtraction against human reference genome (hg38) and then aligned to known microbial 
genomes (custom library). Relative abundance was calculated for each microbe (taxa) based on 
normalized values in tumor and normal adjacent tissue for all cancer types that met described case 
selection criteria. Viral DNA presence, mainly HPV, HBV and EBV, was used as internal pipeline 
validation and for microbial co-occurrence analyses. Our pipeline was designed to identify DNA 
sequences as such, RNA viruses like HCV were not detected. Diversity measurements, alpha (diversity 
within each sample) and beta (differences in composition among samples) per cancer type and across 
cancers were calculated. 
Figure 1 Bioinformatics Pipeline 
 
Bioinformatics pipeline designed to extract microbial profiles from human sequencing data using modified 
PathoScope methods and additional filtering steps described by Zhang et al. [19]. Viral sequences detection used as 




Shannon Diversity Index (alpha within sample diversity) was used to compare between tumor and its 
paired adjacent normal. We analyze difference of proportions of bacterial presence within cancer types by 
racial/ethnic groups comparing tumor to its non-tumor normal. We will use contingency tables and non-
parametric statistical testing such as Chi-Square. Differential microbial abundance between tumor and its 
paired adjacent normal in each cancer type was determined using edgeR (Robinson, McCarthy, and 
Smyth 2010). Bacterial taxa with false discovery rate (FDR) adjusted p value < 0.05 were considered 
significantly different at both genus and species level. Major bacteria taxa present in 50% or more of the 
cases (per cancer type) was defined as core microbiome. Cancer types found to have significant 
microbial read differences were designated for experimental validation using archival (formalin-fixed, 
paraffin-embedded, or FFPE) tumor tissue. All microbial data derived from human DNA sequences were 
kept in an electronic database as described in the Data Management Plan (Appendix B. Data 
Management123). 
Table 2 Available paired cases by cancer cohort in The Cancer Genome Atlas 
TCGA Cohort  Total Files Total Cases Total Paired 
BLCA  455 412 37 
BRCA  1202 1050 137 
CESC 313 305 8 
CHOL 71 51 20 
COAD 561 443 88 
ESCA 248 184 64 
HNSC 587 527 69 
KICH 123 66 57 
KIRC  652 345 250 
KIRP 381 290 88 
LIHC 460 376 84 
LUAD  853 582 200 
LUSC 836 502 221 
OV  634 460 96 
PAAD 221 185 36 
PRAD  608 498 106 
READ 182 168 18 
SARC 277 255 22 
STAD 530 443 88 
THCA 598 502 98 
THYM 136 123 13 
UCEC  599 553 38 
TOTAL 10,527 8,320 1,838 
 
Available WXS primary tumor and solid tissue normal sample sequence files from TCGA solid tumor cancer cohorts 
with at least 10 paired cases from which microbial data could be derived. Data release 10.1 
 
Specific Aim 2. To determine cancer association by correlating microbial abundance & diversity data to 
clinical features & survival data.  
We used relative abundance for each microbe and its correlation to clinical features including basic 
demographics (age at diagnosis, sex, race and ethnicity), tumor stage, tumor grade, treatment type 
(whenever available), histopathology, exposure (alcohol and smoke when available) and survival (days to 
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death and vital status) to derive cancer associations. To determine the association between differences in 
relative abundance in tumor and its adjacent normal and clinical features, paired or unpaired t-test and 
analysis of variance (ANOVA) were used for two- and multi-group comparisons, respectively. Chi-square 
test were used for categorical data. Using differentially abundant microbes and significant clinical features 
as predictors, Cox proportional hazards regression analyses were performed to evaluate the associations 
between each of the potential biomarkers and overall survival outcomes per cancer types.  
Specific Aim 3. Experimental validation of bioinformatics microbial findings from the TCGA cohort using 
FFPE tissue from cancer registry-based population 
TCGA microbial associations for selected cancer types of the stomach and lung were validated in a cross-
sectional fashion with archival population blocks. One hundred-twenty (120) tissue blocks per cancer 
were requested at 1:1 ratio per paired-case (tumor and its paired adjacent normal) in representative 
distributions for Hawaii’s largest racial and ethnic groups. The Cancer Center Pathology Share Resource 
completed tissue retrieval, cut & slide, sectioning, pathology review and nucleic acid extractions. DNA 
was extracted using appropriate purification kit to maximize DNA yield from FFPE (Carrick et al. 2015). 
PCR was performed for species-specific bacterial DNA presence using commercial probe/primers qPCR 
kits (Qiagen Microbial DNA qPCR kit, Qiagen, USA). Samples were run in duplicate and included positive 
and negative controls with each run. Bacterial detection results were correlated with de-identified 
demographic, clinical and survival data provided by Hawaii’s RTR. Experimental data was compared to 
bioinformatics results. Due to budget constraint, we validated up to six (6) of the most abundant or 
differentially abundant bacteria per cancer type. It was determined that to attain enough power, 30 
samples with expected discordant proportion ratio of 0.5 and odd ratios of 0.18 would have at least 80% 
power to detect the bacterial association per cancer type at the significance level of 0.05 using 
McNemar’s test. 
1.5.3 Strengths of the research proposal 
The proposed study is unique in being the first to evaluate cross-cancer associations between bacterial 
abundance and cancer pathogenesis as determined by survival and clinical data with bioinformatics and 
experimental validation design within the local Hawaii population. The proposed study also utilizes 
matched read pairs strengthening the results of the microbial commonalities and differences. The 
availability of TCGA data makes it possible to accomplish the study aims in a timely and cost effective 
manner. Hawaii’s distinctive racially diverse population makes it possible to extrapolate the findings to the 
general population.  
1.5.4 Limitations and Alternative Strategies 
Our sample size is limited by the number of quality paired sequencing files available per cancer type in 
the TCGA databases and budget constraints for validation. Our ability to establish causality is limited by 
the cross-sectional study design. We are limited to pre-existing data which was not collected at time of 
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pathogen exposure or prior to cancer diagnosis. Also, our pipeline was designed to detect DNA species, 
as such one of our limitations is not being able to detect RNA viruses. 
1.5.5 Changes to planned analyses 
All analyses in this research were performed using R version 3.5.1 (2018-07-02) and MS Excel (v. 2013). 
Multiple problems were encountered while processing data through the R shiny app PathoStat since the 
study’s initial pipeline validation with SRA files and were unable to complete differential relative 
abundance analyses using PathoStat. Alternative methods within R-packages were utilized similar to 
those used by PathoStat to determine relative abundance and diversity metrics including vegan R-
package (version 2.5-3), microbiome R-package (version 1.3.3), and phyloseq (version 1.25.3). A list of R 
tools utilized is found in Appendix D2, pp142.  
Due to the nature of the study data and the relative low counts of microbial reads generated from exome 
sequencing data compared to whole genomic and transcriptomic methods we were unable to consistently 
use edgeR (Robinson, McCarthy, and Smyth 2010) or similar methods such as DESeq-2 (Love, Huber, 
and Anders 2014)for differential analyses with count data for all cancer types. Differential relative 
abundance was analyzed using Wilcoxon-Signed Rank and Rank Sum tests using normalized proportion 
data. 
TCGA bioinformatics interrogation was shortened due to data volume and time constraints. In addition, 
archival tissue was limited due to budgetary restrictions and avoiding depletion of sample pool. As such 
convenience sampling was utilized for selection of cases for validation portion of this study. 
1.6 Impact 
Profiling the microbial composition of human tumors is a daunting task that is being facilitated by new 
sequencing technology, bioinformatics tools and merging cooperative networks. The TCGA, one of such 
networks, has catalogued over 11,000 cases across 33 tumor-types. The Pan-Cancer analysis project is 
an effort to compare tumor omics characteristics and clinical data across major tumor types from data 
drawn from the TCGA network. In a Pan like approach using whole exome sequencing and clinical data 
from the TCGA consortium this research examined the relationship between bacteria and cancer 
pathogenesis. This provided a cross-cancer view of tumor-bacterial associations, enabling the 
confirmation or rejection of established or suspected associations, discovery of new associations, 
identification of patterns of co-occurrence, and examination of host-interaction effects. 
1.7 Literature cited 






CHAPTER II. REVIEW OF THE LITERATURE 
 
The literature review is divided into two sections, “The role of tumor microbiota in cancer 
pathogenesis and the impact on racial related disparities,” and “Identification of racial-related 
microbial differences across cancers from human-derived sequencing data.” Portions of the 





2.1 The Role of Tumor Microbiota in Cancer Pathogenesis and the Impact on                           
Racial-Related Disparities 
2.1.1 Abstract 
Cancer is the second leading cause of death in the United States. Etiology varies by cancer type with 
observed differences among racial and ethnic groups in incidence and mortality rates. It is understood 
that while cancer affects all persons, some ethnic and racial groups are at higher risk of developing, 
suffering complications, and dying from cancer. In the United States, despite reduced incidence and 
mortality rates, racial and ethnic minorities continue to show striking differences in cancer outcomes. 
There is evidence that infection burden may contribute to health disparities. Recent studies elude to 
distinct tumor microbial patterns contribution to variation observed among several cancer types, which 
warrants further exploration to understand roles of tumor microbiota behind racial disparities and to 
provide new diagnostic and therapeutic strategies. The review covers what is known about the divergent 
relationship of tumor microbiota in cancer pathogenesis and their potential impact on racial related 
disparities. 
2.1.2 Introduction 
Cancer is one of the leading causes of death worldwide. In United States, 1.7 million individuals are 
diagnosed and nearly 600,000 die from the disease each year (Siegel, Miller, and Jemal 2015, 2016, 
2018). Worldwide, one in five cancer cases are attributed to infectious agents (Plummer et al. 2016, de 
Martel et al. 2012, Parkin 2006). Figure 2. In the United States out of the top 10 leading causes of 
incidence and cancers related deaths, 9 cancer types are known to have marked racial differences 
including cancers of the lung, prostate, breast, colorectal, pancreas, liver, kidney, stomach and cervical 
(Hernandez and Goodman 2004, Gourin and Podolsky 2006, Curtis et al. 2008, Singh 2012, Li et al. 
2013, Li et al. 2014, Sturtz et al. 2014, White et al. 2014, Daraei and Moore 2015, NCI 2015, DeSantis et 
al. 2016, Ha et al. 2016, Ragin et al. 2016, Setiawan et al. 2016, Miller et al. 2017, Scelo et al. 2017, 
Zhang et al. 2017). Of these, 4% of cases are thought to be infection-associated, primarily cases of the 
liver, stomach and cervical cancers (IARC 2012, Parkin 2006, de Martel et al. 2012). A considerable 
proportion of these cancer cases remain with unknown etiological factors underscoring the importance of 
understanding the interplay of contributory factors to include microbial contributions. 
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Figure 2 Global Distribution of cancers attributable to infectious agents 
 
Bar graph displaying the infection attributable fraction of cancers new cancer cases worldwide. Light bar represents 
new cancer cases, dark bar represents attributable fraction in percent of total cases.  The remaining fraction of new 
cases have considerable proportion of unknown etiology. Data source: Plummer et al., Globocan and the American 
Cancer Society (https://www.cancer.org/cancer/cancer-causes/). 
 
2.1.3 Microbiota in Cancer Pathogenesis 
The human microbiome is defined as the aggregation of microorganisms including viruses, bacteria, and 
eukaryotes that live in and on our bodies which genomes contribute to our broader genetic portrait 
(Human Microbiome Project 2012, Rogers 2016, Ursell et al. 2012). The microbiota within each organ 
system is distinct which can drive functionally relevant inter-individual variations and determinants of 
disease (Schwabe and Jobin 2013, Bik et al. 2010). Bacterial community variations, the production of 
bacterial metabolites, and microbial interaction with the human host have been attributed to detrimental 
and beneficial tumoral effects since the 18th century (Nauts 1982, Nauts 1989). Persistent and chronic 
exposure to infectious agents may initiate or promote cancer (Parkin 2006, Plummer et al. 2016). Equally, 
any agent that stimulates immune defenses can minimize the incidence and be beneficial once cancer 
develops (Blaser 2008, van Tong et al. 2017, Parsonnet 1995, de Martel et al. 2005, Chang and 
Parsonnet 2010). This highlights the unique agonistic and antagonistic effects of the human microbiome 
in cancer progression and has become an area of intense exploration.  
The microbiological infections worldwide contribution to cancer pathogenesis ranges from 4% to 31% 
(Plummer et al. 2016, Kuper, Adami, and Trichopoulos 2000, Cogliano et al. 2011, WHO 2018). While 
contribution by specific viral pathogens is firmly established, for bacteria, archea, and eukaryotes agents 
remains controversial particularly for bacterial members of the commensal microbiota. Here we briefly 
discuss known and suspected oncogenic viral and bacterial agents, archea and eukaryotes, which are 
less common, are not discussed. 
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2.1.3.1 Infectious etiological factors 
2.1.3.1.1 Viral 
Viruses are responsible for at least 10% of all human cancers (Moore and Chang 2010) and constitute 
about 63.5% of the new cancers attributed to infections (Plummer et al. 2016). Viruses share common 
characteristics in the development of cancer and have been reviewed in detail by several researchers 
(Parkin 2006, Kuper, Adami, and Trichopoulos 2000, De Flora and La Maestra 2015, Burnett-Hartman, 
Newcomb, and Potter 2008). There are six generally accepted viral carcinogens: human herpes virus 4 
also known as Epstein Barr virus (HHV-4 or EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), 
human papilloma virus (HPV), human T-cell virus-1 (HTLV-1), and human herpes virus 8 also known as 
Kaposi Sarcoma Herpes virus (HHV-8 or KSV).  The seventh viral etiology, human immunodeficiency 
virus-1 (HIV-1), is included because it indirectly promotes carcinogenesis caused by other viruses through 
immunosuppression (Beuth 2005, Monographs 2012).  
Other viruses have been investigated with conflicting or limited evidence regarding their carcinogenic 
effects including polyomaviruses. There is recent limited evidence which proposes a causal relationship 
between Merkel cell polyomavirus (MCPyV) in Merkel cell carcinoma (Cogliano et al. 2011, Shuda et al. 
2008) whereas conflicting evidence remains for the human polyomavirus JC as a risk factor in colorectal 
cancer (Laghi et al. 1999, Lundstig et al. 2007). Recent studies have found associations between viral 
presence with distinct gene expression patterns and cancer aggressiveness (Cancer Genome Atlas 
Research 2014, Khoury et al. 2013). For example, although controversial, presence of HHV-4 exists in 
aggressive breast tumors (Mazouni et al. 2011).  
2.1.3.1.2 Bacterial 
Bacteria have long been associated with cancer, either promoting or protecting depending on site and cell 
type of the colonization (Schwabe and Jobin 2013, Chang and Parsonnet 2010, Mager 2006). High site-
specific colonization and microbial-host dynamics permits a dual role in cancer pathogenesis. 
Inflammation microenvironments created by the host microbiota can promote accumulation of mutations 
and epigenetic changes that lead to cell modulating and tumor-promoting effects (Hattori and Ushijima 
2016, Elinav et al. 2013). Conversely, bacteria and its products can prevent, arrest or regress cancer 
progression by acting directly or indirectly on host inflammatory response and cellular pathways (Nair, 
Kasai, and Seno 2014). This is exemplified by Helicobacter pylori contrasting role in gastric 
adenocarcinoma (increased risk) and esophageal adenocarcinoma (decreased risk). In a study by de 
Martel and colleagues, Helicobacter pylori colonization was associated with 37% risk reduction of 
esophageal adenocarcinoma development in persons 50 years and younger regardless of smoking status 
(de Martel et al. 2005). Helicobacter pylori is widely accepted to play a role in carcinogenesis. In fact 
according to IARC, is the only bacterial agent recognized to have a definite role in the development of 
various cancers including gastric adenocarcinoma and MALT gastric lymphoma, while suspected to play 
a significant role in other malignancies (Parsonnet et al. 1993, Wotherspoon et al. 1991, Murphy et al. 
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2014, Pellicano et al. 2004, Hong et al. 2012). Like Helicobacter pylori, Salmonella enterica serovar Typhi 
is believed to contribute to the development of gallbladder cancer in endemic regions and hepatocellular 
carcinoma in chronic carriers (Koshiol et al. 2016, Caygill et al. 1994). However, it is believed to have 
beneficial effects in the treatment of cancers like melanoma (Hayashi et al. 2009). Other bacteria species 
have been found associated with cancer modulation. Streptococcus bovis (Gold, Bayar, and Salem 2004) 
Bacteroides fragilis (Thomas et al. 2016) and more recently Fusobacterium nucleatum for example have 
been found to be enriched in colorectal tumors by several teams (Kostic et al. 2013, Marchesi et al. 2011, 
Castellarin et al. 2012, Warren et al. 2013, Kumar et al. 2016). Fusobacterium nucleatum has varying 
degrees and distinct patterns of microbial co-occurrence which can result in carcinogenic and anti-
carcinogenic effects (Zitvogel et al. 2017, Marchesi et al. 2011). Effects which are dependent on host-
microbial interactions and location of colonization (Chang and Parsonnet 2010).  
Figure 3 Proposed mechanisms by which bacteria contribute to the alterations and the carcinogenic 
process 
  
Figure displays proposed bacteria direct and indirect mechanisms of action in infection and inflammation associated 
cancers. Bacteria may directly transform cells by disruption of membrane structures that lead to an increase in bacterial 
translocation. This in turn can result in establishment of chronic inflammation and double strand DNA damage by 
bacterial cytotoxins. Bacterial cytotoxins may also lead to beneficial effects by mode of cytotoxins initiated apoptosis, 
halting the progression of the disease. Bacteria can also indirectly alter hormone metabolism, increase immune altered 
responses. Altered patterns leading to dysbiosis can in turn cause chronic inflammation and the release of reactive 
oxygen (ROS) and nitrogen species (RNOS) induced tissue damage and cellular transformation. Alterations of microbial 
community could result in beneficial or detrimental effects to the tumor microenvironment. 
 
2.1.3.1.3 Mechanisms of action 
It is understood that exposure to microbial agents alone is not sufficient to induce the carcinogenic 
process (Moore and Chang 2010). Rather it is the interaction of multiple host risk factors and molecular 
events induced by microbial agents and their products that lead to transformed cancer cells. Common 
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mechanisms of action include direct expression of viral oncogenes or direct and indirect alteration of the 
inflammatory response, as is in the case of bacterial agents (Moore and Chang 2010, Elinav et al. 2013). 
The mechanisms by which viral agents contribute to pathogenesis have been reviewed in detail (Elinav et 
al. 2013, Moore and Chang 2010, Burnett-Hartman, Newcomb, and Potter 2008, Hattori and Ushijima 
2016, De Flora and Bonanni 2011, Kuper, Adami, and Trichopoulos 2000) and are not covered here.  
Mechanisms by which bacteria contribute to the alterations and the carcinogenic process are not well 
understood. It is known however, that similar to viral mechanisms, persistent and chronic infections may 
initiate the process or promote an established cancer (Nauts 1989, Monographs 2012). Alteration of the 
microbial community could also result in beneficial effects to the tumor microenvironment. In fact, 
according with the literature, any agent capable of stimulating host immune defenses can minimize the 
incidence and be beneficial to established tumors. Current proposed mechanisms of bacteria modulation 
have been summarized into 3 general pathways that can be protective or carcinogenic through direct or 
indirect, chronic inflammation or immunosuppression (Monographs 2012). These involve actions that alter 
microbial-host dynamics, disrupt cellular activities or alter the immune cascade in response to the 
bacterial agent, bacterial toxic metabolites, or bile acid degradation Figure 3 (Elinav et al. 2013, Schwabe 
and Jobin 2013, Blaser 2008, Chang and Parsonnet 2010, Mager 2006, Parsonnet 1995, Gagnaire et al. 
2017).  
Modification of the immune cascade in response to infection or dysbiosis is one of the most important 
aspects of tumor-microenvironment cross talk (Elinav et al. 2013). Altered host-dynamics can increase 
bacterial translocation as a direct consequence to changes in microbial composition resulting in increased 
inflammation.  This interaction can result in tumor suppression activities via activation of cancer-
preventing phytochemicals.  Bacterial products and bacterial metabolites may have protective effects on 
survival, reduced growth of cancer cells, or modulate anticancer immunosurveillance at local or distant 
sites (Zitvogel et al. 2017). Butyrate for example, which has anti-inflammatory properties is thought to be 
protective while secondary bile acids are thought to be carcinogenic (Parsonnet 1995, Bordonaro, 
Lazarova, and Sartorelli 2008). Notably African Americans, who suffer disproportionately higher incidence 
and mortality rates for many cancers, have been found to have lower levels of butyrate and butyrate 
producing microbes than other racial or ethnic groups (Hester et al. 2015). These variations in microbial 
composition may be in part responsible for the carcinogenic process in susceptible or genetically 
predisposed populations and can assist in understanding of patient inter-variability of racial related cancer 
disparities (Moore and Moore 1995, Goyal et al. 2016). More recently, it was demonstrated that pro-
inflammatory bacteria were overexpressed in African Americans compared to Caucasian Americans 
colorectal cancer patients (Farhana et al. 2018). In the same study, Caucasian Americans were found to 
have higher diversity and greater proportion of probiotic species (Farhana et al. 2018). This study 
provided evidence of potential microbial contribution to colorectal cancer racial-related cancer disparities. 
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New microbial contributions to cancer, whether beneficial or detrimental, are being discovered by 
improved techniques and integrated data networks and have become the focus of multiple studies 
(Sobhani et al. 2011, Thomas et al. 2016, Marchesi et al. 2011, Warren et al. 2013, Kumar et al. 2016, 
Riley et al. 2013, Chan et al. 2016, Cavarretta et al. 2017, Thompson et al. 2017, Xuan et al. 2014, Yow 
et al. 2017, Gopalakrishnan, Spencer, et al. 2018). Several studies have found that specific bacterial taxa 
are consistently identified in cancer tissue either at increased levels such as Fusobacteria, Alistipes, 
Porphyromonadaceae, Coriobacteridae, Staphylococcaceae, Akkermansia and Methanobacteriales, or at 
decreased levels like Bifidobacterium, Lactobacillus, Ruminococcus, Faecalibacterium, Roseburia, and 
Treponema compared to adjacent or control tissue (Sun and Kato 2016). Differential abundance patterns, 
provide great potential to examine proposed direct and indirect mechanisms of action as well as their 
contributions to cancer pathogenises.   
2.1.3.1.4 Co-occurrence and aggressiveness  
Changes in species diversity or abundance may contribute to increased cancer incidence in susceptible 
populations. Competitive interactions of microbial agents are more apparent at broader taxonomic levels. 
These interactions provide information at the population level for each cancer type allowing for racial and 
ethnic differences to be evaluated. At the species level, patterns of co-occurrence provide individual 
patient information allowing for personalized therapies (Bik et al. 2010). Taxonomic level analyses of the 
microbiome have revealed several microbial candidates implicated in pathology of disease (Xie et al. 
2016, Kumar et al. 2016). Xie et al. (2016) recently showed that co-abundance patterns in the gut alter 
liver disease progression including liver cancer; while Kumar identified possible target proteins in 
Fusobacterium nucleatum and host interaction that explain colorectal cancer progression as a result of 
co-infection. These findings can be applied to preventive or complementary therapies.  Viral-bacterial co-
occurrence has been identified to modulate tumor aggressiveness. Based on epidemiological and 
geographic correlations it is suggested that viral agents may interact with bacteria resulting in more 
aggressive tumors. For example, it is recognized that HHV-4 infected stomach tumors are molecularly 
distinct. HHV-4 is thought to interact with Helicobacter pylori however insufficient evidence exists. In 
hepatocellular carcinoma co-infection with HBV with HCV and their interaction between proteins HBx, 
HCV core and NS5a can also lead to more aggressive tumors. In addition other exposures can act as co-
factors altering the tumor microenvironment and disease outcomes such as alcohol consumption, 
smoking co-morbidities and betel nut chewing (De Flora and Bonanni 2011, Hernandez et al. 2017). 
Furthermore, historical epidemiological data suggests an antagonistic relationship between infectious 
disease prevalence and cancer incidence and cancer specific mortality (Nauts 1989). This antagonistic 
relationship may be affected by the timing of the infection (acute versus chronic), and the interaction of 
the pathogen with the human-host (Hoption Cann, van Netten, and van Netten 2006, Cruz-Munoz and 
Fuentes-Panana 2017). Concurrent acute infections with Staphylococcal or Streptococcal species are 
recognized to have a protective effect in times leading to complete tumor regression (Jeljaszewicz, 
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Pulverer, and Roszkowski 1982). Yet for infections that become chronic, the opposite effect is observed. 
Endemic prevalence can be protective for certain cancer types while it has a promoting role in others  as  
demonstrated by Helicobacter pylori and Salmonella serotype infections (Iyer et al. 2016).  
2.1.4 Commensals and Pathobionts: Cancer Treatment and the Role of Acute Infections  
In cancer patients, treatment is known to alter the host immune responses, induce system barrier failures, 
and promote infections (Zitvogel et al. 2017, Iida et al. 2013, Routy et al. 2018). Bacterial acute infections 
are a common cause of morbidity and mortality in cancer patients and susceptibility is driven by cellular 
disturbances caused by the type of treatment or the cancer type and stage (Rolston 2017, Culakova et al. 
2014). The underlying causes and the effects during and after cancer treatment are not well studied and 
much remains unknown. There is however, important temporal variation involving timing of the treatment, 
number of circulating immune cells (particularly neutrophils) and the characteristics of the bacterial agent 
with differing patient outcomes (Attie et al. 2014). Attie et al. (2014) recently examined cancer-specific 
survival correlation to acute bacterial infection in a colorectal cancer cohort. Study results suggested that 
presence of infection during and up to one year after treatment was associated with poorer prognosis 
independent of age (Attie et al. 2014).  In fact, infection is the cause of death in about half the patients 
with gastrointestinal tumors and sepsis complications developed in about 45% of these where the tumor 
type is thought to be the predisposing factor (Rolston 2017). The infectious agents attributed to sepsis 
complications have been found to be associated with cancer type (Danai et al. 2006).  In addition, there 
are significant racial and gender disparities associated with sepsis incidence and survival rates among 
cancer patients. For example, in a population based longitudinal study (1979 to 2001) risk for sepsis 
among male patients was approximately 30% higher than that of females, while risk for sepsis for African 
Americans and other races was twice that of whites (Danai et al. 2006). This is in part due to differences 
in the microbial gene expressions of each individual affecting differential susceptibility to disease along 
with varying exposures to microbial agents (Blaser 2008, Wallace, Martin, and Ambs 2011). Indeed acute 
infections can propel production of exotoxins influencing the course of an established cancer (Attie et al. 
2014). It has been demonstrated that cancer patients concurrently infected with Staphylococcal or 
Streptococcal species may experience spontaneous tumor regression in all cancer types (Nauts 1982). 
Streptococcal infection have also been identified to contribute to cancer development through chronic 
infection and inflammation (Biarc et al. 2004). This highlights the importance of co-factors and conditions 
at initial colonization which may determine pattern of the host-agent interaction (Kuper, Adami, and 
Trichopoulos 2000). Commensals and pathobionts balance disruptions that can result in non-transient 
changes to the tumor and adjacent tissue microenvironment which dictate the success of the cancer 
treatment in certain individuals (Iida et al. 2013, Gopalakrishnan, Helmink, et al. 2018). As such, 
commensals and pathobionts that exert effects on the tumor and adjacent tissue microenvironment could 
be the key to overcoming tumor-induced immune tolerance (Garcia-Castillo et al. 2016). Commensal and 
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pathobionts may play a role in cancer risk as part of our overall genetic makeup (Dethlefsen, McFall-Ngai, 
and Relman 2007) and may be an important predictor of survival having both anti-tumoral and tumor-
tolerant properties (Blaser 2008, Lai et al. 2014, Zitvogel et al. 2017). Commensal bacteria are involved in 
metabolic processes, inflammation and immunity, while pathobionts support the immune system by 
assisting in the maintenance of the epithelial barrier and in the immune cell maturation process (Hornef 
2015). These groups consist of mutualistic or pathogenic bacteria that are transient or residential 
members of the host’s microbiome which generally do not affect the healthy host unless incited by 
dysbiosis or altered immune responses (Contreras et al. 2016, Garcia-Castillo et al. 2016) 
Commensal bacteria in animal models of tumor microenvironment reveal that treatment is affected by the 
tumor microbiota (Iida et al. 2013). Iida et at. (2013) examined tumor microenvironment after treatment 
and observed that pro-inflammatory genes were decreased in the absence of microbiota and that 
microbiota modulated genotoxicity of therapeutic compounds independent of immune elicited cell death. 
This study suggests that commensal bacteria differentially affect the type of inflammatory response to 
different therapies and highlights the potential to improve cancer treatment by manipulating gut 
microbiome (Iida et al. 2013). We can conclude that microbial-host dynamics lead to cellular changes, 
which result in subsequent divergent cancer modulating effects. Because of this dual modulating effect 
and the high specificity of bacteria to host interactions, identification of bacterial associations are 
important to cancer prevention, diagnosis and treatment strategies. Especially to elucidate potential 
mechanisms involved in bacterial divergent roles in cancer pathogenesis and their impact in racial and 
ethnic-related disparities. 
2.1.4.1 Modulating effects 
A multiplicity of interactions might exist between infection, colonization, and host-microbiome dysbiosis 
that predispose susceptible individuals to cancer, while others are provided protection from the disease. 
There is growing evidence suggesting a dual modulating effect of microbial communities in cancer 
pathogenesis (Zitvogel et al. 2017, Beuth 2005, Nair, Kasai, and Seno 2014, Mager 2006). Is debatable 
however, whether these disturbances are causative or a consequence of cancer pathogenesis with 
enough evidence to suggest both (Garcia-Castillo et al. 2016). Selective adherence is demonstrated in 
the presence of differential microbial composition by anatomical site in tumor compared to non-tumor 
progenitor cells (Garcia-Castillo et al. 2016). 
Butyricicoccus, and lactic acid bacteria (LAB), mainly Lactobacillus and Bifidobacterium, are believed to 
benefit the host through improved intestinal immune cell function, anti-inflammation, anti-tumorigenesis, 
and pathogen exclusion  (Sun and Kato 2016, Kamiya et al. 2016). The beneficial effects of gut 
microbiota on the host are mainly mediated by its metabolites. Short-chain fatty acid (SCFA), including 
acetate, propionate, and butyrate, are the major end-products of gut bacteria fermentation of dietary fiber 
(Rios-Covian et al. 2016). In the 19th century, Coley first proposed the idea of bacterial infection for 
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cancer shrinkage(Jeljaszewicz, Pulverer, and Roszkowski 1982). New evidence suggests that targeting 
the microbiome can improve therapeutic outcomes of anticancer drugs (Gopalakrishnan, Spencer, et al. 
2018). Bifidobacterium for example is thought to be associated with antitumor effects where oral 
administration promotes antitumor immunity and facilitates anti-PD-L1 efficacy a checkpoint blockade 
(Sivan et al. 2015, Routy et al. 2018). In the other hand production of bacteria lipopolysaccharides (LPS) 
is linked to be detrimental to the host through dysbiosis of gut microbiota and modification of antigen 
presentation (Jorgensen et al. 2016). Several studies have examined the role of gut microbiota in 
gastrointestinal and non-gastrointestinal cancer pathogenesis (Sobhani et al. 2011, Golombos et al. 2018, 
Gopalakrishnan, Spencer, et al. 2018, Farhana et al. 2018, Lakritz et al. 2015). Few have evaluated the 
role of the microbiota on the tumor and adjacent tissue (Marchesi et al. 2011, Kostic et al. 2012, Xuan et 
al. 2014, Cao et al. 2016, Thompson et al. 2017, Wang et al. 2017).  
2.1.5 Cancer Racial Related Disparities   
Cancer disparities are observed when in general incidence and mortality rates are improving, yet lag 
behind for certain minority groups. Major efforts have been taken to elucidate the factors influencing 
cancer disparities. The primary goal of these efforts is to develop response strategies that eliminate or 
reduce the marked differences. Despite declining incidence rates around the globe, cancer remains the 
leading cause of death among Asian Americans, Native Hawaiians and Hispanics (Siegel et al. 2015, 
Torre et al. 2016). In addition, in the United States, cancer incidence and mortality rates are 
disproportionately higher among Non-Hispanic Blacks or African Americans for the four most common 
cancers (breast, lung, prostate and colorectal) compared to Non-Hispanic Caucasian American (Siegel, 
Miller, and Jemal 2018). Cancers most commonly associated with infectious agents, like stomach, liver 
and cervical cancers are disproportionately higher among Asian Americans, Native American /Alaskan 
Native and Hispanics (Siegel et al. 2015, Torre et al. 2016, DeSantis et al. 2016). Although the factors 
influencing variation in incidence and mortality rates among racial and ethnic subgroups in the United 
States remain largely unknown, disparities are explained in part by rates of screening & preventive 
service utilization, lifestyle & behavioral risk patterns, tumor biology, and differences in exposure to 
cancer-causing infectious agents (Deshmukh et al. 2017, Wallace, Martin, and Ambs 2011). These 
factors have been reviewed by other authors and are beyond the scope of this work. Briefly, utilization of 
primary & secondary prevention strategies has been historically lower among racial and ethnic minorities 
in the United States perhaps due to cultural variations and limited access to quality care (Kagawa-Singer 
et al. 2010). Racial minorities groups within the United States are less likely to be screened at early stage 
and more likely to receive subpar treatment when compared to Caucasian counterparts; even when 
income and health insurance status are equal (Singh and Jemal 2017).  This seems in accordance with 
the observed cancer screening & preventive service utilization patterns among racial and ethnic minorities 
but does not entirely explains their higher mortality rates. For example, African American women have 
lower incidence of breast cancer yet suffer poorer outcomes and higher mortality rates than any other 
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racial or ethnic group largely due to differences the timing of screening type of treatment, and the 
response to treatment strategies (Wallace, Martin, and Ambs 2011, Newman 2017, Curtis et al. 2008). 
Similarly, among Asian American, Native Hawaiian and Asian ethnic subgroups (Chinese, Japanese and 
Filipino and other Asian and Pacific Island ethnic minorities) living in the United States, colorectal cancer 
screening rates explain in part incidence variation among the ethnic subgroups, although not necessarily 
mortality rates for all subgroups (Hernandez and Goodman 2004). Native Hawaiian suffer 
disproportionate mortality rates indicative of various co-factors resulting in more aggressive tumors and 
poorer survival (Hawaii Cancer Center 2016). Evidence suggests response to treatment and tumor 
aggressiveness to be affected by tumor microenvironment differences and microbial load (Iida et al. 2013, 
Vetizou et al. 2015) which can help unravel the factors involved in racial differences.  
Epidemiological data has shown that lifestyle and behavioral risk patterns influence the variation in 
incidence and mortality observed in racial and ethnic minorities and explain in part racial related 
disparities (Gourin and Podolsky 2006, Curtis et al. 2008, Kagawa-Singer et al. 2010, Iqbal et al. 2015, 
Ha et al. 2016). Data from migrating populations, like the Multiethnic Cohort study, has provided evidence 
regarding inter-ethnic variability of cancer risk due to of lifestyle, behaviors and exposures as exemplified 
by the rates of cancer of Japanese migrants in Hawaii that resemble those of their host rather than the 
country of their birth (Kolonel, Altshuler, and Henderson 2004, Setiawan et al. 2016). Lifestyle & 
behavioral risk patterns such as diet, sex behavior, smoking and alcohol consumption can alter epigenetic 
expression where exposure and susceptibility by cancer type vary among different ethnic groups. These 
play an important part in the continuum of carcinogenesis affecting tumor biology, genetic and epigenetic 
expression patterns and difference of exposure to cancer-causing infectious agents which dominate the 
cancer burden in racial and ethnic minorities un the United States.  
Tumor biology including aggressiveness and differences in exposure to cancer-causing infectious agents 
are a contributory factors in themselves and explain portion of the persistent racial related cancer 
disparities in the United States. There is evidence that prevalence of cancer subtypes have distinct and 
varied patterns within ethnic minorities and likely contribute to more aggressive tumors and poorer 
outcomes in breast, prostate and colorectal cancers (Newman 2017, Newman and Kaljee 2017, Yamoah 
et al. 2015, Chen et al. 1997). Exposure to cancer causing agents are also likely to affect tumor biology 
and is an area of active exploration aside from being a recognizable major risk factor for many of the most 
common cancers. Yet, differences in overall know risk factors for infection- associated cancers do not 
explain racial disparities and much is still to be explored (Setiawan et al. 2016). Disparities in these 
cancer types can be influenced by the prevalence of infectious agents among minority groups and ethnic 
subgroups (Siegel et al. 2015, Torre et al. 2016). Burden of infection-associated cancers depends on 
endemic status and access to preventive and therapeutic means as well as the interplay between 
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behavioral and other environmental factors which predispose racial and ethnic minorities at a greater rate 
(Setiawan et al. 2016).  
2.1.5.1 Impact of the microbiota in racial related disparities 
Recent renewed interest has recognized the microbiome as an important contributor in cancer although 
its role is still unclear. It has been postulated that bacterial community may alter host gene expression 
that could shed light into racial disparities. For example, Cao et al. (2016) examined viral presence across 
23 cancer types and observed that HHV-4 and hepatitis B virus genotypes variants were associated with 
ethnicity in liver hepatocellular carcinoma and stomach adenocarcinoma among Caucasian and Asian 
TCGA cohorts (Cao et al. 2016).  According to Cao et al. (2016) amino acid distribution of the viral 
variants separated the Asian ethnic cohorts into distinct groups which provides additional opportunities in 
the pursuit to understand and eliminate cancer racial disparities and personalized medicine. 
Understanding the complexity of the interactions between screening utilization, behavioral risk patterns, 
tumor biology and differences in exposure to cancer-causing infectious agents and how other potential 
contributory factors, like the very important microbiome, may play an active role in pathogenesis are key 
to reducing and eliminating racial-cancer disparities. In the United States out of the top leading causes of 
cancer 
Figure 4 Potential impact of the microbiota in racial related disparities 
 
Venn diagram showing theoretical intersection between known factors of racial related disparities, infectious 
etiological factors and unknown causes of cancer. Fraction may be explained by pathogen interactions with host as a 





incidence and mortality, several have both a great proportion of unknown causes and notable racial 
differences (Siegel, Miller, and Jemal 2018) while others have a great proportion of attributable or 
suspected microbiological infection etiologies with known racial related differences (Parkin 2006, 
Plummer et al. 2016). It is not impossible to think that a portion of the unknown causes impacted by racial 
related differences may be explained by the microbiological attributable causes (Figure 4). Several 
authors have addressed common biological and non-biological contributory factors for the widening racial 
disparities in cancers of the breast, prostate, lung, stomach, liver, cervix, head & neck and kidney racial 
disparities.  Others have addressed potential microbiological effects in clinical presentation, 
aggressiveness and outcomes of these cancers. Very few have addressed the potential role of 
microbiological infections in racial disparities.  While contributory factors to racial disparities are beyond 
the scope of this work, here we briefly discuss cancer specific known racial differences in disease 
outcomes attributed to a combination of biological and non-biological factors and recent discoveries to 
further understand potential impact of the microbiota in racial-related differences.  
2.1.5.1.1 Breast 
Breast cancer one of the leading causes of cancer incidence and mortality among females in the United 
States with 268,600 cases and 41,760 deaths each year (Siegel, Miller, and Jemal 2018).  Breast cancer 
is classified into four classes, Luminal A, Luminal B, HER2-type enrichment, and basal like, with several 
subtypes based on the estrogen receptor, gene expression and molecular characteristics of the tumor 
(Cancer Genome Atlas 2012). There is clear evidence of differential distribution of breast cancer 
classes/subtypes by racial and ethnic groups with impact on racial disparities in disease burden and 
patient survival.  For example, African American and Hispanic females are more likely to be diagnosed 
with the basal like triple negative (estrogen receptor, progesterone receptor, and human epidermal growth 
factor negative, TNBC) breast cancer compared to Caucasian American and Asian American females 
(Howlader et al. 2014, Sturtz et al. 2014). Yet, when considering age and socioeconomic factors, 
Caucasian American and Hispanic females are at equal risk of being diagnosed with TNBC (Parise and 
Caggiano 2017). However, African American females have higher probability of dying from breast cancer 
overall (Siegel, Miller, and Jemal 2018, DeSantis et al. 2016). Compared to Caucasian American, Asian 
American females have historically lower risk for breast cancer, although true risk may be obscured by 
data aggregation of ethnic subgroups. In fact, invasive breast cancer is the most commonly diagnosed 
cancer among Asian American females with Native Hawaiian females’ rates similar to Caucasian rates. 
According to the Multiethnic Cohort Study, piloted by the Universities of Hawaii and California, highest 
incidence rates are experienced by African American, Japanese, Caucasian American and Native 
Hawaiian with the latter experiencing the highest rates (Kolonel, Altshuler, and Henderson 2004). 
Differential distribution of breast cancer classes/subtypes and incidence and mortality patterns among 
Asians in the United States vary widely across ethnic subgroups. In a study by Telli et al. examining the 
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population-based distribution of breast cancer subtypes among Asian ethnic groups in California, it was 
found that four out of six examined ethnic subgroups, Korean, Filipina, Vietnamese and Chinese females 
were at significantly increased risk of being diagnosed with HER2-positive subtypes compared to 
Caucasian American females (Telli et al. 2011). These breast cancer subtypes, TNBC and HER2-positive 
are known to be more aggressive and have poorer survival outcomes among racial minority groups even 
after controlling for known risk factors (Parise and Caggiano 2017, Telli et al. 2011, Parise et al. 2009). 
Molecular characterization of breast cancer has discovered distinct genetic and epigenetic abnormalities 
with distinct clinical manifestations within each subtype including hypomethylation and high expression of 
DNA repair proteins in basal like breast cancer, high expression of EGFR and HER2 in HER2-type breast 
cancers, and differential estrogen signaling in RPPA reactive Luminal A and Luminal B breast  cancer 
subtypes (Cancer Genome Atlas 2012) Coincidentally, estrogen metabolism has been associated with 
tumor microbial diversity (Chan et al. 2016, Xuan et al. 2014). Microbial dysbiosis also affects estrogen 
levels increasing risk and promoting oncogenesis correlating with gene expression levels, glucoronidation 
of estrogen, and tumor growth pathways (Chan et al. 2016, Xuan et al. 2014, Thompson et al. 2017). 
Presence of pathogenic and commensal microorganisms including virus, bacteria and parasites have 
been found to differentiate TNBC into distinct subtypes (Banerjee et al. 2015, Banerjee et al. 2018)which 
could assist with diagnostics. Recent studies have found an association between HPV or EBV viral 
prevalence and tumor progression, aggressiveness and prognosis (Piana et al. 2014, Huo, Zhang, and 
Yang 2012). Although association remains controversial, positivity could be indicative of ethnic 
differences. Bacteria are also implicated in the modulation of the host inflammatory response suppressing 
and/or activating production of pro-inflammatory cytokines and microbial derived signals (Chan et al. 
2016, Xuan et al. 2014). Pro-inflammatory cytokines including resistin and IL-6 and other genetic factors 
have been implicated in African American persistent breast cancer racial disparities (Deshmukh et al. 
2015). Microbial community has been observed to produce probiotic effects in certain breast cancer 
subtypes by enhancing host immune defenses through activation of toll like receptors such as TLR5 by 
Sphingobium yanoikuyae (Chan et al. 2016).  Is apparent that microbial community composition and 
individual species can be beneficial or detrimental factors in pathogenesis hinting at their functional 
relevance and potential benefit in the understanding of racial related cancer disparities and the pursue to 
eliminate them.  
Banerjee et al. (2015) recently described microbial signatures patterns of co-occurrence in the breast 
microenvironment among four breast cancer types including triple negative (Banerjee et al. 2015, 
Banerjee et al. 2018). The study identified two distinct microbial clusters with four subgroups based on 
viral, bacterial fungal and parasitic signatures in triple negative breast cancer. It is interesting to note that 
triple negative breast cancer, which is biologically more aggressive than other breast cancer types, shows 
significant racial disparities for women of West African ancestry (Jiagge et al. 2016, Newman 2017). This 
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is an important feature that could be indicative of pathogen-host co-evolution and transgenerational 
inheritance of oncogenic mutations with impact on racial related cancer outcomes. 
2.1.5.1.2 Prostate  
Despite the recent drop in prostate cancer incidence rates it remains the second most common cause of 
cancer mortality among men (Siegel, Miller, and Jemal 2016, 2018, DeSantis et al. 2016). Prostate 
cancer accounts for an estimated 164,690 of new cancer cases and 29,430 of cancer deaths in the 
United States each year (Siegel, Miller, and Jemal 2018). There are approximately seven subtypes 
defined by specific gene fusions with varied androgen receptor activity and epigenetic profiles (Cancer 
Genome Atlas Research 2015, Steele et al. 2017). African American males are twice more likely to 
develop and die from prostate cancer than Caucasian American with poorly understood risk factors 
(DeSantis et al. 2016). There is conflicting evidence on the association of race and the receipt of 
treatment, treatment outcomes, overall and disease specific mortality (Shavers and Brown 2002). 
Prostate cancer specific death disparities have narrowed while overall cancer survival disparities in 
prostate cancer patients remain (Steele et al. 2017). In a recent cohort study evaluating potential risk 
factors and clinical relevant variables among 7307 prostate cancer patients and 432 documented prostate 
cancer specific deaths, Williams et al. (2018) found that after adjusting for treatment and potential 
attributable risk factors racial disparities persist in prostate cancer specific mortality among African 
American males (Williams et al. 2018).  Even though disparities are palpable in relation to Caucasian 
American, attributable factors remain elusive thought to be related to unequal treatment, behavioral risk 
patterns and tumor biology. Recent studies looking at the molecular basis of racial disparities point out to 
the interaction between genetics and epigenetics in prostate cancer expressed phenotypes and clinical 
outcomes from androgen biosynthesis and metabolism (Li et al. 2013, Karakas et al. 2017).  It has been 
noted that African American males have higher levels of sex hormones with a dynamic and rapid decline 
in testosterone levels compared to Caucasian American (Hu et al. 2015, Xu et al. 2015). Interestingly, the 
microbial community has the ability to alter androgen and estrogen hormone levels directly or indirectly 
through genetic alterations impacting tumor aggressiveness and has been the focus of multiple efforts 
(Cavarretta et al. 2017, Yow et al. 2017, Cohen et al. 2005, Sfanos et al. 2008, Yu et al. 2015, Golombos 
et al. 2018). Characterization of the prostate microenvironment has identified differences in the microbial 
community composition between prostate tumor tissue and non-tumor specimens, delineating potential 
interaction and molecular mechanisms that may contribute to disease progression and the observed 
racial differences in prostate cancer (Cavarretta et al. 2017, Yow et al. 2017, Karakas et al. 2017, Kumar 
et al. 2018, Porter et al. 2018). These findings collectively can have direct impact in the pursuit to better 
understand and eliminate disparities not only for incidence, but also in disease outcomes. 
2.1.5.1.3 Lung 
Lung cancer is the number one cause of cancer related death in the United States. In 2018, 25.3% of all 
cancer deaths were attributed to the disease (Siegel, Miller, and Jemal 2018). Incidence and mortality 
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rates are higher among males compared to females for all racial and ethnic groups higher among African 
American compared to non-Hispanic Whites (SEER Cancer statistics 2018). Smoke exposure is the major 
risk factor for cancers of the lung, yet does not account for all lung cancer deaths and a fraction remains 
unexplained highlighting the importance of other exposures (CDC 2018). In non-smokers, suggested risk 
factors involve exposures to chemical and biological agents. Factors affecting racial disparities among 
lung cancer patients include geographic variations, baseline comorbidities and stage at diagnosis. 
Likewise these only explain up to 32% of the observed racial differences (Karanth et al. 2018) and much 
remains unknown. Tumor molecular characteristics have been postulated as possible contributory factors 
in differences particularly among African American and Caucasian counterparts. A recent study of the 
molecular landscape of cancer revealed that in non-small cell lung adenocarcinoma, BRAF was mutated 
at a higher frequency and in squamous cell carcinoma programmed death ligand 1 (PD-L1) expression 
tended to be lower in African Americans compared to Caucasians  (Heath et al. 2018). Microbial 
dysbiosis may also be correlated with lung cancer development and could explain some of the observed 
variation. Several studies have linked viral, bacterial and parasitic agents to lung cancer initiation and 
progression. EBV, HPV and MCV viruses have been associated with lung cancer patients from Asia (De 
Paoli and Carbone 2013). Chlamydia pneumoniae has also been implicated in the development and to 
contribute to lung metastasis by several studies (Pevsner-Fischer et al. 2016).  Coincidentally, Chlamydia 
pneumoniae seropositivity has been associated with race, where non-White and non-Black lung cancer 
patients are more likely to have high titers (Mager 2006). However, little is known about the lung 
microbiome, the evidence is limited and conflicting. Despite limited evidence microbial dysbiosis may be 
an active participant in lung cancer and perhaps a contributory factor in racial differences with clinical 
importance that should be further explored. 
2.1.5.1.4 Stomach 
Gastric cancer is the third leading cause of cancer related deaths with approximately 1,033,701 new 
cancer cases diagnosed throughout the world in 2018 (GLOBOCAN at gco.iarc.fr). Despite continued 
decrease in incidence and mortality rates, Asian Americans and Native Hawaiians show striking 
disparities in incidence being twice as likely of being diagnosed with gastric cancer compared to Non-
Hispanic whites (Siegel, Miller, and Jemal 2018). Among Hispanic men incidence is 60% higher 
compared to non-Hispanic whites males while remaining similar to that of other aforementioned minority 
racial and ethnic groups for Hispanic females (cancer.org). Studies have revealed that differences in 
tumor biology and infectious etiology contribute to observed differences including Helicobacter pylori 
strain cytotoxin-associated gene A (Cag-A) and vacuolating cytotoxin A (Vac-A) variation and stomach 
microbiota (Merchant, Li, and Kim 2014, Noto and Peek 2017, Brawner et al. 2017). Gastric cancer and 
Helicobacter pylori contribution to cancer progression is one of the best studied bacterial infection 
associated cancers, although the actual mechanisms remain largely elusive (Chang and Parsonnet 2010, 
Parsonnet et al. 1993). Recent advances in sequencing technology have permitted elaboration on the 
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role of not only Helicobacter pylori, but the contribution of gastric microbiota to cancer pathogenesis and 
their role in the observed differences in different population groups. These have largely concentrated in 
the gastric environment of cancer patients. Recently, Yu et al evaluated the microbiota of gastric cardia 
adenocarcinoma tumor and non-tumor tissue paired samples and found that gastric microbiota as a major 
risk factor Helicobacter pylori relative abundance was significantly higher in patients without family history 
of cancer compared to patients with family history and was associated with tumor grade (Yu et al. 2017). 
There is also a fair body of literature on the role of HHV-4 on gastric cancers. 
2.1.5.1.5 Colon and rectal  
Despite improved prevention strategies and the recent decrease in mortality, colorectal cancer continues 
to be the second leading cause of death in both men and women combined in the United States (Siegel, 
Miller, and Jemal 2018). Incidence and mortality rates vary by racial and ethnic groups with African 
American and Native American /Alaskan Natives having higher mortality and incidence rates that any 
other groups (Siegel et al. 2015, Torre et al. 2016, DeSantis et al. 2016). African Americans are 20-30% 
more likely to be diagnosed with colorectal cancer than their non-Hispanic White counterparts whereas 
Native American and Alaskan Native groups have marked geographic variations, presumably associated 
to environmental, cultural and behavioral factors (White et al. 2014). American Asian and Hispanic ethnic 
subgroups have 10% to 30% lower incidence and mortality rates with great intragroup variability (Siegel 
et al. 2015, Torre et al. 2016). Although racial disparities have often been attributed to health behaviors 
and socioeconomic status, the causes for racial disparities in colorectal cancer are of great exploration 
and debate (DeSantis et al. 2016). Studies suggest that ethnic differences in dietary habits and the 
interactions with gut microbiota lead to non-transient effects in the intestinal lumen and differential 
expression of microbial genes or bacterial metabolites in the colon tissue that leads to the accumulation 
of insults (Kostic et al. 2013, Moore and Moore 1995, Wu et al. 2011). This provides evidence of the 
potential role of microbes in cancer related differences in this multifactorial disease. Recently, microbial 
dysbiosis has been identified to play a potential role in racial related differences in African American 
colorectal cancer patients (Goyal et al. 2016, Farhana et al. 2018). For example, Farhana et al. (2018) 
examined diversity and abundance of microbial composition in African American and Caucasian 
American colorectal cancer patients and found distinct bacterial composition among the groups. African 
American had a greater proportion of unique operational taxonomic units, while Caucasian American had 
greater diversity. There were significant differences in the ratio of Bacteriodetes to Proteobacteria species 
at the phylum level in African American patients compared to their Caucasian counterparts.  
2.1.5.1.6 Liver  
Liver cancers are the second most common cause of cancer in the globe. In the United States liver and 





Table 3 Microbes associated with cancer pathogenesis and potential role in racial related disparities 
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-Higher incidence among 
Asian, Native Hawaiian and 
other Pacific Islander 
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Hernandez 2014  
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associated pathogens 
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Table lists currently known and suspected microbial agents associated with cancer pathogenesis or have been identified as common causes of infection in cancer 
patients which disproportionately impact patient outcomes. Asian, Native Hawaiian and other Pacific Islander subpopulations include Asian Indian, Cambodian, 
Chinese, Filipino, Hmong, Japanese, Korean, Pakistanis, Vietnamese, and those from native origins to Hawaii, Guam, Samoa and other Pacific Islands living in 
the United States. Hispanic subpopulations include Mexican, Cuban, Puerto Rican, South and Central Americans, Dominican and other ethnic groups from 





American and Asian American compared to their White counterparts (Siegel et al. 2015, Torre et al. 
2016). Striking differences are observed within the Hispanic and Asian American ethnic subgroups 
(Siegel et al. 2015, Torre et al. 2016). Ha et al.  (2016) reported that although those of Asian descent 
have the highest incidence rates of hepatocellular carcinoma, about 36% increase incidence was 
observed among those of Hispanic origin (Ha et al. 2016). Studies have found that liver cancer disparities 
are consistent with global variations in hepatitis infection burden and binge drinking among these groups 
(Siegel, Miller, and Jemal 2018, Global Burden of Disease Cancer et al. 2015, Singh, Siahpush, and 
Altekruse 2013). Yet, marked differences remain after controlling for known factors which warrants the 
need to identify potential co-factors in racial disparities (Setiawan et al. 2016). Recently, it has been 
suggested that gut microbiota may play a role in the development and progression of liver malignancies 
driven by altered metabolism of nutrients, bacterial metabolites and aberrant DNA methylation (Henao-
Mejia et al. 2013, Hattori and Ushijima 2016). In animal studies a distinct altered gut microbiota was 
associated with progression of liver disease. Xie et al. (2016) found significant alterations in the 
composition and co-occurrence of several bacterial species including Aropobium, Bacteroides, 
Clostridium and Desulfovibrio species where their composition was correlated with levels of bacterial 
polysaccharides and pathophysiological characteristics (Xie et al. 2016). In human studies an altered 
microbiota has been found in liver hepatocellular carcinoma cases with high levels of Escherichia coli and 
other gram-negative bacteria along with reduced levels of Lactobacillus, Bifidobacterium and 
Enterococcus species (Grat et al. 2016).  
2.1.5.1.7 Cervix  
Cervical cancer is one of the few cancers known to have nearly 100% attributable infectious etiology and 
marked disparities (Plummer et al. 2016). Incidence and mortality rates have significantly declined 
between 1992 and 2015 (Siegel et al. 2015, Torre et al. 2016, Siegel, Miller, and Jemal 2018, DeSantis et 
al. 2016). In the United States there are 13,240 cases (0.8% of all cancer cases) and 4,170 deaths (0.7% 
of all cancer deaths) each year (SEER data).  Still, females living in rural areas have double the risk of 
dying from cervical cancer than females living in urban areas with definite geographical and racial 
patterns (Singh 2012, Rauh-Hain et al. 2018, Zahnd, Fogleman, and Jenkins 2018). Females living in 
rural areas have been found to have 15% to 20% higher mortality rates than their matched counterparts 
in urban areas (Singh 2012). Persistent racial differences remain among African American, Asian 
American, Native American and Hispanics.  African American and Native American are at greater risk of 
cancer specific deaths compared to Caucasian females living in rural areas (DeSantis et al. 2016, Zahnd, 
Fogleman, and Jenkins 2018, Rauh-Hain et al. 2018). Cancer related disparities have been associated to 
rates of HPV exposure (Zahnd, Fogleman, and Jenkins 2018). Zahnd et al. (2018) assessed rural-urban 
disparities by cancer stage with racial and ethnic stratification revealing that rural Non-Hispanic 
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Caucasian females have higher rates of HPV related distant stage cancers. This makes evident the 
exposure differences that may point to the interplay between biological and environmental influences 
among racial and ethnic groups and role of co-factors. Cofactors may enhance susceptibility of certain 
populations to cervical cancer after HPV infection. Chlamydia trachomatis co-occurrence in cervical 
cancer for example, has been found to be an independent predictor and carcinogenic co-factor for racial 
disparities for the observed differences in urban vs. rural dwellers (Zhu et al. 2016). 
2.1.5.1.8 Head & Neck  
Squamous cell carcinomas of the head and neck are a heterogeneous group of cancers categorized by 
the area in which they begin collectively known as head and neck squamous cell carcinoma (cancer.gov). 
It is the ninth most common cancer in the United States (Siegel, Miller, and Jemal 2018). It accounts for 
3% of new cancer cases with marked racial differences in mortality and late stage presentation (Siegel, 
Miller, and Jemal 2018). African American have the highest distant rate for HPV associated oral cancers 
(Zahnd, Fogleman, and Jenkins 2018). Several factors contribute to observed racial differences including 
socioeconomic status, access to care, exposures and biological factors (Daraei and Moore 2015, Ragin 
et al. 2016). Differences in outcomes may be attributed to a combination of these (Ragin et al. 2016). 
Recent studies have identified HPV as an etiological agent for oropharyngeal and invasive laryngeal 
cancers (Tanaka et al. 2018, Hernandez et al. 2014). Infection status has been suggested as a biomarker 
in the interplay of racial disparities. In a study of 87 African American head and neck cancer patients and 
261 matched age and smoking status white patients, Ragin et al, found that when stratifying by HPV 
status significant differences remained among African American and their white counterparts for tumors of 
the larynx (HR 3.36 95%CI 1.62-7.0) after adjusting for socioeconomic status and other confounding 
variables (Ragin et al. 2016). Contributions from other microbes have been suggested. Changes in 
microbial oral communities have been postulated as risk factors and can be used as biomarkers for pre-
cancerous lesions and cancer progression (Schmidt et al. 2014, Wang et al. 2017) Microbial shifts have 
been detected where significantly reduced Firmicutes and Actinobacteria phyla have been observed in 
tumor tissue compared to adjacent normal or non-cancerous normal controls by several teams. Similar 
microbial associations have been observed at the phylum level in Chinese and American population 
samples and it remains to be seen if inter-individual racial variation lays at the genus or species level (Bik 
et al. 2010).  
2.1.5.1.9 Kidney 
Native American and Alaskan Natives have higher incidence and mortality rates of renal cancers than 
other racial or ethnic groups (Batai et al. 2018, Li et al. 2014). Despite overall reduction in renal cancers 
among Caucasian, rates for Native American and Alaskan Natives have remained steady (Li et al. 2014).  
Li et al. (2014) reported that between 2001 and 2009 incidence rate significantly increased for Native 
American and Alaskan Natives compared to Caucasian with an annual percent change (APC) of 3.5% 
versus 2.1% per year respectively (NA/AN 95%CI =1.2, 5.8; white 95%CI = 1.4,2.8) (Bray et al. 2012). 
31 
 
Hispanics also suffer from a disproportionate burden of renal cancers with striking geographic-regional 
differences. The burden is also higher among men for both Native American and Alaskan Natives and 
Hispanics populations (Batai et al. 2018). Risk differences between ethnic groups may be explained by 
common attributable factors including behavior, socioeconomic status, obesity, smoking and presence of 
comorbidities (diabetes or cardiovascular disease), factors that have been linked to microbial dysbiosis. 
However, sex and treatment response differences cannot be explained by the same factors and remain a 
mystery with few hypothesis on the potential microbial effects on immunosurveillance mechanisms and 
therapeutic response (Scelo et al. 2017, Pevsner-Fischer et al. 2016). In a retrospective study, prior 
urinary tract infection was associated risk of developing malignancy with similar proportions on renal 
cancer incidence related to behavioral exposures (smoking and alcohol consumption) and sex differences 
in those infected versus non-infected history (Parker et al. 2004). Although there is limited evidence on 
the microbial compositional structure of the renal cancer tumors and the potential long term effects, 
several studies have now identified differences in microbiota of the urinary tract of healthy individuals that 
may impact renal cancer pathogenesis and help explain differences in sex and race (Lewis et al. 2013).  
2.1.6 Summary 
Cancer is the second leading causes of death in the United States. One in five cancer cases is attributed 
to infectious agents around the world. The divergent relationship of tumor microbiota in cancer 
pathogenesis was discussed along the potential impact of microbiological agents on racial related 
disparities in cancers of the breast, prostate, lung, colorectum, liver, cervical, head and neck, and kidney. 
A considerable proportion of these cancer cases are of unknown etiological that underscore the 
importance of understanding the interplay of contributory factors such as microbial contributions. Recent 
studies have evaluated the microbial content and its influence in cancer pathogenesis. Few have 
identified racial related differences attributable to microbial dysbiosis. Given the close interaction of 
microbes with host immune reaction and the metabolite degradation “it is naïve to believe that our 
microbiome has no impact carcinogenesis” and thus possibly in the observed racial variations which can 
benefit or negatively impact people from certain racial and ethnic groups. Examination of the potential role 






2.2 Identification of Racial-Related Microbial Differences across                                                        
Cancers Derived from Human Sequencing Data 
 
2.2.1 Abstract 
Microbiological infections account for up to 25% of the total global cancer burden, one of the leading 
causes of morbidity and mortality worldwide. Racial-disparities persist in infection-associated cancers. 
Underlying causes for racial disparities are multifactorial and not all well understood. Recent evidence 
points out the potential role of microbial composition in racial-related disparities. While much effort has 
gone into the characterization of the gut microbiota, the microbial compositional differences of tumor 
tissue is less explored. Identification of tissue-associated microbial differences is challenging and 
computationally intensive. New opportunities are becoming available with newer bioinformatics tools and 
merged data networks. Computational frameworks can assist in the interpretation of the microbial impact 
on tumor tissue, cancer pathogenesis and possible roles behind racial-related cancer disparities. Here we 
review current computational frameworks designed to derive microbial information from host-sequencing 
data, along with a brief discussion of post-processing tools which can inform our understanding of racial-
related differences in cancer.  
2.2.2 Introduction 
Cancer is one of the leading causes of morbidity and mortality worldwide.  Annually an estimated 18.1 
million are diagnosed and 9.6 million die from the disease globally (WHO 2018). There is evidence that 
infection may contribute to cancer burden and cancer disparities (Siegel et al. 2015, Torre et al. 2016, 
Deshmukh et al. 2017, Wallace, Martin, and Ambs 2011). Determinants of racial-related disparities are 
complex involving environmental, social, behavioral, cultural and biological cofactors impacting 
development, progression and clinical outcomes of cancers. Recent evidence highlights the importance 
and possible role of the altered microbiota in cancer development, treatment response, and racial 
disparities (Hattori and Ushijima 2016, Goyal et al. 2016, Pevsner-Fischer et al. 2016). Unbiased 
evaluation of microbial patterns across various cancer types may elucidate their role. Characterization of 
the microbiota and its impact on racial-related disparities is challenging and computationally intensive. 
These can be simplified by integrated analyses approach incorporating epidemiological and clinical data 
with microbial compositional characterization, as well as post-process identification of functional relevant 
alterations. Here we briefly review bioinformatics frameworks designed to derive microbial information 
from host-sequencing data and post-processing pipelines designed to identify functional prediction of the 
tumor microbiota as part of integrated approach to understand microbiota impact on racial related 
differences.   
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2.2.3 Infectious disease burden and cancer disparities 
According to the World Health Organization (WHO), microbiological infections account for approximately 
25% of the total global cancer burden (WHO 2018). Infection-associated cancers are commonly attributed 
to viruses including human herpes virus 4, hepatitis B virus, hepatitis C virus, human immunodeficiency 
virus 1, human papilloma virus, human T-lymphotropic virus and herpes virus (IARC 2012). Parasitic 
infections casually linked to cancers include Clonorchis sinensis, Opisthorchis viverini and Schistoma 
haematobium liver flukes (IARC 2012).  Only one bacterial agent, Helicobacter pylori, is affirmatively 
linked to cancer although the burden is substantial with over 1/3 of infection related cancers attributed to 
the bacterium (de Martel et al. 2012, Bouvard et al. 2009, Cogliano et al. 2011). Figure 5. A perturbation 
to the microbial community or the microbiome-host relationship, known as dysbiosis, is widely recognized 
to be a contributing factor in the promotion of disease including cancer (Human Microbiome Project 2012, 
Schwabe and Jobin 2013). Microbial contributions to racial-related disparities in cancer pathogenesis are 
not well understood. Evidence points to possible contribution of infection burden to cancer disparities 
(Sobhani et al. 2011, Zhu et al. 2016, Hernandez et al. 2014, Setiawan et al. 2016).  Therefore, 
characterization of microbial profiles of precancerous and cancerous tissue may revolutionize our 
understanding of cancer pathogenesis and disparities.  
Understanding the complexity of the interactions between commonly identified racial disparities 
contributing factors and exposure to cancer-modulating microbial organisms are key to reducing and 
eliminating racial related disparities. Several studies have evaluated the microbial content and its 
influence in cancer pathogenesis, most have concentrated in gut and oral microbiome, and few have 
identified racial related differences attributable to microbial dysbiosis (Contreras et al. 2016, Schmidt et al. 
2014, Farhana et al. 2018). To our knowledge no work to date, addressing racial differences in the 
microbial composition within the tumor and adjacent tissue microenvironment has been conducted. In 
fact, in recent high throughput sequencing microbial analyses, aside from the histopathological 
descriptions, most do not describe patient population demographics beyond age and sex if mentioned. 
Table 4. Two teams, Cao et al. (sequencing data) and Farhana et al. (colonic effluent) have described 
racial differences in their work. Given the close interaction between microbes and the host responses it is 
important to clearly identify compositional structure and clinically relevant functional pathways with an 
integrated approach. Interpretation of compositional difference contributions is facilitated by new 
sequencing technologies and various computational frameworks some which we review briefly here. 
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Figure 5 Proportion of infectious agents responsible for cancer incidence in both cases worldwide 
 
Cancer cases (all infectious agents) among both sexes attributable to infections shown by infectious agents’ proportion 
of attributable fraction. Helicobacter pylori, a bacterium, is attributed to1/3 of the total global burden. Data source: 
Plummer, de Martel et al. (2016). Chart created through GLOBOCAN interactive (gco.iarc.fr). 
 
2.3.4 Microbial detection in high throughput sequencing data  
Next Generation Sequencing (NGS) also known as high-throughput sequencing technologies provide a 
powerful tool for the evaluation of the role of microbes in cancer development and progression as well as 
disparities across populations. NGS is a useful and unbiased tool for the identification of previously 
undetected or unsuspected causative microorganisms in molecular diagnostics (Daly et al. 2015). It has 
become vital and necessary to the integrative analysis of cancer biology enabling description of the 
mutational and molecular landscape of cancer (Reuter, Spacek, and Snyder 2015). This technology, 
however, produces relatively short reads that limits interpretation. NGS has driven the development of 
new alignment algorithms designed to handle short reads, which in turn has revolutionized the 
understanding of the relationship between genomic variation and phenotype (Reuter, Spacek, and Snyder 
2015, van Dijk et al. 2014). Integrative techniques take advantage of the production of short reads and 
predominance of host-derived sequences to examine pathogen-host interaction including their correlation 
with metabolic and regulatory mechanisms in cancer (Marchesi et al. 2011, Warren et al. 2013, Schmidt 
et al. 2014, Contreras et al. 2016, Arthur et al. 2014, Cristescu et al. 2015, Wang et al. 2017). Several 
studies have examined microbial comminutes (tumor microbiome, gut microbiome, oral microbiome, 
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virome and bacteriome) in cancer populations by high throughput sequencing methods. Table 4. Taken 
together these studies have provided much needed information about microbial diversity, richness and 
abundance variations, across healthy and cancer states. In addition, they afford the opportunity to 
evaluate microbial profile and its correlation to the clinical features. Although establishment of a causal 
relationship requires a more detailed characterization of the human microbiome and microbial population 
dynamics; host-microbial sequencing and integration of clinical and epidemiological data can provide 
valuable information to the understanding of the role microbiota plays in cancer pathogenesis and cancer 
disparities.  
2.2.5 Racial disparities in high throughput sequencing data  
Racial and ethnic groups are underrepresented in some sequencing efforts. Underrepresentation of 
ethnic minorities may also impact interpretation of results from sequencing data. The low representation 
of racial minorities in sequencing efforts may limit the ability to discern population differences in 
mutational frequency (Spratt et al. 2016). According to Spratt et al. (2016) the ability to detect mutations 
in a subpopulation with enough power, depends on the mutational frequency of the background and the 
mutational rate of the target as well as the absolute sample size (Spratt et al. 2016). Recently, Zhang et 
al. (2017) estimated racial disparities in cancer incidence rate, the effect of race on survival and mutation 
burden within TCGA cancer cohorts (Zhang et al. 2017). Racial disparities in cancer incidence, survival, 
and/or tumor mutation burden were observed for bladder urothelial carcinoma, glioblastoma multiforme, 
head and neck squamous cell carcinoma, kidney renal clear cell and papillary carcinoma, lung 
adenocarcinoma and squamous cell carcinoma, ovarian serous cystadenocarcinoma, uterine corpus 
endometrial carcinoma, colon adenocarcinoma, hepatocellular carcinoma and stomach adenocarcinoma 
(Zhang et al. 2017). Similarly, ability to detect microbial differences across racial groups depends on the 
infection and prevalence patterns of the microbe in the background population. This highlights the 
importance of genomic and clinical epidemiological data integration across institutions, particularly of 
catchment areas. Validation against enriched population-based data from catchment areas and clinical 
trials are equally important for meaningful interpretation of microbial detection in cancer particularly when 
looking to address racial-related disparities. Information on race and ethnicity from integrated data 
networks, are typically obtained from self-reported measures, which may introduce bias. In this case, the 
use of ancestral biomarkers may be appropriate to validate self-reported racial/ethnic information and 
understand impact of differential patterns between background and target population on racial disparities. 

















Table 4 Summary of microbial detection in high throughput sequencing data (continued)
 
Table shows studies evaluating microbial comminutes in cancer populations by high throughput sequencing methods.  Microbiome=refers to studies evaluating 





2.2.6 Computational frameworks and microbial detection in cancer 
Data mining high throughput sequencing data using bioinformatics tools and methods provide great 
opportunities in understanding the role of the microbiota in cancer racial-related differences. 
Bioinformatics computational frameworks are able to accommodate user defined parameters and 
deliverables to better understand the basis of biological concepts (Leipzig 2017). Numerous state-of-the-
art bioinformatics tools and methods from data collection to analyses are available today that support 
identification of microbial novel targets in cancer diagnostics, treatment, prevention and control. Several 
studies have demonstrated that pathogenic and commensal microbes can be derived from human cancer 
tissue sequences utilizing various bioinformatics computational approaches and sequential filtering steps 
(Daly et al. 2015, Isakov, Modai, and Shomron 2011, Weber et al. 2002, Xu et al. 2003, Kostic et al. 2011, 
Tae et al. 2014, Salyakina and Tsinoremas 2013). Pathogen detection derived from human sequences 
has been primarily completed by one of three approaches, reference-based or reference-free, or mixed-
methods with one fundamental core pipeline involving the removal of human-host to characterize 
remaining sequencing reads. Pathogen detection algorithms can be classified by the methodology, 
meaning the order in which the human sequencing reads are identified or removed, whether the human 
reads are removed before or after extracting pathogen reads, and what happens to remaining unmapped 
reads. Figure 6. Here, we review bioinformatics computational frameworks designed to identify 
microbiota derived from human sequences by computational subtraction, marker-based filtration, or mix-
methods approaches with applications in human cancer.  Computational frameworks that strictly match 
sequencing reads to pathogen libraries or those designed for direct metagenomics analyses are not 
included. See Noecker et al. and Nooij et al. for an in depth reviews of these tools (Nooij et al. 2018, 
Noecker et al. 2017).  
 
Computational subtraction methods for microbial identification and discovery derived from human tissue 
sequences were first introduced about 15 years ago (Xu et al. 2003, Weber et al. 2002). These early 
approaches involved creation of cDNA library and sequential subtraction of human-expressed sequence 
tags to derive pathogenic and commensal organism information from human disease and were 
computationally intensive. Newer methods take advantage of high throughput data repositories’ 
unmapped-to-human sequences and have lower computational requirements. In high throughput 
sequencing, about 10% of the reads are flagged unmapped to the human genome after alignment, which 
could in part belong to the human microbiome or yet uncharacterized human genome (Tae et al. 2014). In 
fact, this characteristic shortfall provides the basis to multiple bioinformatics approaches (Table 5) which 




2.2.6.1 Reference-Based: Computational subtraction methods are mostly reference-based approaches.  
Reference-based by definition require mapping to a reference, in this case human host genome, then 
allocating all leftover unmapped-to-human reads to pathogen target genomes.  Bioinformatics 
computational frameworks such as PathSeq (Kostic et al. 2011) and SRSA, short RNA subtraction and 
assembly (Isakov, Modai, and Shomron 2011), consider unmapped-to-human sequencing reads as input 
data and are able to lower computational costs while facilitating novel discoveries.  
 
Figure 6 Generic pipeline of computational frameworks designed to identify microbial reads from human 
derived sequences 
 
Figure shows generic pipeline divided into 5 general steps, quality filter pre-process, map, alignment and assembly 
match (match processing), identification & classification (quantitation processing), microbial output processing, and 
microbial analyses with integrated epidemiological and clinical data . During quality filter, sequencing reads are 
trimmed, during the processing steps, reads are mapped and aligned to either human or pathogen reference sequences 
or other key identifying factor before the final steps of identification and analyses of identified sequences. The final 




PathSeq combines alignment and de novo assembly with a two-pass subtraction process (Kostic et al. 
2011).  It aligns the sequencing reads to target genomes and quantify their abundance based on the total 
number of aligned sequencing reads and the genome coverage, enabling identification of both 
commensals and pathogens whether known or novel (Kostic et al. 2011).  However, the two-pass filtration 
process may eliminate a high number of sequences, which can increase filtration costs and limit 
identification.  PathSeq has been utilized in pathogen identification for various infection-associated and 
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inflammation associated cancers types, notably yielding the association between Fusobacterium 
nucleatum with colorectal cancer and Bradyrhizobium enterica in cord colitis (Kostic et al. 2012, Bhatt et 
al. 2013).  SRSA utilizes short RNA mapping and assembly to identify pathogens in relation to host 
sequencing reads (Isakov, Modai, and Shomron 2011).  SRSA has capability for use in microbial 
identification in infection-associated cancers.  However, initial work was limited to mycoplasma detection 
in HIV-1 cell lines and its computational methods are also not freely available.  Unlike SRSA, CaPSID, 
computational pathogen sequence identification (Borozan et al. 2012), is web-based and an open source 
platform, that similar to PathSeq, performs mapping and de novo assembly. CaPSID differs in its single-
pass alignment and filtration process where both human and pathogen reads are aligned to reference 
genomes while separating those that do not match either for de novo assembly simultaneously (Borozan 
et al. 2012).  Its potential in cancer microbial differential analyses was demonstrated by Borozan et al. 
(2012) in STAD-TCGA and stomach adenocarcinoma samples from other cancer networks (Borozan et 
al. 2018). Borozan et al. (2018) evaluated HHV-4 variants to determine oncogenic potential differences 
among samples from different country origins providing evidence of the potential for future studies in 
HHV-4 ethnic and racial differences in gastric cancer.  
 
Similar reference-based computational subtraction methods with potential in cancer microbiome and 
racial differences downstream analyses include PathoScope 2.0 (Hong et al. 2014), SURPI, sequence-
based ultra-rapid pathogen identification (Naccache et al. 2014), VirusScan (Cao et al. 2016) and 
MetaShot (Fosso et al. 2017).  Unlike PathSeq, SRSA and CaPSID, PathoScope 2.0 does not perform de 
novo assembly, instead it utilizes penalized statistical mix-model and probabilistic pathogen identification 
(Hong et al. 2014).  It also provides detailed reports with core and optional module format that enable 
user customization.  A target reference genome must be present for precise identification of microbes. 
PathoScope is designed to identify low abundant strains, making it an ideal tool for host derived microbial 
analyses.  PathoScope is able manage the low abundance relative to human host microbial reads in 
sequencing data. Zhang et al. (2015) incorporated PathoScope 2.0 methods for relative abundance 
estimation with its WGS PathSeq-based microbial detection pipeline in gastric cancer clinical samples, 
Human Genome Project derived and TCGA sequencing samples (Zhang et al. 2015).  SURPI was also 
designed for pathogen detection from clinical samples for surveillance similar to PathoScope 2.0 with the 
capacity for quantitative and semi-quantitative identification; meaning it can perform mapping and de 
novo assembly for divergent microbial analyses (Naccache et al. 2014).  SURPI has been validated 
against samples from colon and prostate cancer derived datasets. VirusScan is also a referenced-based 
computational subtraction approach designed to profile viral composition, abundance and integration sites 
in human tumors utilizing unmapped-to-humans and poorly mapped to human genome reads (Cao et al. 












Table displays computational workflows designed to derive microbial content from human sequences by subtractive and filtering methods broadly categorized as 





cohorts, LIHC and STAD, utilizing VirusScan.  MetaShot is similar to prior mentioned reference-based 
approaches in that it shares a two-step filtration method to identify candidate pathogens; however, is a bit 
more stringent in its taxonomic assignment (Fosso et al. 2017).  This feature enables functional 
annotation with great potential in racial disparities studies. On the other hand, its stringent approach 
comes with higher computational costs and has yet to be validated in cancer datasets.  
2.2.6.2 Reference-Free: Other methods like marker-based approaches utilize pre-defined target genomic 
markers like k-mers, single nucleotide polymorphisms (SNP), or unique tag libraries to identify and retain 
pathogen information while removing human host sequences from further consideration.  Reference-free, 
marker-based approaches such as ConStrains, conspecific strains (Luo et al. 2015) rely on the creation 
of SNP profiles to predict pathogen strains contained within the sequencing sample. However, 
approaches such as this are not completely reference-free, rather minimally reference-dependent (Luo et 
al. 2015). ConStrains infers microbial abundance of conspecific strains utilizing a SNP patterns and de 
novo assembly with prediction estimation based on Metropolis-Hasting Markov Chain Monte-Carlo model. 
Although ConStrains has not been used in cancer genomic data, it has the capability for functional 
analyses which are pivotal in understanding divergent microbial effects in cancer particularly those of 
infectious etiology. 
2.2.6.3 Mixed-method approaches: Mix-methods can be reference-free, like intersection analysis or 
reference-based like in mixture-model approaches, which utilize both reference and marker-based 
methods.  Mixture model approaches differ from traditional computational subtraction in that these either 
map against a pre-determined pathogen reference in sequence (Bhaduri et al. 2012, Fosso et al. 2017), 
against both human and pathogen in parallel (Naeem, Rashid, and Pain 2013), or some combination (Xia 
et al. 2011) of these before filtering out human host sequences. RINS, rapid identification of non-human 
sequences (Bhaduri et al. 2012), uses intersection analysis and pre-defined query reference that include 
genomes of viruses, bacteria or any other pathogen rather than first mapping to the human reference 
genome.  RINS was validated in prostate cancer and has low computational requirements, but can only 
detect the pathogens that are explicitly defined within the query reference. This risks removal of unknown 
sequences and hinders novel pathogen discovery. Mixture model approaches utilize expectation 
maximization algorithms to calculate genome relative abundance of non-host microbial sequences to 
obtain meaningful data of the relative abundances. GRAMMy, genome relative abundance estimation 
framework using mixture model theory (Xia et al. 2011), is a mixture model approach designed to use 
either mapping or de novo assembly in the absence of a reference genome for relative abundance 
estimation at different taxonomic levels. These approaches facilitate identification of pathogens within the 
tumor microenvironment directly from human sequences and streamline functional prediction and 
correlation with epidemiological and clinical features of the population.  
47 
 
2.2.7 Computational pipelines and functional prediction of microbial differences 
Recent work in gut microbiome have revealed the utility of taxonomic differences, epigenetic, heritable 
and co-occurrence patterns in the understanding of racial disparities (Brooks et al. 2018). Microbial 
compositional differences and racial variations have been thoroughly reviewed in Gupta et al. (Gupta, 
Paul, and Dutta 2017). From these and other works we understand that accurate interpretation of 
microbial impact cancer disparities involve more than compositional differences across racial and ethnic 
groups. Functional annotation and prediction of molecular process are equally important in the 
identification of clinically relevant microbial interactions in the human host. Many post-processing tools 
have been developed to translate microbial compositional outputs of the before mentioned tools into 
predicted mechanisms through which microbiome may influence host immune responses, gene 
expression and protein expression. For example pipelines such as PICRUSt (Langille et al. 2013), 
Tax4Fun (Asshauer et al. 2015), and ShortBRED (Kaminski et al. 2015) can assist in the identification of 
functional annotations and in the description of subtle differences across racial and ethnic groups.  
Although these tools are designed to predict functional profiles from 16S rRNA gene derived 
metagenomic data, they have application in human genome sequencing derived microbial profiles when 
used in integrated approaches. PICRUSt (phylogenetic investigation of communities by reconstruction of 
unobserved states) pipeline infers microbial community host-associated functional composition based on 
gene annotation databases such as the Kyoto Encyclopedia of Genes and Genomes (KEGG) reference 
genomes or the Clusters of Orthologs Group (COGs) (Kanehisa et al. 2002). Similarly, Tax4Fun predicts 
the functional capabilities of microbial communities based on 16S rRNA datasets which provide a good 
approximation to functional profiles obtained from metagenomic shotgun sequencing approaches and has 
been successfully used to identify signs of ethnic acculturation in oral microbiota (Hoffman et al. 2018). 
ShortBRED quantifies abundance of functional gene families and predicts protein profiles within the 
sample including antibiotic resistance and virulence factors protein families which are pivotal in the 
understanding of outcome racial-related differences. 
2.2.8 Summary 
There is great diversity present in the human tumor microenvironment that makes identification of the 
microbial community challenging. Sequencing technologies and use of these computational tools permit 
the discovery of new microbes that are non-culturable and would otherwise remain undiscovered (Relman 
1998). Profiling and characterization of the microbial community and functional annotations can provide 
information on the effects of microbiota on colonized tissue, progression of inflammation, alteration of 
cellular processes and effects on tumor promoting genes within the tumor microenvironment. 
Computational frameworks for microbial detection evaluated here are broadly classified as reference-
based or reference-free and mainly utilize computational subtraction, marker-based or mixture 
approaches. Here, we reviewed few bioinformatics computational frameworks, PathSeq, SRSA, CaPSID, 
SURPI, PathoScope, VirusScan, MetaShot, ConStrains, RINS, and GRAMMy which have been used or 
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have potential for such microbial diversity evaluations. These methodologies could help shed light to the 
role of the microbiota in cancer racial related disparities especially in infection associated-cancers.  
Further phylogenic and protein functional predictions from bioinformatics pipelines such as PICRUSt, 
Tax4Fun and ShortBRED among others, provide important clues in understanding microbial differences 
and commonalities as well as the potential impact on differential outcomes. These tools help us better 
understand the role of microbes in cancer pathogenesis and identify differences among ethnic groups. 
Differences in ethnic groups may highlight effectors that impact the treatment decision making process 
and potential for targeted therapies to help reduce or eliminate cancer disparities across the continuum of 
cancer disease.  
2.2.9 Literature Cited  
Located in Appendix E. Literature Cited, complete list, pp. 147  
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CHAPTER III. RESULTS 
 
Results section is divided into two manuscripts, “The landscape of bacterial presence in tumor and 
adjacent normal tissue across tumor types using raw exome sequencing data from The Cancer 
Genome Atlas (TCGA) cohorts,” which describes microbial profiles of a subset of 9 cancer cohorts from 
the TCGA data. The second manuscript is entitled, “Bacterial diversity correlates with survival in 
infection-associated cancers of the head & neck, liver and stomach,” that touches on the correlation 
of microbial co-occurrence in viral associated cancers of the head & neck, liver and gastric which are 





3.1 The landscape of bacterial presence in tumor and adjacent normal tissue across tumor types 
using raw exome sequencing data from The Cancer Genome Atlas (TCGA) cohorts 
 
3.1.2 Abstract 
Objective: Several studies have evaluated the viral composition in human tumors using unmapped to 
human sequencing data, bacterial composition derived from human whole exome sequencing data is less 
explored.  We interrogated bacterial presence in tumor and adjacent normal tissue pairs utilizing whole 
exome sequencing to generate microbial profiles. Identification of microbial composition directly from 
tumor tissue permits studying the relationship between microbial changes and cancer pathogenesis.  
Methods: We screened 4777 whole exome sequencing files from 813 cases within 9 TCGA cancer 
cohorts including carcinomas and adenocarcinomas of stomach (STAD), liver (LIHC), colon (COAD), 
rectal (READ), lung (LUAD) and bladder (BLCA) as well as squamous cell carcinomas of head and neck 
(HNSC), lung (LUSC) and cervix (CESC). Data files were processed through a bioinformatics pipeline 
designed to generate microbial profiles from raw whole exome sequences. Viral DNA presence was used 
as internal validation and for microbial co-occurrence analyses. Diversity metrics were calculated to 
compare taxa within sample, between tumor and its paired adjacent normal and across cancer cohorts. 
Differential abundance was examined using Wilcoxon signed-rank and rank sum tests within each tissue 
type and between tumor and adjacent normal tissue. Bacterial taxa with false discovery rate (FDR) 
adjusted p value < 0.05 were considered significantly different at both genus and species level.  Presence 
of Helicobacter pylori, Fusobacterium nucleatum and Selenomonas sputigena was confirmed by 
quantitative polymerase chain reaction in a cross-sectional fashion with paired tumor and adjacent normal 
formalin-fixed, paraffin-embedded tissue from an independent population from the Hawaii Tumor 
Registry. Results: Microbial profiles for stomach, liver, colon, rectal, lung, head & neck, cervical and 
bladder TCGA cohorts were generated. Several taxa were found to be common across cancer types at all 
classification levels. There was a difference in species richness between tumor and its adjacent normal 
with significant difference observed in alpha and beta diversity metrics.  Conclusion: We demonstrate the 
ability to identify differential composition of bacteria species from human tissue whole exome sequencing 
data. Paired analyses revealed significant differences in bacterial shifts across STAD, LUSC, COAD and 
HNSC cohorts whereas little or no differences were evident in CESC, LUAD, LIHC, READ and BLCA 
cohorts in adjusted models. Profiles are suggestive of microbial shift changes with advanced disease. 
Experimental validation confirmed 60%-80% of the predicted bacterial differential abundances.  Our data 
highlights the importance of analyzing adjacent tissue which can be indicative of cancer stage 
progression and the need to examine both, microbial relative abundance and rate of positivity within the 




Studies evaluating the role of infectious agents in the etiology of cancer have mainly concentrated in the 
possible role of single organisms. Newer studies have examined the role of the gut microbiota in 
gastrointestinal and distant cancers (Grat et al. 2016, Routy et al. 2018, Golombos et al. 2018, 
Gopalakrishnan, Spencer, et al. 2018). Bacteria have been associated with cancer progression exerting 
beneficial or detrimental effects depending on the time and site of the colonization (Nauts 1989, Schwabe 
and Jobin 2013). Their highly site specific colonization enables modulation of the tumor microenvironment 
(Mager 2006, Chang and Parsonnet 2010). Microbial-host dynamics can promote or inhibit host immune 
response (Paulos et al. 2007, Elinav et al. 2013). These changes lead to the accumulation of insults and 
epigenetic changes that can change the course of a developing or established tumor(Hattori and Ushijima 
2016). Evidence demonstrates that infection-associated cancer subtypes are molecularly distinct (Cancer 
Genome Atlas Research 2014, Cancer Genome Atlas 2015), which highlights the importance of microbial 
modulation within the tumor cells. These findings are significant and reveal important microbial patterns 
and mechanistic pathways in host response to cancer. However, these can be limited in that they do not 
examine the microbial community composition directly within the tumor and the surrounding tissue 
microenvironment.  
Microbial presence within the tumor and adjacent tissue can inform disease progression, and bacterial 
roles in cancer pathogenesis (Thomas et al. 2016). Presence information can be derived from human 
whole exome sequencing data (Tae et al. 2014), similar to transcriptomics or metagenomics methods. 
Bioinformatics tools facilitate profiling of tumor virome and bacteriome using human sequencing data in 
the context of cancer-associated pathogenesis (Kostic et al. 2011, Borozan et al. 2012, Naccache et al. 
2014, Hong et al. 2014, Chen et al. 2013). However, most studies extract microbial (viral, bacterial and 
other) using RNA sequencing data. For example, Khoury et al. (2013) interrogated 18 TCGA cancer 
cohorts sifting through 3775 cases to characterize viral DNA presence and integration sites within tumor 
tissue derived RNA sequencing data. Here Khoury described important HPV, HBV and HHV-4 differential 
integration sites across TCGA cancer cohorts and highlighted the utility of RNA sequencing data for 
tumor virome characterization (Khoury et al. 2013). However, this study lacked validation in tumor tissue 
either direct or cross-sectional. Similarly, Tang et al. (2013), examined viral gene expression and host 
fusion, building a viral expression map across 19 of TCGA cancer cohorts using RNA sequencing data 
(Tang et al. 2013). Salyakina et al. (2013), -9 cohorts, and Cao et al. (2016), -23 cohorts, also examined 
viral expression in tumor and normal specimens within TCGA cohorts (Salyakina and Tsinoremas 2013, 
Cao et al. 2016). Cao et al. (2016) demonstrated the ability to identify associations between different viral 
strains and ethnic differences (Cao et al. 2016). These works were all based in RNA sequencing derived 
pathogen information. Cantalupo et al. (2018) on the other hand, examined viral integration using RNA, 
whole exome and whole genome sequencing data across 22 of the TCGA cancer cohorts mapping viral 
prevalence differences and commonalities within the sample population (Cantalupo, Katz, and Pipas 
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2018). None of these experimentally validated their findings. Similar to viral profiling, RNA sequencing 
data has been used for bacterial composition characterization. Riley et al. (2013) examined bacterial DNA 
integration in 852 TCGA tumor and normal specimens (Riley et al. 2013). They discovered significant 
bacterial gene integration within various TCGA cohorts. However the highest integration rates were 
detected in cohorts for which no matched or paired normal sample data was available including stomach 
adenocarcinoma and acute myeloid leukemia (Riley et al. 2013). Robinson et al. (2017) later examined 
potential bacterial contamination across 5 TCGA cohorts including acute myeloid leukemia, breast, 
gliobastoma, ovarian and stomach adenocarcinomas using RNA sequencing data from paired tumor and 
adjacent normal samples (Robinson et al. 2017). It was found that potential contaminants were present 
across all cohorts such as Staphilococcus epidermis, Cutibacterium acnes and Ralstonia species after 
controlling for batch effects (Robinson et al. 2017). Like Riley (2013), Robinson et al. (2017) did not 
include experimental validation. Additional bacteriome identification has been completed. Zhang et al. 
(2015) developed a workflow for the identification of low abundant microbial species using whole exome 
and RNA sequencing data derived from the human genome project based on PathSeq (Zhang et al. 
2015). Zhang offered experimental validation in gastric biopsies and TCGA whole genome sequencing 
data (Huo, Zhang, and Yang 2012). This study demonstrated the ability to identify low abundant microbes 
in relation to host. Other studies examining tumor microbiota derived from human sequences have looked 
at mutation interaction and gene expression associations in one or few cancers. Thompson et al. (2017) 
examined bacteria composition in TCGA breast cancer cohort and associated expression profiles with 
direct 16SrRNA sequencing validation of bacterial presence with samples from whom RNA sequencing 
data had originally been derived (Thompson et al. 2017). Thompson found that bacteria presence 
correlates tumor growth pathway genes. While Greathouse et al. (2018) examined the lung microbiome 
and the association with TP53 mutation using 16SrRNA can confirm findings with TCGA lung cancer data 
(Greathouse et al. 2018). Taken together these studies highlight the feasibility of microbial profile 
identification and functional characterization, however the use of RNA sequencing data may not be the 
best approach at characterizing bacteria signatures. Use of RNA sequencing could amplify cDNA library 
artefacts rather than a true reflection of actual RNA abundance and reflects presence of pathogens that 
are actively being expressed at one specific time (Wang, Gerstein, and Snyder 2009). On the other hand 
whole exome sequencing data represents the gene expression profiles with over 85% of the known 
disease causing variants (Choi et al. 2009). Therefore to identify potential association of bacteria to in 
cancer pathogenesis, whole exome sequencing may provide a better picture.  To our knowledge, no 
works have yet examined cross-cancer microbial composition differential profiling using whole exome 
sequencing data from tumor and adjacent normal in a strict paired design. We interrogated tumor and 
adjacent normal tissue from a paired solid cancers cases from the Cancer Genome Atlas, generating 
bacterial composition across 9 cancer types encompassing 3758 total tumor and adjacent solid tissue 
53 
 
normal samples. To validate results, we performed quantitative polymerase chain reaction (qPCR) in 
selected differentially abundant taxa with an independent sample population. 
 
3.1.4 Results 
3.1.4.1 Identification of microbial sequences in TCGA WXS data  
We generated microbial profiles for 1690 samples representing 813 cases across 9 human cancers within 
the TCGA cohorts. We examined raw whole exome sequencing (WXS) files from 441 STAD, 376 LIHC, 
443 COAD, 168 READ, 502 LUSC, 582 LUAD, 527 HNSC, 305 CESC, and 412 BLCA. Combined, over 
223 billion reads were processed (Table 6). Previously described methods (1.5.2 Methods and Planned 
Statistical Analyses) were used to characterize the bacterial reads derived from human sequences. 
Briefly, 3758 sequencing files from primary tumor and adjacent normal tissue were pre-processed using 
SAMtools and Picard to extract unmapped-to-human reads (Li et al. 2009, BroadInstitute 2018). 
Sequences were then trimmed and quality filtered, and processed using a series of filtering and alignment 
steps based on a modified PathoScope 2.0 workflow (Hong et al. 2014, Zhang et al. 2015) to subtract 
additional human sequences and determine microbial relative abundance present within the sample 
(Figure 1 Bioinformatics Pipeline). Primary tumor and its paired adjacent normal with detected bacterial 
reads on either sample were selected at a 1:1 ratio for analyses (Table 7). In Table 6 the number of 
paired cases selected along with the total number of sequencing reads distribution per cancer type is 
displayed. READ had the largest proportion of reads per sample with 6 billion reads among 36 samples 
followed by COAD with 28 billion reads. Table 7 displays a comparison of aligned, unmapped, mapped to 
human, and mapped to microbe reads found within 9 TCGA cancer cohorts. We observed an average 
microbe to human read ratio of 0.005%. CESC presents the highest ratio of 0.04%. Overall, 
approximately 99% of the total reads detected in CESC were of viral origin. 
 





WXS=whole exome sequence. Table shows total binary alignment/map (BAM) format raw WXS sequencing files 
meeting selection criteria and total of paired tumor and solid tissue normal within each cohort screened and selected 
for bacterial presence. 
Table 7 Sequence comparison of aligned reads in 9 TCGA cancer cohorts 
 
Table shows total sequence alignment/map (SAM) format aligned sequencing reads. Human reads is the cumulative 
total number of mapped to human reads after filtering and subtraction steps. §In CESC the proportion of bacterial reads 
was 5% and 6% in tumor and adjacent normal respectively 
We detected bacterial DNA presence in 94% of the primary tumors and 92% adjacent solid tissue normal 
samples (Table 8). Viral DNA presence, mainly HPV, HBV and EBV, was used as internal pipeline 
validation and for microbial co-occurrence analyses. Our pipeline was designed to identify DNA 
sequences as such, RNA viruses like HCV were not detected. Viral DNA presence was detected in 33% 
and 35% of the tumor and adjacent solid tissue normal samples respectively. The highest proportion of 
viral DNA positivity was detected in colon and cervical cancers. Colorectal (COAD and READ) and HNSC 
cohorts were found to have the highest proportion of cases with bacterial DNA. The lowest proportion of 
samples with any bacterial DNA presence were observed in BLCA cancer cohort (76% of the samples), 
while the lowest proportion of microbial to human reads ratio were observed in LUAD cohort. 
Table 8 Proportion of samples with microbial reads at any detection level 
 
Included cancer types and number of samples with microbial presence at any level. No difference was observed in 




3.1.4.2 Population Characteristics 
We analyzed 813 paired primary tumor and adjacent solid tissue normal cases from TCGA. From these, 
85 STAD, 81 LIHC, 88 COAD, 18 READ, 221 LUSC, 200 LUAD, 69 HNSC, 8 CESC, and 28 BLCA with 
microbial reads were analyzed (Table 9). Table 9 displays population demographics and clinical 
characteristics for all 9 cohorts. Clinical data was available for 746 cases. Only paired samples with 
available clinical data were used in association analyses. 69% of cases were White (independent of 
Hispanic origin), 9% were African American (independent of Hispanic origin), 4% Asian, and 1% were of 
other racial groups. Age at diagnosis ranged from 20 to 90 years of age with a mean of 64 years (SD 
±11.9). There were some expected differences in age at diagnosis among the cancer cohorts with the 
youngest population belonging to the CESC cohort (47±13.5.). There was an 8% difference in the overall 
proportion of females to males (54% vs 46% respectively). 48% of the tumors were classified as       
Stage II-III. 
3.1.4.3 Taxonomic Composition across Cancer Types 
Our pipeline detected 1,264,775 quality WXS microbial reads representing 1353 unique bacteria taxa 
from which 882 were shared across cancer cohorts (Table 10). From these, 12 species were present in 
all cohorts including Actinomyces oris, Bradyrhizobium sp. BTAi1 Bradyrhizobium sp. ORS, Cutibacterium 
acnes, Escherichia coli, Leptothix cholodnii, Neisseria sicca, Ralstonia insidiosa, Rhodopseudomonas 
palustris, Shingomonas melonis, Sphingomonas panacis and Bradyrhizobium diazoefficiens, and 24 
species, Bacillus subtilis, Cutibacterium acnes, Escherichia coli, Mycoplasma mycoides, Corynebacterium 
pseudotuberculosis, Ralstonia pickettii, Bacillus mycoides, Mitsuaria sp. 7, Streptomyces gilvosporeus, 
Bacteroides fragilis, Roseateles depolymerans, Psychromicrobium lacuslunae, Bacteroides 
thetaiotaomicron, Bacteroides dorei, Bacteroides ovatus,, Bacteroides vulgatus, Bacteroides caecimuris, 
Alistipes finegoldii, Bradyrhizobium sp. BTAi1, Rothia mucilaginosa,  Flavonifractor plautii, Arthrobacter 
sp. IHBB 11108, Sphingomonas koreensis and Roseburia hominis were found to frequently co-occur in 
tumor and adjacent normal samples across cohorts and are described in more detail in the next section 
(3.1.6.4 Core Microbiota).  Taxonomic composition was found to be similar to that previously reported in 
RNA-seq, WGS or WXS data (Cantalupo, Katz, and Pipas 2018, Zhang et al. 2015, Yu et al. 2017, 
Robinson et al. 2017, Khoury et al. 2013). One of the important findings is bacteria shifts observed in 
tumor compared to adjacent normal in most cancer types. Eight major phyla were found among all cancer 
cohorts with significant differential relative abundances (pvalue <0.05). Taxa from the Proteobacteria 
phylum were found in all nine cancer types. Bacteroidetes were highest in COAD. Firmicutes were higher 
in STAD tumor and BLCA adjacent normal compared to their paired corresponding tumor tissues. 
Fusobacteria were present at low levels across various cancer types including STAD, LUSC, HNSC and 





Table 9 Demographics and clinical characteristics summary 
 
Basic demographics characteristics from cases with available clinical data. *Fraction with clinical data; -- not applicable/no data; Other Race includes groups with 





adjacent normal with greater that 1% at the phylum level are shown. Shifts in bacteria abundance were 
evident in STAD, COAD, CESC and BLCA cancers while less evident in LIHC, LUAD and READ, where  
the bacterial composition between tumor and its adjacent normal were virtually indistinguishable at the 
phylum level. STAD had a significant increase in Bacteroidetes (6% in adjacent normal compared to 11% 
in tumor) and Firmicutes which, composed nearly half of the total reads found in tumor while less than 
10% in adjacent normal (Figure 9-B). A 15% decrease was observed in the Proteobacteria like species in 
STAD. In COAD, we detected a significant decrease of Bacteroidetes (-21%) in tumor, while 
Proteobacteria (+20%) levels were increased compared to adjacent solid tissue normal. In LUSC, there 
was a slight opposite shift between Proteobacteria (lower) and Actinobacteria (higher) in tumor compared 
to adjacent solid tissue normal. In addition, the tumor appeared to be colonized by higher levels of 
Firmicutes which were relatively absent in the adjacent normal tissue. In HNSC, Actinobacteria decreased 
by 17%, while Bacteriodetes increased 9% in tumor compared to adjacent normal. CESC had a 
significant change in the number of Actinobacteria colonizing the tumor tissue, almost entirely shifting to 
1% compared to 25% in adjacent normal. BLCA cohort cancer appeared to have the greatest shift 
change in composition where tumor was colonized almost entirely by Proteobacteria (98% vs to 50%) 
compared to adjacent normal. Three species, Escherichia coli, Cutibacterium acnes and Bradyrhizobium 
sp. BTAi1 were found to be present in all 9 cohorts. Several Bradyrhizobium spp. and Escherichia spp. 
strains were detected in multiple cohorts at different rates in either tumor or adjacent normal. Escherichia 
coli and Cutibacterium acnes, were found to be consistently present across samples. Other species were 
found across all cohorts with at least 1 read, including those before mentioned and Bradyrhizobium sp. 
ORS 285, Leptothrix cholodnii, Nisseria sicca, Rasltonia insidiosa, Rhodopseudomonas palustris, 
Sphingomonas melonis and Sphingomonas panacis. Figure 7. Measures of total read absolute 
abundance, reads proportional relative abundance and percent prevalence provided different 
interpretation regarding the taxonomy compositional structure. We point out that all three measures must 
be used for accurate characterization of the tumor microbiota with greater weight to percent population 
prevalence and relative abundance when identifying clinically relevant taxonomy to avoid erroneous 
conclusions. 
 3.1.4.4 Core taxa characterization  
Identification of core microbiota is important to the understanding of the tumor microenvironment and the 
role bacteria play in cancer pathogenesis (Sun and Kato 2016). We therefore wanted to identify differences 
and commonalities of species shared within each cohort’s tumor and adjacent normal pairs and across 
cancer cohorts in order to identify clinically relevant differences and commonalities in species. A positivity 
detection threshold of ≥ 0.2% relative abundance was set. Assuming that each identified taxa is present at 
least once in each sample with a minimum of 1 read, a positivity detection rate of 0.2% was deemed 
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reasonable. Core taxa was defined as that identified at a minimum positive detection rate, present in the 
majority of population, and shared between tumor and adjacent normal pairs with a minimum of 20% 
prevalence in each sample type. Core taxa was calculated based on study assumptions and verified using 
microbiome-R package (version 1.3.3). Microbial core composition using microbiome package was 
calculated using default settings and taxa positivity detection rate of 0.2% and prevalence of 20%. All taxa 
identified for each cohort were evaluated in all cohorts regardless if met core criteria.  




Mean relative abundance (normalized proportions) of top 10 bacteria species most commonly identified within each 
cohort and defined as core taxa in tumor (L) and adjacent normal (R). 
 
Top core taxonomic identification is shown in Figure 7. Bacillus subtilis was the most frequent taxa 
identified in the population, yet the based on proportion of reads and relative abundances across cohorts 
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was very low and its presence is masked by higher read taxa. COAD had the highest proportion of taxa 
present across all cohorts with 467 species shared between tumor and adjacent normal. It also had the 
 




Compositional bar graph showing size of individual core taxonomies (left horizontal bars) and intersect of shared 
species in tumor and normal samples across cohorts. 24 species, were found to frequently co-occur in tumor and 
adjacent normal samples across cohorts. Each column represents intersect of shared species. In tumor samples 2 
species are shared across all 9 cohorts, Escherichia coli and Cutibacterium acnes (blue arrow top), and 3 species are 
shared in all 9 cohorts in adjacent normal, Escherichia coli and Cutibacterium acnes, and Bradyrhizobium sp. BTAi1 







Figure 9-A Landscape of bacterial shift changes in tumor and adjacent normal tissue across tumor types 
 
Proportion of bacterial reads and composition shift in tumor and adjacent normal paired samples at the phylum level illustrated with pie charts. Figure shows 
anatomical site proximity between cancer types. Phyla >1% is shown. Reads proportions in tumor compared to adjacent normal in READ and LUAD cohorts are 






Figure 9-B Landscape of bacterial shift changes in tumor and adjacent normal tissue across tumor types 
 
Proportion of bacterial reads and composition shift in commonly infection-associated cancers tumor and adjacent normal paired samples at the phylum level illustrated 
with pie charts. Phyla >1% is shown.  Figure shows anatomical site proximities between cancer types. Proportion of Actinobacteria, Firmicutes and Proteobacteria 





Table 10 Taxonomy classification counts distribution across cancer cohorts per sample type 
 
Table displays primary tumor, adjacent normal and shared taxa counts with mean per cohort alpha and beta diversity measures. n=total unique taxa counts per 
cohort. Boxed represents α (alpha diversity means) and β (beta diversity means defined as a ratio of unique and shared species within each cohort. Yellow bars 





most varied community with a mean alpha diversity difference of -12.3 indicating greater community 
abundance in the adjacent normal samples (Figure 10). In COAD, 12 species were identified as core 
microbiota, confirmation with microbiome R package resulted in 24 species. List of core taxa is available 
in Supplemental Table A1 (pp. 114). We found an inverse proportion of the Bradyrhizobium like reads in 
CESC and LUSC. In CESC the number of Bradyrhizobium like reads were 22 times higher in tumor than 
in its paired adjacent normal, while number in LUSC were higher in the adjacent normal. Bradyrhizobium 
like reads proportion were also significantly higher in COAD tumor than that of its adjacent normal.  Like 
Bradyrhizobium, Escherichia spp. reads including Escherichia coli, Escherichia fergusonii and 
Escherichia albertii were detected in multiple cohorts. Escherichia species were inversely proportional in 
colon and liver samples with a higher abundance in LICH tumors and colon adjacent normal samples 
compared to their respective pairs. Although Escherichia are present in all cohorts their normalized reads 
abundance are negligible when compared across cohort.  
3.1.4.5 Diversity Metrics, Alpha and Beta diversity 
Microbial diversity is associated with cancer and treatment outcomes (Gopalakrishnan, Spencer, et al. 
2018). We therefore examined within sample diversity (alpha diversity as defined by Shannon-Weiner), 
measures of evenness and species richness and between sample diversity (beta diversity) in tumor and 
adjacent normal tissue paired cases within each cancer cohort. Diversity measures were calculated using 
vegan package (version 2.5-3) and Microsoft Excel (v.2013). Measures were calculated at the taxonomy 
or operational taxonomic units (OTU) level and collated at the species level (by aggregating strains and 
subspecies of the same species). Species richness, the number of species per sample, was overall 
slightly higher in adjacent normal compared to tumor samples (average total tumor species 358 vs 382 in 
adjacent normal) Tumor richness was higher among STAD, LIHC, CESC and BLCA cohorts. In COAD, 
LUSC and READ richness was higher in adjacent normal, while there were no differences noted in in 
HNSC and LUAD cohorts. Diversity varied by age, sex and histopathological staging at varying degrees 
across different cancer cohorts and is presented in detail in cancer specific findings. 
 
3.1.4.6 Cancer Specific Findings  
We compared the bacterial relative abundances and bacterial diversity in tumor and its paired adjacent 
solid tissue normal for each cancer type and across cancer groups. All specimens with bacterial reads 
were considered (Table 8). Likewise, per study assumptions all bacterial taxa identified by the 
bioinformatics pipeline were considered equally important and with equal weight. All taxa were analyzed 
for differential abundance (Table 11). Association testing of each significant taxa with clinical and 
demographic factors are presented. Clinical relevance was established by relative abundance difference 









Fraction of species 
≤1 read 
Fraction of species 
>1 ≤10 read 
Fraction of species 
>10 read 
STAD 706 283 287 136 
LIHC 290 141 110 39 
COAD 1028 371 428 229 
READ 279 130 98 33 
LUSC 741 228 289 224 
LUAD 820 259 382 180 
HNSC 452 164 189 99 
CESC 120 58 37 25 
BLCA 195 101 67 27 
Totals (%) 4631 1735 (38) 1887 (41) 992 (21) 
Table shows Fraction of taxa collated at species level with at least 1 hit. 38% of the identified taxa hits had ≤1 read 
across all paired samples within each cohort. Read fractions of less than 1 read occurs when sequences map to multiple 
top hits.  
 
3.1.4.6.1 Stomach  
We examined 170 STAD paired primary tumor and adjacent normal sample sequences from 85 cases. 
From these, 56% were male, average age at diagnosis was 67 years (±10.5 SD). Most were White (63%) 
and most classified as tumor stage II-III (55%). Table 9. Average read per sample was 360 in tumor and 
107 in adjacent normal. Average number of species per sample in tumor were 24 compared to 19 in 
adjacent normal. We detected 1050 bacteria OTUs corresponding to 14 phyla, 32 classes, 62 orders, 135 
family, 315 genus and 706 unique bacterial species. There was a significant difference in the proportions 
of taxa in tumor compared to taxa numbers in adjacent normal (Fisher, p=0.007). Four species, Bacillus 
subtilis, Arthrobacter sp. IHBB11108, Cutibacterium acnes, and Mycoplasma mycoides were found to be 
present in 20% or more of either sample type.  Relative abundance of Selenomonas species were 
consistently higher in tumor compared to adjacent normal across samples. Selenomonas sputigena was 
the most prevalent species in tumor samples with 13% of the total reads in tumor (Figure 10), while 
Helicobacter pylori strains made 60% of the total reads in adjacent normal. Wilcoxon signed rank test was 
used to examine the differential abundance between tumor and adjacent normal pairs. Differential relative 
abundance for 10 taxa representing 4 major phyla and 7 genus levels were found to be higher in tumor 
than in adjacent normal (Figure 11). However this difference was not statistically significant (p=<0.05 
FDR= 1). Presence of Helicobacter pylori, was found to be significantly higher in the adjacent normal 
compared to tumor tissue (log2fc = -4.8, p=<0.0001 FDR= 0.01). 
 
Because gastric cancers molecular subtypes are associated with Epstein Barr virus, we evaluated 
presence of HHV-4 as internal validation and co-infection analyses. HHV-4 was detected in 25 tumor and 
25 adjacent normal samples. Status of HHV-4 did not differed within the paired sample population. 
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However, the proportion of reads detected in tumor were significantly higher than those detected in 
adjacent normal tissue samples at a ratio of 102:1. There was no correlation between HHV-4 status and 
Helicobacter pylori presence however there was a positive trend of Helicobacter pylori and HHV-4 
infection status (correlation coefficient=0.17, 95%CI=0.02-0.31, p=0.03). Presence of Helicobacter pylori 
was positively correlated with histopathological type. In males, Helicobacter pylori status was strongly 
correlated with intestinal type papillary adenocarcinoma (likelihood ratio= 5.5, p=0.02, phi=1). In females 
there was a weak correlation between Helicobacter pylori and unspecified type carcinoma (likelihood ratio 
4.8, p=0.03, phi=0.32). Fusobacterium nucleatum was detected in 9% (n=8) with a median relative 
abundance of 0.001 (range 0.002, 0.25). Veillonella parvula was 4 times higher in tumor compared to 
adjacent normal (log2fc=4.5, p=0.03, FDR=1) though not significant after multiple test correction. The 
odds of tumor presence of Vellionella parvula in tumor were 3 times the odds of presence in adjacent 
normal (OR: 3.2, 95%CI: 1.1-9.2, p=0.03). In tumor tissue presence of Selenomonas sputigena was 
correlated with presence of Fusobacterium nucleatum (correlation coefficient=0.48, 95%CI 0.30, 0.63, 
p=<0.001) and weakly correlated with HHV-4 status (rho=0.24) however not with presence of 
Helicobacter pylori. In adjacent normal, presence of Selenomonas sputigena was correlated with HHV-4 
status and Helicobacter pylori presence (rho= 0.31 and rho=0.26 respectively).  
 
Figure 10 Microbial composition differences in tumor and adjacent normal paired samples for STAD 
 
Figure shows Krona plot with compositional differences among 7 taxonomic levels in STAD cohort. Krona plot is 
colored from red to green clockwise with the most abundant taxa shown in red. Percent within wedges represent 
relative abundance by total number of reads present in the population. All taxa were included in the data, for 




Figure 11 Log 2 Fold Change (l2fc) of top taxa in STAD cohort 
 
Figure shows log 2 fold change of differential abundant taxa in a paired test in STAD. Each dot represent a species 
within the genus, colored by phylum. Each species with Wilcox signed rank test p<0.05 are shown. Firmicutes were 
the most predominant phyla with 7 species. Only H pylori (in adjacent normal) was statistically significant after 
adjustment for multiple testing (FDR).  
 
3.1.4.6.2 Liver 
A total of 162 samples from 81 paired cases were examined. The majority of the cases were male (57%), 
White (79%), and mean age at diagnosis was 64 years (±14.7 SD). In LIHC, 68 out of 81 paired cases 
were positive for bacterial reads at any detection level. Within these cases, we identified 6 phyla, 12 
classes, 31, order, 61, family, 122 genus and 290 unique bacterial species (Table 10). There was no 
difference in the number of taxa present in tumor compared to normal at the OTU level or at collated 
species level (p=0.62 at OTU, p=0.71 collated at species). Overall, Escherichia coli was the most 
abundant species, detected in 68% of cases (Figure 12).  We found no difference in bacterial 
composition between tumor and adjacent normal in paired tests. We note a small 5% decrease in the 
level of Betaproteobacteria like reads in tumor compared to adjacent normal with Ralstonia pickettii the 
most predominant in both. Rhodococcus erythropolis like reads were uniquely identified in adjacent 
normal tissue as significantly different within the tissue type (p=0.002, FDR=0.05). Rhodococcus spp. are 
known laboratory contaminants. In tumor, Delftia acidovorans like reads were also uniquely identified, 
however difference was not significant after FDR multiple test correction (p=0.006, FDR=0.07). For 
verification, differential analysis was repeated using count data with DESeq2 package. No differentially 




Figure 12 Microbial composition in tumor and adjacent normal paired samples for LIHC 
 
 
Krona plot with compositional differences among 7 taxonomic levels in LIHC cohort. Proteobacteria dominated both 
tumor and adjacent normal, with Escherichia coli like reads making up 85% of tumor and 63% of adjacent normal 
total reads. Viral like reads represented 2% of the tumor and adjacent normal (dominated by HBV). All taxa ≥ 1% are 
shown. Firmicutes made up 2% of adjacent and were relatively absent in the tumor (0.09%) while Actinobacteria 
made up 9% of the adjacent normal reads compared to 4% in tumor. Cutibacterium acnes dominated the adjacent 
tissue while Rhodococcus spp. dominated the Actinobacteria in tumor 
 
 
Given LIHC viral infectious etiology, HBV and HHV-4 viral reads were evaluated as internal validation and 
co-occurrence with bacteria presence. These were detected in 10 LIHC cases. The number of HBV reads 
in tumor were twice the number of reads in adjacent normal. HHV-4, was noted to be present only in 
tumor samples. HBV and HHV-4 like reads represented <2% of the total tumor or adjacent normal reads. 
Most samples with positive identification of HBV or HHV-4 did not have bacterial content. Of those with 
bacterial reads, most commonly co-occurred with Actinobacteria and Proteobacteria like species. 
Diversity metrics were completed with paired cases with at least 1 bacterial read (Table 12). Richness 
varied by tumor stage and sex, higher males classified as stage I (p=0.03) while no differences were 
observed in alpha diversity when stratifying by tumor stage and sex. There were no differences in beta 




Table 12 Richness and Diversity in Hepatocellular carcinoma 
 
Table 3.8 displays richness (total number of species) and diversity (Shannon-Wiener index of diversity) by sex and 
sample type across tumor stage. Overall, males are associated with higher species richness (Estimate=4.5±2.1, 
p=0.034). In tumor stage I, males have higher species richness compared to their paired adjacent normal (p=0.02), 
yet there is no difference in species diversity in tumor compared to adjacent normal. Significant numbers in bold. 
 
3.1.4.6.3 Colorectal cancers 
A total of 212 samples from 88 colon (COAD) and 18 rectal (READ) paired cases were examined. Most 
COAD cases did not report race or ethnic backgrounds (49%), 42% were White. Mean age at diagnosis 
was 71 years (±12.3SD), and 70% were classified as stage II-III (Table 9). READ were younger on 
average with mean age at diagnosis of 63 years (±14.6 SD) and 61% were males. Similar to COAD, 44% 
were white, while 50% did not report racial background and most were classified as stage II-III.  In COAD, 
average read per sample mapping to bacterial genome was 2006 reads in tumor compared to 3962 reads 
in adjacent normal. Mean species per sample was significantly different in tumor compared to adjacent 
normal (mean difference=12.3, p=0.016, 95%CI 2.4, 22.2). Table 10.  A total of 1028 species 
corresponding to 19 phyla, 42 classes, 97 orders, 198 families, 433 genus were identified in COAD. For 
READ average read number per sample was 569 reads in tumor and 708 reads in adjacent normal, while 
the average number of species per sample was  significantly lower in tumor with 20 species per sample 
compared to 29 in adjacent normal (p=0.008). A total of 420 taxa were identified in READ, from which 279 
were unique belonging to 8 phyla, 21 class, 41 order, 84 family, and 146 distinct genus (Table 10). Both 
colon and rectal cancers had a small proportion (<1%) of reads mapping to viral genomes across 7 




Figure 13 Microbial composition in tumor and adjacent normal paired samples for COAD 
 
 
Krona plot with compositional differences among 7 taxonomic levels in COAD cohort. In adjacent normal, 74% of the 
reads were identified as Bacteroidetes, with a read distribution among several species with the majority identified as 
B. vulgatus. Proteobacteria reads made up 18% of the adjacent normal reads dominated by E. coli. A significant shift 
in the proportion of Bacteroidetes to Proteobacteria was observed between tumor and adjacent normal. 
Proteobacteria increased to 51 % of tumor reads in relation to adjacent normal and an equal reduction in 
Bacteroidetes (43%) dominated by Bacteroides fragilis. Viral like reads represented <0.1% of both tumor and 
adjacent normal (dominated by HBV). All taxa ≥ 1% are shown.  
 
In colon samples, overall a significant proportion (66%) of the reads mapped to Bacteroidetes, 28% to 
Proteobacteria, 4% to Firmicutes, 1% to Verrucombia and 1% to Actinobacteria phyla like reads. 
Bacteroides to Firmicutes ratio was similar in both tumor and adjacent normal. While a significant shift in 
the level of Proteobacteria to Bacteriodetes were observed between tumor and adjacent normal     
(Figure 9). The ratio of Proteobacteria to Bacteriodetes was significantly increased in colon tumor 
compared to its adjacent normal (log2 P/B tumor =0.24, log2 P/B adjacent normal=-2.03). There was no 
difference in within sample diversity index or the evenness spread (t=1.35, p=0.18, 95%CI=-0.017, 0.005) 
by sample type. We wanted to know if differences existed when stratifying by sex, age at diagnosis, race 
and tumor stage. Intra-sample diversity measured by Shannon-Wiener diversity index did not differ by sex 
or age group (p=0.46). Observable differences by race, tumor stage and site of resection were found. In 
linear regression model, alpha diversity index differences were not significant after controlling for other 
variables. Differential abundance were measured by Wilcoxon Signed Rank test. Bacteroides vulgatus 
was found to be significantly different (p=<0.00001, FDR=0.001) between sample types, however the    
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log 2 fold change was negligible at 0.8 higher in adjacent normal compared to tumor (Figure 14). edgeR 
differential abundance test resulted in 52 species. Similar to Wilcoxon Signed Rank test results, 
Bacteroides vulgatus was identified by edgeR as significantly different with a log fold change of almost 4 
times higher in adjacent normal than in tumor (p=<0.00001, FDR=<0.00001, LFC= 3.6).  Multiple studies 
have reported overabundance of Fusobacterium nucleatum in tumor tissue associated with colorectal 
cancer pathogenesis (Castellarin et al. 2012, Kostic et al. 2012, Kostic et al. 2013, Warren et al. 2013, 
Kumar et al. 2016). Based on these reports we wanted to evaluate the presence of Fusobacterium 
nucleatum in our data set. Overall, Fusobacterial reads represented less than 1% of the total reads 
mapped in COAD. Of these, 84% were identified as Fusobacterium nucleatum. We found that there were 
considerable differences between detected Fusobacterium reads in tumor and those detected in adjacent 
normal specimens within the COAD cohort (Figure 3.6). The relative abundance means within tumor and 
within adjacent normal samples differed significantly (tumor p=<0.0001 FDR=0.002, adjacent normal 
p=0.006 FDR=0.05, respectively). In paired test by Wilcox Sign Rank, mean relative abundance 
differences were non- significant when comparing tumor to adjacent normal samples (p=0.004, FDR=0.5, 
l2fc= -1.36). 
 
Figure 14 COAD Log 2 fold change of significant taxa  
 
Figure shows fold change (Log2) differential abundant taxa collated at species name in COAD. Each dot represent a 
species within the genus, colored by phylum. Species above zero are higher in tumor, below are higher in adjacent 
normal. Bacteroidetes were the most predominant phyla with 5 species. B. vulgatus (in adjacent normal) was 




Figure 15 Fusobacteria abundance in COAD cohort 
 
Figure shows Absolute abundance (total reads) of Fusobacteria phyla in COAD by sample type. Each bar represent a 
genus, colored by species. Fusobacterium nucleatum and Fusobacterium hwasookii were more abundant in tumor 
compared to adjacent normal. 
 
In rectal cancer samples there was no difference in the proportions of taxa in tumor compared to taxa 
numbers in adjacent normal (Fisher, p=0.72). Four Bacteroides species and Escherichia coli were found 
to be present in 30% or more of either sample type. Escherichia coli like reads were the most abundant 
detected in 86% of the cases. Differential relative abundance did not yield significant taxa. Relative 
abundance of 3 taxa were consistently higher in adjacent normal compared to tumor while Bacteroides 
fragilis was 2 times higher in tumor. However this difference was not statistically significant after 
adjustment for multiple testing (p=<0.02 FDR= 1, l2fc= 1.06).  We note a small change in the 
Proteobacteria to Bacteroidetes ratio, mainly driven by an increase in Enterobacteria (11% increase), 
decrease in Betaproteobacteria (6%) in tumor and a significant increase of Bacteroides vulgatus in 
adjacent normal. HHV-4 and HPV viral reads were also detected in a small fraction of the samples. HHV-
4 were detected in tumor samples and HPV in adjacent normal (Krona plot). There was significant 
difference in richness by sex and sample type (p=0.008). Species richness was significantly higher in 
adjacent normal tissue of females compared to males.  There were no differences in Shannon alpha 




Table 13 Richness and Diversity in rectal adenocarcinoma 
 
Table displays richness (number of species) diversity (Shannon-Wiener index of diversity) and Shannon evenness 
stratified by sample type and sex. 
 
3.1.4.6.4 Cancers of the lung 
Sequencing files from tumor and adjacent normal specimen pairs corresponding to 421 cases of lung 
squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) were analyzed. Of these, 23 cases 
in LUSC and 17 cases in LUAD had one or both pairs without microbial reads or only viral like reads. 
Clinical data was not available for 26% of LUAD cases (52 /200 cases). Demographic characteristics of 
both patient populations are summarized in Table 9. Overall 52% were male and 12% did not report or 
had missing data. Mean age at diagnosis was 66.8 years (±9.3 SD) with majority self-reporting as being 
Non-Hispanic White in both cancer cohorts (67% and 81% in LUSC and LUAD respectively). Stratified by 
sex and sample type, there were no significant differences in age at diagnosis, race, ethnicity, primary 
diagnosis, tumor stage, or survival days. In LUSC 43% were classified as stage II-III compared to 30% in 
LUAD. All available samples with bacterial like reads were examined for bacterial composition. Paired 
tumor and adjacent normal samples were used for correlation analyses. 
  
In LUSC, a total of 9,622 reads in primary tumor and 50,630 reads in adjacent normal were mapped and 
aligned to 1049 unique OTUs. From these 51% of the tumor reads were identified as viral like reads 
compared to 15% in adjacent normal.  Mean bacterial reads per sample was 107 with approximately 7 
bacterial species found per sample. We identified 12 phyla, 26 class, 65 order, 132 family, 310 genus, 
and 741 unique species. From the 741 species, 335 were shared in tumor and adjacent normal with 80 
unique species found in the tumor tissue and 326 in the adjacent normal respectively (Table 10). In 
analyses of variance total number of unique species was significantly lower in tumor compared to the 
number of shared species and unique species in adjacent normal (F=655.7, p=0.0001). Based on the 
significant number of reads mapped/aligned to viral reads we wanted to explore the differences in 
distribution across tumor and adjacent normal. We found a total of 46 unique species corresponding to a 
number of Torque-teno-viruses, HHV-4 and other Herpesviridae species, where 26 of these were shared 
between tumor and adjacent normal tissue. There was a non-significant difference in the total number of 
viral reads in tumor compared to normal and no difference in the number of unique or shared viral species 
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between tumor and adjacent normal. Several bacterial species reads were found consistently throughout 
samples belonging to Proteobacteria, Firmicutes and Actinobacteria phyla. The most abundant taxa in the 
population was Bacillus subtilis, present in 55% of tumors and 56% of the adjacent normal, yet the 
highest number of reads were identified as Sphingomonas spp., present in <20% of the sample 
population. Similarly, Proteobacteria, Actinobacteria and Firmicutes were the most abundant phyla in 
LUAD. 
 
The proportion of viral like reads in LUAD was smaller compared to LUSC cohort, contrary to LUSC it was 
lower in tumor compared to adjacent normal 5 fold. We identified 820 unique bacterial species classified 
among 12 phyla, 27 class, 35 order, 131 family, and 306 genus. From the 820 species, 449 were shared 
in tumor and adjacent normal with 190 unique species found in the tumor tissue and 181 in the adjacent 
normal respectively. Table 10. There was no difference in the number of unique species or shared 
species between tumor and adjacent normal. Like in LUSC, the most abundant taxa in the LUAD sample 
population was Bacillus subtilis, present in 53% of tumors and 63% of the adjacent normal and a total of 
110 reads across. Highest number of reads in LUAD were among Cutibacterium acnes (1282 reads 
present in 25% of tumors and 22% of adjacent normal), Mitsuria sp7 (1223 reads present in 26% tumors 
and 29% of adjacent normal), and Delftia acidovorans (1093 reads present in 14% of tumors and 17% of 
adjacent normal). (Supplemental Table A.1 Core taxonomy across cancer types). 
 
Figure 16 LUSC Log 2 fold change of significant taxa 
 
Figure shows fold change (Log2) differential abundant taxa collated at species name in LUSC. Each dot represent a 
species within the genus, colored by phylum. Species above zero are higher in tumor, below are higher in adjacent 
normal. Proteobacteria were the most predominant phyla with 11 species. No significant taxa was identified after FDR 




We compared the species composition within tumor and within adjacent normal in LUSC and LUAD. In 
Wilcoxon rank sum test 54 species were identified in LUSC tumor and 64 in its adjacent normal to have 
ranks significantly different (FDR<0.05). In LUAD 89 species were identified to have ranks significantly 
different across samples within tumor (FDR<0.05) and 79 species in adjacent normal.  In paired Wilcoxon 
signed rank test, comparing differential relative abundance between tumor and adjacent normal we found 
12 taxa in LUSC (Figure 16) and 22 taxa in LUAD (Figure 17) to be differentially abundant between 
tumor and their paired adjacent normal with pvalue <0.05, however there was no difference after 
correcting for multiple testing (FDR=1). 
 
Figure 17 Log Fold Change (l2fc) of top taxa in LUAD cohort 
 
Figure shows fold change (Log2) differential abundant taxa collated at species name in LUAD with pvalue <0.05. 
Each dot represent a species within the genus, colored by phylum. Species above zero are higher in tumor, below 
are higher in adjacent normal. Proteobacteria were the most predominant phyla with 15 species.  No significant 
differential abundance was detected (FDR pvalue adjustment > 0.05). 
 
We observed a shift in the ratio of Proteobacteria to Actinobacteria phyla composition in LUSC (log2 P|A 
tumor =2.63, log2 P|A adjacent normal=5.13) while compositional shift changes in LUAD were negligible 
(log2 P|A tumor =2.30 and log2 P|A adjacent normal=2.40). Figure 9. We then asked if there were 
differences within sample diversity within and between tumor and adjacent normal samples within each 
lung cancer cohort. When stratifying by sex and sample type, there were no statistically significant 
differences in species richness, within sample alpha diversity (measured by Shannon-Wiener Index), or 
the evenness spread (defined as alpha diversity / log normal (species richness)) in either cohort overall. 
There were observable differences in alpha diversity by age at diagnosis groups, tumor stage. Table 14. 
Younger female patients at diagnosis in the LUSC cohort, had higher within sample diversity in tumor 
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compared to adjacent normal.  While LUAD, when looking at tumor staging, females had higher diversity 
in adjacent normal compared to tumor although these were not significant in analyses of variance. 
 




LUSC (top) and LUAD (bottom) diversity measures in patients of different age groups at diagnosis and different tumor 
staging stratified by sample type and sex. Table shows global pvalue with significance codes (0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 
0.05 ‘.’ 0.1 ‘ ’ 1) for individual variables.  -- data not available. In LUSC the 40-50 age group has significant differences 





3.1.4.6.5 HPV associated cancers of the head & neck and cervical cancer  
We analyzed 69 squamous cell carcinoma of the head and neck region (HNSC) and 8 cervical squamous 
cell carcinoma specimens from TCGA. Demographic characteristics of patient population with available 
clinical data are summarized in Table 9. There were significantly more males than females (70% vs 30%) 
in our subset of paired HNSC sample population. Because the established association with HPV etiology, 
we examined viral read presence in both cancers. Overall we detected viral like reads in 14% of HNSC 
(20/143) and 100% of CESC samples (16/16), while bacterial like reads were detected in all samples for 
both cancer types (Table 8). We found that proportion of bacteria versus viral reads for HNSC and CESC 
cancers were opposite to each other. In HNSC bacterial reads accounted for more than 99% of the total 
reads while in CESC bacterial like reads were less than 1% of the total (Figure 18Figure 1).   
 
Figure 18 Microbial composition in HNSC and CESC 
 
Krona plots of HNSC and CESC cancer cohorts total reads. HNSC and CESC had inversed proportion of viral and 
bacterial presence. Krona plots are colored clock-wise (6th hour mark) from red to green tones in descending order of 
total reads detected, slices show percent proportion of major phyla. 
 
 
HPV like reads were detected within the HNSC cohort in agreement with previous findings (Tang et al. 
2013, Wang et al. 2017). HHV-4 was detected in approximately 13% of HNSC samples. HNSC 
specimens with positive detection of HPV like reads were not found to be co-infected with HHV-4. 
Contrary to that in CESC HPV and HHV-4 were found to co-occur in several samples. Based on casual, 
epidemiological and meta-analysis data (Zhu et al. 2016) linking Chlamydia trachomatis co-infection to 
susceptibility to cervical cancer after HPV infection, we evaluated co-occurrence of the bacterium and 
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HPV in CESC. We found no evidence of Chlamydia trachomatis reads in our subset of CESC samples, 
interestingly we found evidence in HNSC tumor samples. The presence of HPV was correlated with 
presence of top abundant taxa in HNSC and CESC (Figure 19).  
 




Correlation matrix. Matrices show Spearman correlation coefficients. Color depth indicate strength and significance of 
the correlation. Color gradient from red, positively correlated to blue, negatively correlated. In HNSC, HPV is 
correlated with presence of alpha herpesvirus-1 and with R. mucilaginosa. In CESC HPV has a negatively trend with 





No significant correlation was found between HPV status and diversity or bacterial abundance in CESC.  
HPV status was correlated with microbial abundance HNSC. 
We examine differential abundance within tissue type and between tumor and adjacent normal paired 
sample within each cohort. Relative abundance was not significantly different for either tumor type 
compared to adjacent normal. In HNSC, there were no differences in bacterial diversity means in paired 
tests comparing tumor to adjacent normal (p=0.6). Slight differences were observed by anatomical site 
among HNSC larynx, LOP (lip, oral and pharynx overlap), and tongue (base and non-specified) when 
compared against floor of mouth within each tissue type when stratifying by sex and sample type. In 
analyses of variance, anatomical site was a predictor of alpha diversity (p < 0.001). When stratifying by 
sample type and sex, alpha diversity was slightly higher among females adjacent normal sample with 
significant differences by anatomical site (p=0.002) after controlling for sample type, tumor stage, smoke, 
age, sex and race (Table 15).  
 
Table 15 Diversity measures in HNSC anatomical sites and tumor stage by sample type and sex 
 
Table shows alpha diversity index (Shannon-Weiner index of diversity) across different anatomical sites and tumor 
stages in HNSC cohort stratified by sample type and sex. Significant figures (pvalue) are bolded. –NA 
 
Measures of evenness and species richness (diversity index) were measured by various methods and 
good correlation by pairwise analysis between these methods was observed when evaluating each tissue 
site separately and in paired analyses. In general diversity index means in tumor were lower compared to 
adjacent normal tissue in HNSC. There was no difference in CESC diversity index means between tumor 
and adjacent normal samples (p=0.11). We note, that samples with lower diversity index in tumor 
compared to adjacent normal were more likely to be of the atypical pleomorphic squamous cell subtype 




3.1.4.6.6 Bladder  
We examined 850 files from 412 BLCA cases. From these, most were technical replicates. A total of 56 
paired tumor and adjacent normal samples sequences were selected for further evaluation at a 1:1 ratio. 
The majority of the cases were male (68%), White (89%) and 92% non-Hispanic. Mean age at diagnosis 
was 69 years (±10.7 SD) and 50% were classified at pathological tumor stage IV (Table 9). All cases 
were positive for at least 1 bacterial read at any detection level. Within these cases, we identified 7 phyla, 
12 classes, 31, order, 60, family, 105 genus and 195 unique bacterial species      (Table 10). Overall, 
Proteobacteria were the most abundant species, making 93% of the total reads with Stenotrophomonas 
maltophilia the most abundant species (61% of the total reads). However, prevalence within the sample 
population was low. Positive detection was identified in 3 tumor and 1 adjacent normal.  
 
Figure 20 BLCA overall microbial composition 
 
Krona plot of microbial composition among 7 taxonomic levels in BLCA tumor and adjacent normal. Plot shows 
proportion of bacterial and viral reads present in all samples combined magnified to highest taxonomy level. In BLCA 
93% of the reads were identified as Proteobacteria, with Stenotrophomonas maltophilia reads making 61% of these. 
Stenotrophomonas maltophilia was detected in 3 tumor and 1 normal samples. This highlights measurements of 
prevalence must be taken into account for accurate interpretation.  
 
There was a significant shift in the total number of reads classification at the phylum level in tumor 
compared to adjacent normal (Figure 3.2B). BLCA adjacent normal reads were distributed among 
Proteobacteria (50%), Firmicutes (25%), Actinobacteria (20%), while almost all (98%) of the tumor reads 
were from the Proteobacteria phyla. Despite, when considering total number of reads, relative abundance 
and percent positivity (presence above relative abundance of 0.2% threshold), we found no statistically 
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significant differences between paired tumor and adjacent normal samples. We compared the relative 
abundances by Wilcoxon rank sum test within tumor and within adjacent normal and signed rank test 
between sample types. No taxa were found to be differentially abundant in paired analyses after multiple 
test correction. However, we note that Cutibacterium acnes reads were uniquely identified in BLCA tumor 
samples (p=0.03 FDR=1, L2FC= 3.1). Because the large number of non-paired files filtered out, we 
completed unpaired differential analyses (PathoStat-edgeR function). When considering all available 
tumor and adjacent normal files regardless of 1:1 pairing, several species were found to be differentially 
abundant in tumor compared to normal after FDR multiple test correction including Mathylobacterium 
radiotolerans, Pseudomonas aeruginosa and Pseudomonas putida identified to be higher in adjacent 
normal (p= < 0.001, FDR = < 0.05, LFC=1.61, 2.99 and 1.65 respectively) and Cupriavidus metallidurans 
higher in tumor (p= < 0.001, FDR = < 0.05, logFC -3.47). Stenotrophomonas maltophilia was not 
identified as differentially abundant in paired or unpaired analyses. With the exception of two cases 
originating from  
 
Table 16 Diversity measures in BLCA anatomical sites, age at diagnosis and tumor stage stratified by 
sample type and sex 
 
BLCA diversity measures in samples from diverse anatomical sites, patients of different age groups at diagnosis and 
different tumor staging stratified by sample type and sex. SW: Shannon-Wiener index of diversity. –NA 
 
 
same institution, these taxa did not often co-occurred. Coincidentally, cases identified with co-occurrence 
were also identified to drive the proportion of Stenotrophomonas maltophilia presence in BLCA cohort. 
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Presence of a combination of these species could be indicative of disease status or sepsis. Bacterial 
alpha diversity was associated with age at diagnosis in BLCA (rho =-0.32, p=0.02). In analyses of 
variance age at diagnosis was an independent predictor of alpha diversity (F= 4.06, p =0.049) when 
controlling for sample type, race and sex (Table 16). In fully adjusted model, there are no significant 
differences in alpha diversity. Likewise although alpha diversity means were higher in adjacent normal 
overall, no statistical significant differences were noted in paired tests by sex, race, anatomical site or 
tumor stage.  
 
3.1.5 Validation of bacterial species in gastric and lung cancers 
To validate our methods and bioinformatics detection of significant species we selected stomach and lung 
cohorts based on known infectious and no known infectious etiological factors. Bioinformatics findings 
were validated with tissue from an independent population by species-specific qPCR. Institutional Review 
Board approval was obtained from the University of Hawaii IRB. Paired tumor and adjacent normal FFPE 
samples from the Hawaii Tumor Registry-Discard Residual Repository (Hawaii RTR) were requested at a 
similar 1:1 ratio per case. DNA was extracted using appropriate purification kit to maximize yield 
(Methods). We selected 21 gastric cases and 60 lung adenocarcinoma cases on the basis of paired 
tumor and adjacent normal availability.  Quantitative PCR reactions were performed per methods section 
in duplicate. Duplicate discrepancies were retested.  
In TCGA STAD cohort, Selenomonas sputigena had the highest proportion of mapped reads detected in 
tumor samples compared other species with a prevalence of 18% of tumor compared to 9% of adjacent 
normal samples. Its presence was correlated with presence of Fusobacterium nucleatum in tumor 
(rho=0.48, p=<0.001) and with Helicobacter pylori in adjacent normal (rho=0.26, 0.01). There was a 
correlation between Selenomonas sputigena presence and HHV-4 status (tumor: rho=0.24, p=0.05 
adjacent normal: rho=0.31, p=0.004). In the other hand, Helicobacter pylori was found to be differentially 
abundant between tumor and adjacent normal pairs with significant higher prevalence in adjacent tissue 
compared to tumor samples (n=23 and n=7, respectively), whereas Fusobacterium nucleatum was 
detected at very low abundance levels uniquely identified in 8% of tumor samples.  We therefore wanted 
to validate detection of Selenomonas sputigena, Fusobacterium nucleatum and Helicobacter pylori in in 
tumor and adjacent normal specimens. Of the Hawaii RTR gastric cases, 76% were over the age of 60 
(n=16), 62% were females (n=13), 95% were other than White (n=20), 62% were classified as poorly 
differentiated grade III (n=13), 24% were from the gastric antrum (n=5) and 43% non-specified (n=9). 
Compared to our subset of TCGA gastric cancers (n=85) where 75% were over the age of 60 (n=62), 
44% were females (n=37), 36% were other than White (n=31), 56% were classified as grade III (n=48), 




Overall, positive detection in RTR dataset was almost half that of TCGA-STAD dataset (27% vs 47%). 
Compared to STAD, in RTR gastric samples there was no association between bacterial presence and 
tissue type. We believe this could be due to the small sample size in Hawaii RTR compared to TCGA-
STAD and the racial composition difference were TCGA-STAD were mostly White compared to Hawaii 
RTR, mostly Asian ethnic subgroups and Hawaiian. One of the most significant findings is the, detection 
of species presence by qPCR in with similar patterns of co-occurrence. Selenomonas sputigena was 
detected in 10% (n=2) of tumor samples, Fusobacterium nucleatum and Helicobacter pylori in were 
detected in 14% (n=3) each. Two cases were positive for Selenomonas sputigena and Fusobacterium 
nucleatum. In RTR dataset, bacteria presence in tumor of Helicobacter pylori, Fusobacterium nucleatum 
and Selenomonas sputigena was associated with tumor stage and anatomical site.  
 
Table 17 Proportions tables predicted versus observed in gastric cancer 
 
Association between bacterial presence in tumor and adjacent normal in STAD (predicted) and RTR (observed) 
detection proportions. Table shows count of positive samples and proportions (%) for Helicobacter pylori, 
Selenomonas sputigena and Fusobacterium nucleatum with McNemar’s (chi-square) test and pvalues. There was an 
association between tissue type and bacterial presence for Helicobacter pylori and Fusobacterium nucleatum in 
STAD while no association was found in RTR gastric samples.  
 
Compared to STAD, Selenomonas species had very low abundance and were uniquely detected in lung 
adenocarcinoma adjacent normal tissue (upper lobe) of patients classified at stage I. Presence of 
Selenomonas species was similarly validated. We selected tumor and adjacent normal samples from 60 
lung adenocarcinoma cases from the Hawaii RTR.  These cases 75% (n=45) were over the age of 60), 
27% (n=16) White), 33% (n=20) classified at stage I. For convenience, we utilized commercially available 
Selenomonas primers (Selenomonas sputigena). Similar to TCGA-LUAD cohort, in Hawaii RTR dataset, 
Selenomonas was uniquely identified in adjacent normal tissue. Our results confirmed Selenomonas was 
uniquely in adjacent tissue. Contrary to TCGA bioinformatics detection in the upper lobe, Hawaiii RTR 
population detection was in the lower lobe. Perhaps this is related to inter-individual differences and 
further studies are needed to confirm. These results suggest that bacteria presence as well as bacterial 
composition differences in tumor tissue can be predicted from whole exome sequencing data to 
Helicobacter pylori N Selenomonas  sputigena N Fusobacterium nucleatum N
T (+) (-) T (+) (-) T (+) (-)
(+) 4 (17) 3 (5) 7(8) (+) 3 (3) 12 (19) 15 (18) (+) 0 (0) 8 (9) 8 (9)
(-) 19 (82) 59 (95) 78 (92) (-) 5 (6) 65 (84) 70 (82) (-) 0 (0) 77(91) 77(91)
23(27) 62 (73) 85 (100) 8 (9) 77 (91) 85 (100) 0 (0) 85 (100) 85 (100)
Chi-sq 10.2 Chi-sq 2.1 Chi-sq 6.1
p 0.001 p 0.146 p 0.001
Helicobacter pylori N Selenomonas  sputigena N Fusobacterium nucleatum N
T (+) (-) T (+) (-) T (+) (-)
(+) 1 (50) 1 (5) 2 (10) (+) 0 (0) 2 (10) 2 (10) (+) 2 (10) 1 (5) 3 (14)
(-) 1 (50) 18 (95) 19 (90) (-) 0 (0) 19 (90) 19 (90) (-) 0 (0) 18 (86) 18 (86)
2 (10) 19 (90) 21 (100) 0 (0) 21 (100) 21 (100) 2 (10) 19 (90) 21 (100)
Chi-sq 0 Chi-sq 0.5 Chi-sq 0
p 1 p 0.48 p 1
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determine clinically relevant species. Continued detection of other species at different abundance levels 
with larger population size should further confirm our findings. 
 
3.1.6 Discussion 
This study showed differences in microbial composition in paired tumor and adjacent normal tissue 
sequencing samples across 9 TCGA cancer cohorts. Through our microbial detection methods we 
showed differential bacterial abundance in stomach and colon adenocarcinomas. Our findings are 
consistent with other reports. Further, we used viral detection as internal validation and our findings which 
are consistent with previous reports. The role of Helicobacter pylori in cancer has been firmly established 
in stomach adenocarcinoma we add potential interaction with microbial community in the adjacent tissue 
as sign of disease progression. We note that measures of relative abundance alone or total number of 
reads do not provide sufficient information regarding the compositional differences in the tumor 
microenvironment. Measures of total reads, relative abundances and prevalence in the population need 
to be taken into account for a more accurate description of the differences within and across cohorts. In 
LIHC we determined that there was no difference in bacteria composition within paired samples when 
comparing tumor to its adjacent normal tissue, however there was an observable difference within tissue 
type in the cohort. Moreover although the number of species per sample appeared to be similar both 
tumor and adjacent normal, diversity varied by stage, age at diagnosis and sex which could have 
potential clinical significance particularly when we seek to uncover targetable biomarkers to improve 
patient outcomes. We identified HPV reads in all CESC paired samples as previously reported (Tang et 
al. 2013, Cantalupo, Katz, and Pipas 2018). In cancers of the head and neck, HPV was detected in 5% of 
the samples. Although previously reported detection of HPV for this group of cancers ranges from 20% to 
21% (Cantalupo, Katz, and Pipas 2018, Khoury et al. 2013, Hernandez et al. 2014) we feel confident that 
our results are similar to those previously reported using WXS data. Our study included a very small 
sample of 69 paired cases. From these 7 samples (6 tumor, 1 adjacent solid tissue normal) 
corresponding to 6 cases (1 female, 5 male) were positive for HPV. In CESC we found a (weak) negative 
correlation between HPV and Bradyrhizobium sp. which varied by pathological stage. We note that our 
sample size was small; perhaps correlation may be more prominent with increased sample size. 
Interestingly, Riley et al. reported that Bradyrhizobium like species including Bradyrhizobium BTAi1 were 
the most-common strain level operational taxonomic units found within the 1000 Genomes Project which 
supported lateral gene transfer (Riley, 2013). Laurence et al. pointed out that Bradyrhizobium sp. were 
found to be common contaminants due to ultrapure water systems within the 1000 Genome Project and 
many high-throughput efforts (Laurence et al. 2014 PMID 24837716).  Riley, notes that although 
contamination can be suspected, presence of the microbe may be due to diet and lifestyle differences in 
the population, highlighting that little is known about the composition of the human microbiome. Riley et 
al. utilized data derived from Chinese population. Microbial profiles in this study were derived from TCGA 
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project which encompasses different racial groups, primarily Caucasian Americans. Data has been 
collected at various Institutes, and was sequenced at different Centers. Although, water system or 
laboratory contaminants could be a source of reads, strict use of paired samples should assist with 
misidentification. We note that presence varied among cohorts with highest total reads among CESC 
(originating from University of Washington) and COAD (originating from Christiana Healthcare and 
Indivumed). CESC numbers of reads in tumor were 22 times higher compared to adjacent normal, while 
number of Bradyrhizobium like reads in COAD tumor were 7 times that of adjacent normal.  We also note 
that often both case pairs had bacterial reads for Bradyrhizobium like species. Bradyrhizobium 
diazoefficiens and Bradyrhizobium BTAi1 are nitrogen fixating bacteria and their role in disease is 
unknown. Nevertheless, these species may have a potential role in cancer pathogenesis and cancer 
therapy by means of their Hsp70 family molecular chaperone protein interaction with p53 (Deocaris et al. 
2007, Shevtsov, Huile, and Multhoff 2018). Our study is not without its limitations, the low reads relative to 
human sequences may not be sensitive to magnitude of differential expression and it may be less 
powered because our paired analyses filtration which resulted in a low number of cases analyzed. We sat 
limits to protect against this by not including any cancer cohorts with less than 15 specimens (smallest 
sample size CESC with 16 specimens). Our integrated analysis of exclusive 1-to-1 paired samples is not 
sensitive to tissue specific baseline relative abundance, or inherited 16S compositional assumptions. 
Each patient served as their own control eliminating interacting and confounding factors. In addition we 
provide simple and easy to interpreted results for complicated microbial data across a subset of TCGA 
cancer cohorts. We conclude that identifying microbial composition in tumor and adjacent normal tissue, 
using whole exome sequencing data provides useful and comparative tool similar to transcriptome and 
metagenomic methods to study bacterial composition in cancer. Further qPCR validation of bacterial 
presence with tissue specimens from Hawaii Tumor Registry as an independent population strengthens 
our findings. We highlight co-occurrence of Selenomonas sputigena and Fusobacterium nucleatum in 
tumor tissue of stomach adenocarcinoma. These oral species have been identified in the tongue coating 
of gastric patients but have not been identified in the tumor tissue previously (Xu et al. 2019). Future 
studies seeking to characterize the microbiota within the tumor microenvironment should consider 
examination of the adjacent tissue weighing prevalence within the population with equal weight to the 
total amount of reads detected. This will facilitate microbial functional predictions and distinguish between 
true presence and laboratory artifacts and possible contamination. 
3.1.7 Materials and Methods 
3.1.6.2 Cancer Database  
The data used in this study were derived from the TCGA consortium (phs000178 versions v9.p8 and 
v10.p8 under Project-14778, Deng, PI). TCGA cancer types with whole exome sequencing case pairs 
meeting selection criteria were downloaded. Cases were defined as solid tumor cancer types within 
TCGA that had human aligned sequencing reads, paired primary tumor and solid tissue normal raw 
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exome sequences in BAM file format, plus available clinical data. Paired cases were selected at 1:1 ratio 
for the bioinformatics interrogation 
3.1.6.3 Computational Framework for Microbial Detection  
TCGA Level-1 data were used to derive microbial information. For microbiota identification we used a 
bioinformatics pipeline designed to generate microbial profiles from human whole exome sequencing 
binary version of Sequence Alignment/Map (BAM) files based on PathoScope 2.0. PathoScope 2.0 
quantifies microbial strain level proportions found in metagenomics sequencing data (Hong et al. 2014). 
PathoScope 2.0 pipeline is freely available for download at: http://sourceforge.net/projects/pathoscope/. 
Quality trim and filtering were completed using SAMtools and Picard. Additional BLAST step was used to 
subtract any remaining human reads using a custom library. Pipeline produced 3 reports of quantified 
microbial proportions. Reports were used for bacterial differential analyses. Viral DNA detection o include 
bacterial phages was used as internal validation. We corroborated viral DNA detection rate, mainly HPV, 
HBV and HHV-4 (EBV) to previous RNA sequencing works by other authors (). Presence of viral DNA 
was also used in co-occurrence correlation analyses. R-software was used for phylogenic classification 
and statistical analyses. 
3.1.6.4 Core Microbiota  
Identification of core microbiota was completed under study assumptions of relative abundance positivity 
threshold of ≥ 0.2% per microbe with a minimum prevalence of 20% in the population. Core taxa 
identification was verified using microbiome R package (version 1.3.3) with default settings and detection 
and prevalence rates per study assumptions. Any species identified within each cohort were then 
compared across all cohorts regardless of study assumptions. Visualization of shared taxa was 
performed with UpSetR package (Alexander Lex et al. UpSet: Visualization of Intersecting Sets, IEEE 
Transactions on Visualization and Computer Graphics (InfoVis’14), vol.20, no.12, pp.1983-2014. 
Doi:10.1109/TVCG.2014.2346248).  
3.1.6.5 Diversity metrics and Differential abundance analyses 
Diversity measurements of alpha diversity (within sample diversity) and beta diversity (between samples) 
were completed for each cancer type. Mean differences of 15% are considered clinically relevant. 
Analyses were completed using R-software packages, phyloseq (v.1.25.3) and microbiome (v.1.3.3). 
Alpha (Shannon-Wiener Index, Simpson Index of Diversity and Fisher’s alpha) and Beta diversity were 
calculated using vegan R package (v.2.5-3). Differential relative abundance were determined using 
DESeq2 (v.1.21.24), edgeR (v.3.23.5) for count data and Wilcoxon Signed Rank test for compositional 
data within R-platform. Due low abundance relative read count nature of our data, use of DESeq2 and 
edgeR packages was limited to few cancer types. Wilcoxon Signed Rank test was used across all cancer 
types for differential analyses. Bacterial taxa with false discovery rate (FDR) adjusted p-value <0.05 were 
considered significant at genus and species level.  Correlation between the tools is beyond the scope of 
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this study. We note that all 3 methods identified similar species as differentially abundant, although 
edgeR on average identified a greater proportion compared to DESeq2 and Wilcoxon Signed Rank test 
using R. A list of R-packages used is located in Appendix D. R-Package toolspp 134. 
3.1.6.6 Statistical analyses 
To determine the association between differences in relative abundance in tumor and its adjacent normal 
and clinical features, paired or unpaired t-test and analysis of variance (ANOVA) were used for two- and 
multi-group comparisons, respectively. Equivalent non-parametric tests were used for non-normally 
distributed data and to account for compositional structure of microbial relative abundances. Chi-square 
test was used for categorical data. 
3.1.6.7 PCR validation 
Institutional Review Board approval from the University of Hawaii was obtained prior to any procedures. 
We experimentally validated bioinformatics findings with de-identified archival tissue from the Hawaii 
Tumor Registry-Discard Residual Repository (RTR), a unique collection of formalin-fixed, paraffin-
embedded (FFPE) tissue from cancer patients diagnosed within the catchment area of the Hawaii Tumor 
Registry. The Hawaii Tumor Registry is one of three population-based registries associated with the 
National Cancer Institute (NCI) and the Surveillance, Epidemiology, and End-Results (SEER) program. 
Archival tissue from a total of 161 paired cases from gastric (21) and lung (80) cancers were selected for 
validation. Specimen retrieval, cut & slide, sectioning, pathology review and nucleic acid extraction were 
performed by the University of Hawaii Cancer Center Pathology Shared Resources. DNA was extracted 
from FFPE using Qiagen All Prep FFPET Kit (Qiagen, Valencia, CA) and quantified by NanoDrop 
spectrophotometer (Thermo-Scientific, Wilmington, DE). PCR were completed using 30ng of DNA for 
every 25µl of reaction mix using commercially available species-specific primer-probe kits (Microbial DNA 
qPCR assay kits 330033, Qiagen, Valencia CA) per manufacturer’s instructions under the following 
conditions: Activation: 10 minutes 95ºC, followed by 45 cycles of Denaturation and Annealing at 95ºC for 
15 seconds and 60ºC for 2 minutes. Samples were tested in duplicates plus positive and negative 
controls. Discrepancies were resolved by repeat qPCR. Due to budgetary constraints, species-specific 
validation was limited to Helicobacter pylori, Fusobacterium nucleatum, and Selenomonas sputigena. 
3.1.6.8 Other analyses 
KRONATM plots (https://github.com/marbl/Krona/wiki) were created for relative abundance visualization 
using Excel macro enable templates. Quantified proportions of bacteria and viruses generated from the 
bioinformatics pipeline were used to generate plots. Including total per microbe read count, average reads 
per microbe, percent population prevalence and relative abundance data. 
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3.2 Bacterial diversity correlates with survival in infection-associated cancers of                                      
the head & neck, liver and stomach 
 
3.2.1 Abstract 
Objective: One in five cancers are attributed to infectious agents and the extent of the impact on the 
initiation, progression and disease outcomes may be underestimated. Infection-associated cancers are 
commonly attributed to viral, and to a lesser extent, parasitic and bacterial etiologies. There is growing 
evidence that microbial community variation rather than single agent, can influence cancer development, 
progression, response to therapy, and outcome. We wanted to examine the microbial within sample 
diversity of paired tumor and adjacent normal tissue across infection-associated cancer types in order to 
provide an improved understanding of microbial diversity and abundance patterns of the tumor 
microenvironment and their influence on clinical presentation and survival. We hypothesized that 
microbial diversity can be a predictor of overall survival and identify racial-related differences that in turn 
may influence therapeutic decisions. 
Methods: We evaluated a subset of tumors in The Cancer genome Atlas (TCGA) from head & neck 
squamous cell carcinoma (HNSC), liver hepatocellular carcinoma (LIHC) and stomach adenocarcinoma 
(STAD). Alpha diversity (within sample diversity) as well as presence of specific relevant bacterial and 
viral species was compared between paired tumor and adjacent normal samples. Association of specific 
microbial presence with overall survival was also evaluated. Cox proportional regression and generalized 
linear models were used to correlate bacterial diversity with clinical presentation and overall survival.  
Results: A total of 470 paired tumor and adjacent normal were analyzed. In STAD, presence of HHV-4 
was associated with poorer survival in the presence of Selenomonas sputigena (HR: 2.23, 95% CI 1.26, 
3.94, p=0.006) and high diversity index was associated with poorer overall survival outcomes (HR: 2.31, 
95%CI 1.1, 4.9, p=0.03).  In LIHC, lower microbial diversity were associated with poorer overall survival 
(HR: 2.57, 95%CI: 1.2, 5.5, p=0.14) while high diversity appeared to have a favorable effect. In HNSC 
there was a small non-significant trend between high diversity and favorable survival while interestingly, 
Rothia mucilaginosa status was associated with poorer overall survival outcomes (HR: 6.17, 95%CI: 1.3, 
29.7, p=0.02 (controlling for smoke)). Rothia mucilaginosa was correlated with presence of HPV. 
Conclusion: We show a comprehensive analysis of within sample diversity derived directly from human 
tumor sequences and survival outcomes. Bacterial within sample diversity correlates with survival in 






Microbiological infections account for up to 25% of the total global cancer burden, one of the leading 
causes of morbidity and mortality worldwide (WHO 2018). Despite declining incidence rates in the United 
States, cancer remains the leading cause of death among Asian Americans, Native Hawaiians and 
persons of Hispanic origin (Siegel et al. 2015, Torre et al. 2016). Racial-disparities persist in infection-
associated cancers including liver, gastric and cancers of the head & neck (NCI 2015). Liver, gastric and 
head & neck cancers are in the top ten causes of cancer related deaths worldwide with marked racial 
differences. Underlying causes for racial disparities are multifactorial and not well understood (Gourin and 
Podolsky 2006, Singh, Siahpush, and Altekruse 2013, Merchant, Li, and Kim 2014). Recent studies 
suggest a potential role of microbial composition in racial-related disparities (Brooks et al. 2018). While 
much effort has gone into the characterization of the gut and oral microbiota, compositional differences of 
tumor tissue are less explored. Identification of tissue-associated microbial differences is challenging and 
computationally intensive. There is growing evidence suggesting microbial communities have a dual 
modulating effect in cancer pathogenesis (Mager 2006, Paulos et al. 2007). In addition, viral-bacterial co-
occurrence have been identified to modulate tumor aggressiveness (Pandya et al. 2015). Based on 
epidemiological and geographic correlations it is suggested that viral agents may interact with specific 
bacteria resulting in more aggressive tumors and poorer outcomes. For instance, it is recognized that 
HHV-4 infected stomach tumors are molecularly distinct, while its interaction with Helicobacter pylori 
remains unconfirmed. In hepatocellular carcinoma co-infection with HBV with HCV and their interaction 
between proteins can also lead to more aggressive tumors. New evidence has hinted at the association 
of gut microbial dysbiosis with cancer clinical outcomes, even potentially influencing racial-related 
differences (Gopalakrishnan, Spencer, et al. 2018, Farhana et al. 2018). Gopalakrishnan et al. (2018) 
determined that a highly diverse gut microbiome can provide improved antitumor response while low 
diversity with high abundance of unfavorable bacteria such as Bacteroidales, may result in weakened 
antitumor presentation capacity (Gopalakrishnan, Spencer, et al. 2018). To our knowledge, no studies 
have examined microbial within sample diversity derived directly from the tumor microenvironment in 
humans and its relation to survival and potential impact on racial differences. We aimed to study 
differences in tumor and normal tissue microbiome diversity and determine if this has any relationship 





3.2.3 Material and Methods 
3.2.3.1 TCGA Data: We had previously derived microbial relative abundances and bacterial diversity data 
from solid tumors from The Cancer Genome Atlas (TCGA) network using bioinformatics workflow based 
on PathoScope 2.0. Microbial profiles and diversity metrics are available for 22 cancer cohorts. Microbial 
profiles have associated de-identified relevant clinical data downloaded from data commons under project 
Project-14778 (Y. Deng, PI). For this work, we selected three infection-associated cancers (head & neck, 
liver and stomach) to retrospectively examined the relationship between bacterial diversity (within sample 
diversity) and cancer overall survival. Other caners commonly attributed to infectious etiology were not 
selected on the basis of low paired sample availability. To determine if a relationship exists, we compared 
within sample diversity to survival time in tumor and adjacent normal pairs. Bacterial diversity associations 
to clinical features including basic demographics (age at diagnosis, sex, race and ethnicity), tumor stage, 
tumor grade, site of resection, histopathology, exposure (alcohol and smoke when available) and viral 
infection status were also examined.  
3.2.3.2 Data availability: The microbial profile data used in this study is maintained by the University of 
Hawaii Bioinformatics Core, CIM John A Burns School of Medicine per Data Management Plan and User 
Certification Agreements for each TCGA cohort.  
 
3.2.4 Statistical Analyses 
Association to cancer overall survival was derived from diversity data among living and deceased groups. 
To determine the association between difference in bacterial diversity (within sample), in tumor and its 
adjacent normal samples and the clinical features, pairwise t-test and analysis of variance (ANOVA) were 
used for multi-group comparisons. Chi-square test were used for categorical data. Using bacterial 
diversity and significant clinical features as predictors, Cox proportional hazards regression analyses 
were used to evaluate the associations between diversity and overall survival per cancer type. Tukey’s 
HSD post hoc tests were also carried out. All analyses were carried out n R platform. A complete list of 
packages and applications is provided as supplemental data. 
 
3.2.5 Results 
3.2.5.1 Microbial diversity profiles.  
Bacterial within sample diversity measured by Shannon-Wiener index of diversity were obtained from a 
subset of 3 infection-associated cancers from TCGA cancer cohorts per previous (3.1). A total of 470 
paired tumor-adjacent normal samples encompassing 235 cases from cancers of the head & neck 
squamous cell cancers (HNSC), liver hepatocellular carcinoma (LIHC), and stomach adenocarcinoma 
(STAD), were examined. Of the 470 samples, 11% (1 from HNSC, 28 samples from LIHC and 23 from 
STAD) had no detectable bacteria presence. 7% of samples, (7 from HNSC, 15 from LIHC and 11 from  
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STAD) had single bacteria.  In both cases diversity indices are represented as zero. All cases with at 
least one bacteria species present in either tumor or normal were considered for analyses. Viral presence 
(HBV, HHV-4 or HPV) was detected in 31% of samples without bacterial presence. Overall sample 
population and microbial profile characteristics and are summarized in Table 18. 
Table 18 Microbial diversity profiles among infection associated cancers 
Table of population characteristics for HNSC, LIHC and STAD cohorts stratified by sample type. A proportion of 









3.2.5.2 Relative abundance differs by race 
Gut microbiota composition and relative abundance signatures have been associated with racial 
differences in colorectal cancer patients and healthy individuals (Farhana et al. 2018, Brooks et al. 2018). 
We wanted to evaluate if similar patterns existed when examining the microbial composition within the 
tumor microenvironment. To do this we compared relative abundance profiles stratifying by race.  
Figure 21 Relative abundance in HNSC cohort in tumor and adjacent normal by racial groups 
 
Figure shows top-20 taxa at genus level average relative abundance per sample type across different racial groups 
within the HNSC cancer cohort. NR: not reported. Differences between tumor and adjacent normal in each racial group 
are observed. Paired samples of Asian (n=1) and Black or African American (n=9) have less diverse microbial signature 
patterns compared to White and not reported (considered a mixed-race group). While the tumor samples of White and 
non-reported have a higher number of different genus, in Asian and Black or African American tumor tissue has far 
fewer species compared to their paired adjacent normal and to other groups. Bacillus spp. (dark purple) are over 
abundant in the tumor tissue of Asian and Black or African Americans compared to White, where Bacillus is higher in 




Figure 22 Relative abundance in LIHC cohort in tumor and adjacent normal by racial groups 
 
Figure 23 Relative abundance in STAD cohort in tumor and adjacent normal by racial groups 
 
Figure 22 and 23 show top-20 taxa at genus level average relative abundance per sample type across different racial 
groups within the LIHC and STAD cancer cohorts. NR: not reported. An interaction between submitter site and race 






In HNSC, at genus level average relative abundance per sample type across differs by racial groups. 
Acidovorax are present in all except Asian patients (n=1).  Bacillus are the being the only genus present 
in the tumor (light purple bar) among Asian. In head & neck, Sphingomonas genus is present across all 
racial groups with the smallest proportion among Black or African American samples. While the tumor 
samples of White and non-reported appear to have a more diverse tumor microenvironment, in Asian and 
Black or African American tumor tissue has far fewer species compared to their paired adjacent normal 
and to other racial groups. Among the three cohorts, LIHC patient samples had the lowest number of taxa 
at the genus level, with most reads mapped to Escherichia coli. Relative abundance patterns are similar 
across all racial groups paired samples within the cohort. Black or African American group in LIHC shows 
greater abundance of Pseudomonas and Ralstonia species. LIHC shares some species with HNSC in 
similar patterns across Black or African American and White patient samples such as presence of 
Variovorax which is not present in STAD.  
In previous studies (Tae et al. 2014) comparing tumor and matched blood specimens, it was reported that 
microbial signatures (including virus, bacteria and other species) related ethnic differences where in fact 
due to specific stamp signatures corresponding to the institutions where specimens originated or where 
processed. Authors concluded that these signatures could correspond to contamination or laboratory 
artifacts (Tae et al. 2014).Based on this report, we wanted to know if observed racial differences were 
associated with the institution from which they originated. Because our strictly paired analyses, if 
microbial signatures are potentially contamination, we would expect the same relative abundance 
patterns in tumor and adjacent normal paired samples. We compared relative abundance of specific taxa 
found to be prevalent and differentially present within the sample population across submitter site 
institutions and between samples from different racial groups originating from same institution. All HNSC 
specimens in our study originated and were processed at the same institution and no comparisons were 
performed. It is presumed that observed variation is attributed to racial and clinical presentation 
differences. LIHC samples used in this study originated from a diverse population enrolled at different 
institutions including University of North Carolina, University of Pittsburgh, Mayo Clinic Rochester, 
Christiana Health, and University of Florida among others. All LIHC specimens were processed at the 
same institution. In LIHC there were no overall differences across submitter sites in pairwise comparison 
using Wilcox test with Bonferroni correction for multiple testing. In analyses of variance adjusting for race 
and sample type, some species were identified as significantly associated with submitter site. Ralstonia 
pickettii (F(10, 147)= 24.4, p=<0), Klebsiella pneumoniae (F(10, 147)=1.97, p=0.04), Rhodococcus 
erythropolis (F(10,147)= 2.73, p=0.004) and  Bradyrhizobium japonicum (F(10,147)=2.23, p= 0.02). 
Ralstonia pickettii and Rhodococcus erythropolis association were dependent on sample type present at 
different frequencies. Escherichia coli, the most abundant species detected in LIHC cohort, was also 
associated with submitter site in linear regression model. White specimens (n=1) from a single site, had 
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greater abundance of Escherichia coli compared to those originating from other sites. A two-way ANOVA 
was carried out on Escherichia coli relative abundance by submitter site and race. There was a 
statistically significant interaction between submitter site and race on the relative abundance of 
Escherichia coli (F(7, 141)=7.5, p=0). A Tukey’s HSD post hoc test was carried out. Originating from the 
University of Florida relative abundance was For Whites compared to Black or African Americans, relative 
abundance of Escherichia coli was significantly different across institutions (mean difference 380.8, p.adj 
(BH)=0.04).  
STAD, subset of samples originated from different institutions including, Asterand, Christiana Health, the 
International Genomics Consortium, University of Pittsburgh, ABS-AUPUI, National Cancer Center of 
Korea, and Indivumed. All STAD specimens in this study were processed at a single institution and 
different from those in LIHC. However, racial minority groups were uniquely recruited from specific 
institutions; we presumed that institutions with only one racial group will be inherently different when 
examining racial differences between institutions. Similarly, we compared the relative abundance of top-
taxa within the background (White) population across institutions, and across the racial groups within 
same institution as applicable. In Asterad, White population specimens had similar abundance patterns of 
top-taxa in tumor and adjacent normal. Relative abundance differences were observed for Helicobacter 
pylori, Streptococcus and Selenomonas species within the White population. Abundance of these species 
was not associated with submitter site (F(8, 161)=0.6969, p=0.69). Presence of Bacillus subtilis among 
samples originating from the National Cancer Center of Korea were significantly different compared to 
other sites (p= 0.006). We found no evidence to suggest interaction between submitter site and race on 
species relative abundances. When comparing White and Black or African American from the same 
institution, distinct patterns emerged. Despite, bacterial relative abundance differences between 
originating institutions, in pairwise comparison with Bonferroni correction were not statistically different. 
We conclude that observed relative abundance differences between tumor and paired adjacent normal 
across racial groups in STAD are true observations not due to artifacts from the originating sites. Similar 
to previous studies gut microbiota findings we find that relative abundances of certain taxa are associated 
with race. 
3.2.5.3 Microbial diversity differs by race 
We examined within sample diversity (alpha diversity) from all cases positive for microbial presence in at 
least one of their tumor or adjacent normal samples. In paired analyses comparing tumor to its adjacent 
normal, within sample diversity indices were not significantly different for any of the three cohorts (Figure 
24). Approximately 8% (n=19) of the samples had no reported racial background. We considered these to 
be a mixed group. We performed student t-test for continuous variables and Chi square test for 
categorical variables to examine differences in population characteristics in order to ascertain differences 
in microbial abundance and diversity profiles. Across cohorts, stratifying by sample type, there were no 
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significant differences in the proportion of male-to-females, the age at diagnosis, vital status. There were 
significant differences in the proportion of racial minorities as previously noted by Zhang et al. (Zhang et 
al. 2017) and the presence and absence of viral agents associated with cancer initiation and 
aggressiveness (Pandya 2015). Microbial profiles show similar patterns in tumor and adjacent tissue 
samples across different racial groups (Figure 25). Figure 25 shows composite bar graph by sample type 
and racial background across HNSC, LIHC and STAD cancers. Evenness, a measure of the relative 
abundance is illustrated with a line graph on a secondary axis which show the relation between the 
diversity index and species abundance from 1 indicating complete evenness (most species are similar) 
and 0 highly diverse. We also examined clinical presentation and exposures within the groups across the 
racial groups. Population differences within the cohorts were considered to build proportional hazards 
models. 
In HNSC, we observed small trends in the number of species (p= 0.05). When stratifying by race, stage, 
vital status, morphology or tumor grade did not differ significantly. Bacterial diversity differed by 
anatomical site. Among HNSC patients, there were no significant differences, when considering bacterial 
species relative abundance and presence or absence of in microbial profiles at any level, including 
Corynebacterium pseudotuberculosis, Rothia mucilaginosa, Capnocytophaga ChDC OS43, Treponema 
denticola, Ralstonia pickettii, Streptomyces gilvosporeus, Sphingomonas melonis, Sphingomonas 
sanxanigenens, and Arthobacter. Two Actinomyces species, Actinomyces pacaensis (presence, not its 
relative abundance) and Actinomyces myeri (its relative abundance, not its presence) were significantly 
different across the racial groups within HNSC (p=0.03). When stratifying by race, there were no 
differences in exposures including the number of cigarettes per day; however, significant differences in 
smoke years were observed (p=0.001). Diversity means by race did not differed significantly in HNSC. 
(Table 18).  
For LIHC there were no differences in clinicopathological presentation including primary diagnosis and 
resection site, except for tumor stage when stratifying by race and sex. In LIHC race proportions were in 
itself significantly different with no female of Asian background (Table 18). While species richness was 
not significant across the different racial groups in LIHC, within sample diversity measures were 
significantly different among racial groups (Student-t-test, Shannon Index of diversity, p=0.01; evenness, 
p=<0.001). We also observed a significant difference in the ratio of males-female patients among racial 
groups although there were no differences overall. There were no differences in survival status by race, 
however we noted significant differences in the days survived by racial groups (Student t-test, p=0.03). 
Asian patients within the LIHC cohort were significantly younger (mean 53.3 (10.5)) compared to White 
(mean 65.8 (15.2)) and the non-reported mix race group (mean 62.4 (11.9)) (Wilcoxon, p=<0.001). 
Microbial profiles for LIHC patients were significantly different when stratifying by race and sex. Viral 
presence of HBV differed both by sex and race while presence of HHV-4 did not (Table 18). HBV 
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presence was significantly higher among Asian patients (presence and abundance p=<0.001). 
Bradyrhizobium spp. presence were slightly different by sex in LIHC. In pairwise tests, diversity was 
significantly different between White and Asian patients (BH p.adj=0.009). We conclude that differences 
in bacterial diversity for LIHC differ by race and this relationship is dependent on HHV-4 infection status 
(F(1, 53)=4.8 p=0.03).  
 
Table 19 Shannon-Weiner diversity index in tumor and adjacent normal pairs  
 
Table shows with sample diversity indices across cohorts by different racial groups. Females of Asian background are 
underrepresented in HNSC and LIHC cohorts and Blacks females in STAD. Analyses of variance examining adjusting 
for sample type, race and sex shows significant differences in within sample diversity in LIHC and STAD 
 
Significant within sample bacterial diversity were observed in STAD cohort where Black or African 
American patients fell within the highest diversity quartiles both in tumor and adjacent normal. There were 
significant differences with histopathological grade, and site of resection while no difference in in tumor 
staging within the population. When stratifying by race, significant differences in primary diagnosis 
(p=0.022) and age at diagnosis (p=0.027), and site of resection (p=0.022) were observed. Viral presence 
was significant among females of different racial groups. HHV-4 positive status was significantly higher 
among White females compared to other racial groups (13% non-White). Microbial species detected 
differed across racial groups and by sample type. Several species including Fusobacterium nucleatum, 
Lactobacillus amylovorrus, Lactobacillus salivarius, Campylobacter concisus, Lactobacillus fermentum,  
Neisseria enlongata were unique to tumor samples. Bacillus subtilis (presence, not its relative 
abundance), was deferred by race with highest prevalence among White patients with differential 
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abundance in tumor compared to its adjacent normal (White: 61% versus 59.3%, Not reported 50% 
versus 66.7%, Black 33% versus 66.7%, and no difference among Asians, (F(4,165)=8.7, p=<0.0). 
Cutibacterium acnes, Mycoplams mycoides and Ralstonia pickettii presence were significantly different 
among different racial groups in tumor, while in adjacent normal, Arthrobacter presence was the different 









Figure shows paired t-test comparing tumor to adjacent normal within sample bacterial diversity. HNSC has a 
marginal trend of lower diversity in tumor compared to adjacent normal at 0.05 compared to no difference in LIHC 
and STAD. Despite there is an observable bimodal trend in STAD with presence and absence of taxa resulting in 
diversity index of zero in one sample over the other and a slightly higher mean in adjacent normal samples. Compared 









Figure shows the microbial diversity profiles for infection associated cancers in tumor and adjacent tissue samples 
among different racial groups with standard error bars. Average absolute observed abundance (pink bars), within 
sample diversity index as determined by Shannon-Weiner index (green bars), and evenness (y-axis) of species 
abundance per racial group in each cohort is shown as line graph. Shannon diversity index measures the relative 
proportion of species abundance (Summation of species by the natural log of total species within a sample). Evenness 
is a measure of the relative abundance (Shannon index by natural log of total species) from 1 indicating complete 
evenness and 0 highly diverse. Here is being used as a complement to index of diversity calculated with vegan R-
package in which both are calculated separately. In HNSC, Asian (n=1) have the lowest combined diversity measures 
(low number of species with high degree of evenness) compared to Asian in LIHC (n=7) and STAD (n=16) where 
despite absolute abundance being low, the species present are from diverse origin. White patients in contrast, although 
number of species within the sample are high, these appear to be from similar origin resulting in low combined indices 
of diversity. Overall although similar, diversity indices between tumor and adjacent normal are contrasted specially in 










3.2.5.4 Microbial within sample diversity is associated with overall survival.  
Based on the different patterns observed in bacterial within sample diversity identified in each cohort, we 
wanted to test for the interaction between diversity and race, sex and other clinical features to overall 
survival. Comparisons were completed by vital status. Overall, among HNSC patients, there were no 
significant associations between overall survival and clinicopathological features including sex and 
microbial diversity. Yet significant interaction was observed between sex and microbial diversity of the 
adjacent tissue relationship to survival when stratifying by vital status (two-way ANOVA, F(2, 43)=6.28 
p=0.004)). We then tested the relationship of diversity and overall survival stratifying based on tertiles of 
Shannon Diversity index. HNSC deceased male patients with high bacterial diversity in the adjacent 
normal tissue, on average lived shorter days after diagnosis than males with low diversity. While female 
counterparts had opposite effects (Figure 27, B). There were no significant associations in HNSC 
between diversity quartiles and survival. We conclude that any relationship between diversity and survival 
are dependent on the interaction with sex in HNSC cohort subset.   Although not significant, HPV status 
appears to have an effect on survival which is dependent in bacterial presence and smoking status. 
Figure 26 Racial diversity differences by cohort in tumor and adjacent normal samples 
  
  
Figure shows Wilcoxon (unpaired) test comparing Shannon bacterial diversity index by racial groups across cohorts in 
tumor (A) and adjacent normal (B). Bacterial within sample diversity is significantly different in STAD tumor (Wilcoxon, 
p=0.4) and in LIHC adjacent normal (Wilcoxon, p=0.02), while no difference is observed in HNSC in either tissue type 








 Figure 27 Bacterial Diversity relationship with survival in HNSC and LIHC is dependent on sex 
 









Rothia mucilaginosa was found to be differentially abundant, predominant in adjacent tissue (log2fc=-4.44, 
p=0.001 FDR=0.32).  In Cox proportional hazards, we observed a small a non-significant association with 
detrimental and HPV positive infection status (Figure 28). 
 
Figure 28 HNSC Hazard Ratios based on Cox proportional hazards 
 
Figure shows Cox proportional hazards forest plot based on adjusted model with interaction terms of smoke and 
clinicopathological characteristics within the HNSC cohort. Overall, there is no increased risk associated with 
bacterial diversity. Males are at lower risk than females and HPV status appears to have an association with 






In LIHC bacterial diversity was associated with overall survival with significant differences between low to 
intermediate levels diversities compared to low and high diversity index quartiles (Figure 29). Sex, race 
 
Figure 29 LIHC overall survival is associated with microbial within sample diversity  
 
 
Figure shows survival curve based on Kaplan Meier estimates (created with survminer) for the relationship between 
bacterial within sample diversity and overall survival with global pvalue. Strata with risk set size is shown in table. 
Time in days survived after diagnosis or days to last follow up (censored). Censoring over time are delineated by “+” 
within the survival lines for each strata.  Low diversity =0 to 0.4, intermediate-low =.4 to 1.4, intermediate-high=1.4 to 
2.3, and high diversity =2.3 to 3.2.   Intermediate-low versus low diversity (HR: 2.4, 95%CI: 1.2-5.0, p=0.02). 
Proportional assumptions violations corrected in Cox hazards model   
 
and age were also associated with overall survival in LIHC. Similar to HNSC, LIHC cohort had an 
interaction between sex and diversity tertiles. Among living males (n=16), lower tumor bacterial diversity 
is associated with shorter days survived after diagnosis with opposite effect in females (n=14) at the same 
diversity range. Contrary to HNSC, bacterial diversity in the adjacent tissue had a negative effect among 
females and favorable effect among males (Figure 27, E). Intermediate diversities are associated with 




In Cox logistic regression model, intermediate-low bacterial diversity was associated with more than 
double the risk compared to those at low, intermediate-high and high diversities(HR: 2.4, 95%CI: 1.7-5.0, 
p=0.02), as is positive HBV infection status (HR=5.8, 95%CI:1.4-24.7 p=0.02). Analysis of deviance 
revealed significant interaction between age at diagnosis and HBV infection status with overall survival 
(supplemental data). 
Figure 30  LIHC Hazard Ratios based on Cox proportional hazards 
 
Figure shows Cox proportional hazards forest plot based on adjusted model with interaction of clinicopathological 
characteristics found to be significantly different within the LIHC cohort. After adjusting for interacting features, 
diversity intermediate-low quartile are at higher risk.   
 
 
In STAD, overall survival was associated with bacterial diversity quartiles where higher diversity resulted 
in poorer survival outcomes (Figure 31). Significant interaction between sex and tumor diversity tertiles 
was observed among those alive at time of censoring (F(2, 45)=3.6, p=0.03). Post hoc analyses revealed 
significant difference between males with high diversity compared to males with intermediate diversity 
indices (diff=-888, -1762 to -13.4, adjusted p value (BH)=0.04). Overall survival was associated with 
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demographic characteristics including race (p=0.006) and age at diagnosis (p= 0.001). There was no 
correlation between overall survival and sex alone. We then tested the correlation between diversity, race  
 
Figure 31 STAD overall survival is associated with microbial within sample diversity  
 
STAD Kaplan Meier survival curve (created with survminer) for the relationship between bacterial within sample 
diversity and overall survival with global pvalue (p=0.008). Strata with risk set size are shown in table. Time in days 
survived after diagnosis or days to last follow up (censored). Censoring over time are delineated by “+” within the 
survival lines for each strata.  Low diversity =0 to 0.8, intermediate-low =.8 to 1.6, intermediate-high=1.6 to 2.4, and 
high diversity =2.4 to 3.6.   Low versus high diversity (HR: 2.8, 95%CI: 1.3-6.0, p=0.01). Proportional assumptions 
violations corrected in Cox hazards model (supplemental data). 
 
and age at diagnosis. We observed there was correlation between bacterial diversity and race (Chi-sq 
=27.4, df=9, p=0.001) and no correlation with age at diagnosis (rho= -0.008, 95%CI= -0.235, 0.063, 
p=0.25). Analyses of variance were carried out to compare the relationship between survival days and 
diversity controlling for both age and race. We concluded that the relationship between diversity and 
survival days is dependent on the interaction with race, where Asian patients with lower diversity have 
better survival outcomes compared to White (HR=0.16, 95%CI=. 0.37, 0.7, p=0.014). Hazards by 
clinicopathological features were also examined. In STAD, tumor histopathological stage was associated 
with diversity. Bacterial diversity was on average higher at higher tumor stages. Whites classified at tumor 
stage III had on average higher diversity indices than other racial group. Tumor stage was in turn 
associated to survival days (Chi-sq=43.3, p=<0.0).  Relationship between survival days and stage was 
dependent on diversity (F(27,129)=2.3, p=<0.001).  Cox proportional hazards revealed that those 
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classified at tumor stages II to III with lower diversity indices survived longer days after diagnosis 
(HR=0.037, 95%CI=0.17, 0.8, p=0.01). 
Figure 32 STAD Hazard Ratios based on Cox proportional hazards 
 
Figure shows Cox proportional hazards forest plot based on adjusted model with clinicopathological characteristics 
found to be significantly different within the STAD cohort. Infection status have no effect on survival.  Increase in 
diversity  is proportionally associted with increased risk. Patients within the higher diversity quartiles  are at increased 






In high throughput sequencing data while microbial cancer associations have gained interest in recent 
years, insufficient attention has been paid to the potential of addressing racial disparities. Previous 
studies have identified bacterial diversity as a modulator of treatment response where a highly diverse gut 
microbiota that includes beneficial bacteria exerts beneficial treatment outcomes; compared to a gut with 
a less diverse ensemble and high prevalence of pathogenic bacteria which can have the opposite effects 
(Gopalakrishnan, Spencer, et al. 2018).  Other studies have found that gut and oral microbiota diversity 
contributes to racial differences in cancer (Farhana et al. 2018) and in healthy adults (Brooks et al. 2018, 
Gupta, Paul, and Dutta 2017, Hoffman et al. 2018). Studies have focused on tumor viral detection or 
bacterial metagenomics profiling of the gut and oral microbiota. In this study we examined the relationship 
between bacterial relative abundances and diversity to overall survival in three infection-associated 
cancers of the stomach, liver and head & neck to determine if similar to previous studies we could identify 
bacterial differential patterns associated with race and overall survival. To do this we utilized previously 
created microbial abundance and diversity profiles from a total of 470 paired tumor and adjacent normal 
samples corresponding to 235 cases.  Across the three cohorts, majority, 74% (n=174) were self-reported 
as non-Hispanic White, 10% were Asian, 8% were Black or African American and 8% were of no reported 
racial background and considered to be a mixed race group. From these, 40% (n=93) were females, and 
55% (n=131) were deceased. We compared bacterial diversity associations to clinical features including 
basic demographics (age at diagnosis, sex, race and ethnicity), tumor stage, tumor grade, site of 
resection and histopathology.  Smoke exposure (in head & neck cancers) and viral infection status of 
Epstein-Barr virus (HHV-4), human herpes virus –B (HBV) and human papilloma virus (HPV) were also 
examined.  We found that across all three infection-associated cancers examined here, the relationship 
between microbial diversity and survival differs by tissue type, tumor versus the adjacent normal and are 
dependent on the interactions with sex and race. Interactions with race and sex also differ by survival 
status. We believe that the interactions with sex are perhaps related to the absence lower number or 
absence of females within the 3 cohorts examined, these associations are stronger in gastric and liver 
cancers than in cancers of the head & neck. We found that microbial tumor and adjacent tissue diversity 
were on average lower among persons of Asian background compared to White counterparts. African 
Americas in the other hand, had similar within sample diversity to White in HNSC, lower in LIHC and 
higher in STAD. We also noted that bacterial within sample diversity relationship to overall survival had 
opposite effects in STAD compared to LIHC while no differences were observed in HNSC.   
In STAD cohort, higher bacterial diversity was associated with poorer outcomes (HR= 2.77, 95%CI=1.3, 
6, p=0.01) with differences among different racial groups. For example Asian persons had lower risk of 
death compared to White (HR=0.16, 95%CI=0.04, 0.7, p=0.01). Yet, among those who were deceased, 
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tumor average bacterial diversity was higher among Asian compared to other groups. Among those living 
at time of censoring, there was a divergent association with days survived after diagnosis. Here, higher 
tumor tissue within sample diversity, appears to be associated with longer days, while higher diversity in 
the adjacent tissue is associated shorter days. We noted that Asian patients had the lowest average 
diversity indices in the adjacent tissue. This could explain the protective effect Asian persons had within 
our STAD subset compared to White. Black or African Americans (n=3) had higher bacterial diversity in 
the adjacent normal which similarly could be associated with their poorer outcomes. The bimodal diversity 
is suggestive of microbial species overturn (dysbiosis) and colonization in disease progression. We also 
examined microbial (viral and bacterial) presence, relative abundance and co-occurrence patterns. In 
STAD, presence of HHV-4 was associated with poorer survival (HR: 2.23, 95% CI 1.26, 3.94, p=0.006). 
However relative abundance of HHV-4 was not correlated with survival days. Prevalence of HHV-4 was 
higher among non-Hispanic Whites who suffered the poorer survival outcomes in the STAD subset. In 
LIHC, lower microbial diversity were associated with poorer overall survival (HR: 2.57, 95%CI: 1.2, 5.5, 
p=0.14) while high diversity appeared to have a favorable effect overall. Interestingly we observed that 
compared to White, Asian and African American patients who were deceased at censoring, had low 
bacterial diversities and opposite outcomes were Asian appear to do poorer while African American have 
longer survival days. Bacterial diversity in the adjacent normal appears to have no effect while diversity in 
the tumor does. Among deceased LIHC patients, bacterial within sample diversity in the tumor is lower 
diversity is associated with lower number of days survived after diagnosis. We also found a divergent 
effect of bacterial presence and relative abundance on race and sex and tumor stage. Interactions 
between several clinicopathological features and diversity were found. We tested for the possibility of site 
submitter interaction and found that cohorts have specific signatures by race which are associated or 
dependent on age and sex. Escherichia coli presence and relative abundance in LIHC of was associated 
with submitter site and race. In linear regression model accounting for interacting terms, submitter site 
was associated with race. In analyses of variance this explained 27% of the variation (R2=0.27, adjuster - 
R2-squared =.20.  In pairwise analyses using Wilcoxon rank sum test, sites with similar racial recruitment 
were highly correlated.  We interpreted this as the difference in recruitment for racial minorities across 
different cohorts were the effect of the site is modulated by race. Since racial groups were recruited from 
specific sites it is logical that the two are interacting, while White patients were recruited from multiple 
sites. These interaction effects are predominant in LIHC cohort. We observed that for some bacterial 
species there was significant interaction between bacterial abundance and the originating institution. 
Previous studies have suggested that microbial differential patterns are dependent the submitting 
institution rather than other features including demographics of age, sex and race(Tae et al. 2014). In our 
analyses we found that in LIHC, bacterial signatures patterns differ by submitting institution with high 
correlation between sites with similar enrollment patterns. We discovered an interaction between the 
submitting institution, sample type and race. Although the possible effect of contamination at submitter 
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cannot be ruled out, our paired analyses design should account for this. Small sample representation of 
racial minorities may influence our ability to detect hidden or masked associations. Future studies with 
larger sample size should confirm our findings. Here we shown a comprehensive analysis of within 
sample diversity and relative abundance derived directly from human tumor sequences and survival 
outcomes. We conclude that bacterial within sample diversity correlates with survival in HNSC, LIHC and 
STAD cancers and these associations are dependent on the interactions with sex and race with divergent 
associations of beneficial or detrimental effects with overall survival by cancer type.  
3.2.8 Literature Cited 




CHAPTER IV CONCLUSIONS & FUTURE DIRECTIONS 
 
4.1 Summary of conclusions 
In this study we built microbial profiles for solid tumor cancers within the TCGA Network in order to 
determine epidemiological and clinical significance of microbial differential abundance between paired 
and adjacent normal tissue using whole exome sequencing data. We screened more than 200 billion 
whole exome sequencing reads, generating detailed microbial documentation for more than 800 tumor 
and adjacent normal samples across 9 cancers types. We have presented the microbial composition in 
STAD, LIHC, COAD, READ, LUSC, LUAD, HNSC, CESC and BLCA cohorts and examined potential 
roles in carcinogenesis, overall survival, as well as the impact on racial disparities in STAD, LIHC and 
HNSC cancers. We demonstrated the ability to identify differential composition of bacteria species from 
human tissue creating a platform for current and future research while addressing important health 
disparities research questions. This dissertation advances the concepts of cancer tumor 
microenvironment by the detailed examination of both, the tumor and adjacent tissue microbial 
composition directly derived from human sequences. We showed that bacterial shifts between tumor and 
adjacent normal, as well as their microbial diversity and differential abundances could be indicative of an 
active role of bacteria in disease progression and cancer pathogenesis determined by overall survival 
outcomes.  Further, validation by qPCR of Helicobacter pylori, Fusobacterium nucleatum and 
Selenomonas sputigena in gastric cancer and Selenomonas sputigena in lung adenocarcinoma with 
tissue samples from an independent population from the Hawaii Tumor Registry demonstrates that our 
simple methods for the identification and interpretation of complex microbial data, are equivalent to 
complex transcriptomics and metatranscriptomics methods.  Altogether this study has provided a cross-
cancer view of tumor-bacterial associations.  
Our results show that bacterial within sample diversity correlates with overall survival which, confirm and 
extend current knowledge of bacterial diversity patterns and viral co-occurrence as demonstrated by 
HPV, HHV-4 and HBV patterns of co-occurrence.  Importantly our results argue against monomicrobial 
actions on cancer pathogenesis and overall survival. Furthermore, it highlights the importance of utilizing 
paired sample data together with measures of absolute read abundance, relative abundance and 
population prevalence in studies evaluating microbial composition and their impact on differential 
outcomes in order to avoid wrongful conclusions. We also highlight the following findings: 
 Significant differential abundance of Helicobacter pylori in STAD and Bacteroides vulgatus in COAD 
tumor compared to adjacent normal samples. Differential abundance may be indicative of disease 
progression rather than a beneficial or protective effect.  In disease progression, bacterial community 
may lead to unfavorable effects by destroying the integrity of cellular barrier, enabling pathogenic 
bacteria to exert damage or reactivating viral pathogens.   
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 Diversity is correlated with tumor stage and overall survival in HNSC, CESC, LUSC, LUAD, STAD 
and LIHC cancers. We observed that differences in clinical presentation and survival among cancer 
patients from different cohorts may be explained by bacterial abundance patterns. There are 
observed differences across racial groups. However, we are hesitant to conclude bacterial diversity or 
the relative abundance patterns impact racial disparities.  In order to make such assertions racial 
minority groups’ representation must be enriched in these of studies.  
 We find that examining paired tumor and adjacent normal tissue is pivotal when evaluating the role of 
bacteria in the tumor microenvironment. Failing to do so can lead to wrongful interpretations. We note 
in our analyses that potential significant taxonomic associations disappear under strict paired 
conditions. 
 Bacterial associations with cancer may be poly-microbial. Our study show the interaction between 
viral presence of HPV, HBV and HHV-4 and several bacterial species with overall survival as 
demonstrated in STAD, LIHC and HNSC cancers. This is supported by previous studies findings 
(Parsonnet 1995, Warren et al. 2013).  
 Diversity relationship to overall survival is dependent on sex race and other clinical factors with 
opposite effects by per cancer type as demonstrated in STAD and LIHC. In STAD higher within 
sample bacterial diversity appears to have negative association with overall survival, while the 
association in LIHC is a positive one. 
This study is not without its limitations, we found that bacterial reads were low in relation to human-host 
total number of reads which is an inherit restriction of working with human-derived whole exome 
sequencing data. We recognize that bacterial diversity and relative abundance divergent association with 
various tumor types, this does not signify causality. Our findings are limited to an association with the 
pathogenic process as determined by differential overall survival outcomes and further studies are 
needed to elucidate the mechanisms and the depth of the involvement. Also our pipeline design was 
unable to detect RNA viral reads which would have been important in the correlation analyses of viral 
interactions. We cannot rule out potential contamination. We examined submitter site and processing site 
and do not believe this to be a factor in our analysis. In addition, our strict paired design should control for 
potential contamination effect. We note that there is underrepresentation of racial minorities in our paired 
data subset of solid tumor cancers that hinders racial disparities analyses. Further, self-reported data and 
missingness including treatment information limit generalization of results. Nevertheless, validation of 
bioinformatics findings with the Hawaii Tumor Registry, an independent population derived from a diverse 
racial and ethnic population sample pool, strengthens our results.  
4.2 Future Directions  
As part of this project we downloaded and build microbial (viral and bacterial) profiles for 22 solid tumors 
from the Cancer Genome Atlas Network creating a platform for interdisciplinary collaboration that can 
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help move forward ongoing and future research. Presented here are the analyses for 9 of those cancers. 
These were selected on the basis on known infectious etiology, STAD, LIHC, HNSC, CESC and BLCA, or 
inflammation associated with no known infectious etiological factors, LUSC, LUAD, COAD and READ, 
that we considered key in identifying racial and ethnic differences in priority populations.  Our efforts led 
to several abstract publications and presentations. This project will continue to analyze remaining 13 
cancer cohorts and begin functional prediction analyses on the first 9 included here and continue to 
validate specific taxa in selected cancer cohorts. We can now better appreciate the diversity present in 
the human tumor microenvironment that makes identification of microbial communities so challenging. 
Nevertheless, this information can provide us with the necessary tools assess the effects of microbiota on 
the colonized tissue. Cross-cancer analyses such as this one, facilitate identification of inter-individual 
variation patterns and can answer additional questions about the beneficial or detrimental effects in 
different cancer lineages. Additional questions may include mechanistic approaches and mutational 
characterization, the prediction of clinically relevant functional differences and discovery of actionable 
pathways that can inform patient care and therapeutic approaches. 
Possible Research Questions: 
1. What are the clinical applications from microbial data derived from human sequencing reads and 
how can this help the understanding of racial variance and the impact on widening racial 
disparities? 
2. Do bacterial relative abundance, diversity and co-occurrence patterns predict functional relevant 
inter-individual differences within the cancer type and across cancer types? If so, how can this 
best be applied in the application of primary and secondary prevention strategies and inform 
patient care  
3. What are the mechanisms involved in microbe-host interaction effects and how can we best 
identify actionable pathways to reduce and eliminate racial and ethnic related disparities through 
microbial modulation? 
4. Are bacteria diversity and relative abundance patterns associated with tumor somatic mutations 
and gene expression profiles? If so, what communities may be involved and to what degree? Are 
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A. Supplemental data 
A.1 Core taxonomy across cancer types 

















 % ±SD 
STAD  
Bacillus subtilis 48 51 12.5 12.1 
Mycoplasma mycoides 31 31 8.4 13.2 
Cutibacterium acnes 31 29 16.3 19.6 
Arthrobacter sp. IHBB 11108 22 29 16.8 6.4 
Rothia mucilaginosa 26 24 7.8 6.2 
     
LIHC  
Escherichia coli 67 67 89±30 84±31 
Cutibacterium acnes 30 33 5±9 4±16 
Ralstonia pickettii 31 32 3±21 4±30 
     
COAD  
Escherichia coli 93 94 31±35 30 ±32 
Bacteroides fragilis 81 86 14 ±20 10 ±14 
B. thetaiotaomicron 73 81 6 ±10 6 ±7 
Alistipes finegoldii 63 69 3 ±6 4 ±6 
Bacteroides vulgatus 68 77 7 ±10 12 ±16 
Parabacteroides distasonis 59 65 2± 4 3 ±6 
Bacteroides dorei 63 75 4 ±9 5 ±9 
Bacteroides ovatus 61 68 2 ±3 2 ±3 
Bacteroides caecimuris 53 68 1 ±2 1 ±2 
Roseburia hominis 60 60 1 ±2 1 ±1 
Flavonifractor plautii 53 57 1 ±2  1 ±1 
Cutibacterium acnes 53 55 1 ±2 1 ±4 
     
READ  
Bacteroides dorei 31 36 29±15 32±12 
Bacteroides vulgatus 44 72 25±7 37±19 
B. thetaiotaomicron 67 67 38±28 44±29 
Bacteroides fragilis 78 67 35±22 33±21 
Escherichia coli 89 89 70±28 67±25 
     
LUAD     
Bacillus subtilis 53 63 14±16 13±17 
Mycoplasma mycoides 34 44 8±10 7±7 
C. pseudotuberculosis 30 36 13±12 11±11 
Arthrobacter sp. IHBB 11108 38 30 14±19 14±19 
Cutibacterium acnes 25 22 18±18 18±18 
Mitsuaria sp.7 26 29 12±10 19±20 
R. depolymerans 23 22 8±9 14±8 










Core taxonomy across cancer types (continued) 

















 % ±SD 
LUSC     
Bacillus subtilis 55 56 35±22 42±23 
Mycoplasma mycoides 41 45 35±24 39±23 
P. lacuslunae 37 36 34±23 42±23 
     
C. pseudotuberculosis 33 37 35±22 40±24 
Cutibacterium acnes 26 46 38±26 40±27 
Streptomyces gilvosporeus 22 27 38±27 36±22 
Bacillus mycoides 22 20 33±23 39±26 
HNSC     
Bacillus subtilis 43 67 4±9 8±13 
Mycoplasma mycoides 35 45 3±6 2±5 
C. pseudotuberculosis 28 45 2±5 5+-9 
Streptomyces gilvosporeus 22 33 1±2 2±4 
Arthrobacter sp. IHBB 11108 23 46 1±4 5±9 
CESC     
Escherichia coli 50 38 81±12 51±16 
Bradyrhizobium BTAi1 38 25 46±7 91±9 
S. koreensis 38 13 65±13 58±0 
     
BLCA     
Bacillus subtilis 71 68 29±22 27±18 
Arthrobacter sp. IHBB 11108 39 50 20±16 30±25 
Mycoplasma mycoides 39 46 11±8 17±17 
C. pseudotuberculosis 36 29 24±15  18±15 
     
Percent of positive samples and average relative abundances (shown as percent) with plus/minus standard 
deviation in tumor and adjacent normal across nine TCGA cohorts.  STAD: stomach adenocarcinoma; LIIC: 
liver hepatocellular carcinoma; COAD: colon adenocarcinoma; READ: rectal adenocarcinoma; LUAD: lung 
adenocarcinoma; LUSC: lung squamous cell carcinoma; HNSC: head & neck squamous cell carcinoma; 
CESC: cervical squamous cell carcinoma; BLCA: bladder carcinoma.  
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A.2 Diversity in cancers of the head & neck, liver and stomach 
Variable Reference Estimate SE p-value OR  95%CI 
HNSC             
Intercept Shannon Diversity 2.92 1.02 0.005 18.53 [2.45, 139.97] 
Sample type Adjacent normal 0.21 0.14 0.133 1.23 [0.94, 1.61] 
Age at diagnosis   0.00 0.01 0.737 1.00 [0.98, 1.01] 
Sex Female 0.35 0.18 0.050 1.42 [1.00, 2.01] 
Race White           
Asian   -0.80 0.59 0.180 0.45 [0.14, 1.45] 
Black or AA   0.15 0.24 0.529 1.16 [0.72, 1.88] 
NR   0.79 0.43 0.066 2.21 [0.95, 5.14] 
Ethnicity Hispanic           
Not Hispanic   0.52 0.26 0.052 1.68 [0.10, 2.83] 
NR   0.39 0.38 0.304 1.48 [0.70, 3.12] 
Tumor Stage stage i           
stage ii   -1.28 0.63 0.047 0.28 [0.08, 0.98] 
stage iii   -0.67 0.64 0.291 0.51 [0.15, 1.79] 
stage iv   -0.97 0.63 0.127 0.38 [0.11, 1.32] 
Tumor grade -- -- -- -- -- -- 
Anatomical site Floor of mouth           
Hard palate   1.24 0.69 0.074 3.44 [0.88, 13.37] 
Larynx   -0.93 0.38 0.016 0.40 [0.19, 0.84] 
Lip,Oral,Pharynx, overlap   -0.60 0.40 0.135 0.55 [0.25, 1.21] 
Tongue, base   -0.97 0.49 0.052 0.38 [0.14, 1.01] 
Tngue, NOS   -0.92 0.39 0.019 0.40 [0.18, 0.86] 
              
LIHC             
Intercept Shannon Diversity 3.04 0.64 <0.0001 20.90 [5.94, 73.40] 
Sample type Adjacent normal -0.17 0.17 0.328 0.85 [0.60, 1.18] 
Age at diagnosis   -0.01 0.01 0.259 0.99 [0.98, 1.00] 
Sex Female 0.15 0.18 0.394 1.16 [0.82, 1.65] 
Race White           
Asian   -1.28 0.35 <0.0001 0.28 [0.14, 0.56] 
Black or AA   -0.38 0.38 0.319 0.68 [0.32, 1.45] 
NR   0.61 0.78 0.434 1.84 [0.40, 8.59] 
Ethnicity Hispanic           
Not Hispanic   -1.10 0.50 0.028 0.33 [0.13, 0.88] 
NR   -1.89 0.84 0.026 0.15 [0.03, 0.79] 
Tumor Stage -- -- -- -- -- -- 




Variable Reference Estimate SE p-value OR  95%CI 
LIHC Anatomical site -- -- -- -- -- -- 
              
STAD            
Intercept Shannon Diversity 1.56 0.91 0.090 4.77 [0.78, 29.05] 
Sample type Adjacent normal 0.28 0.26 0.280 1.32 [0.79, 2.20] 
Age at diagnosis   0.00 0.01 0.706 0.99 [1.00, 1.01] 
Sex Female 0.03 0.21 0.887 1.03 [0.68, 1.56] 
Race White           
Asian   -0.20 0.49 0.683 0.82 [0.31, 2.15] 
Black or AA   1.26 0.59 0.033 3.53 [1.10, 11.29] 
NR   -0.71 0.36 0.053 0.49 [0.24, 1.01] 
Ethnicity Hispanic           
Not Hispanic   NA NA NA NA NA 
NR   NA NA NA NA NA 
Tumor Stage stage ia           
stage ib   0.27 0.49 0.587 1.30 [0.50, 3.42] 
stage ii   0.84 0.55 0.131 2.31 [0.78, 6.86] 
stage iia   0.42 0.46 0.369 1.52 [0.06, 3.81] 
stage iib   0.57 0.05 0.231 1.78 [0.69, 4.57] 
stage iii   1.93 0.96 0.046 6.87 [1.03, 45.80] 
stage iiia   0.93 0.50 0.064 2.53 [0.95, 6.75] 
stage iiib   1.19 0.57 0.038 3.29 [1.07, 10.10] 
stage iiic   1.05 0.73 0.150 2.86 [0.67, 12.16] 
stage iv   0.51 0.51 0.153 1.66 [0.60, 1.56] 
Tumor grade G1           
G3   0.33 0.30 0.273 1.39 [0.77, 2.51] 
GX   0.05 0.70 0.460 1.67 [0.42, 6.64] 
G norm   NA NA NA NA NA 
Anatomical site body of stomcah NA NA NA NA NA 
Cardia   -0.21 0.28 0.457 0.81 [0.47, 1.41] 
Fundus   -0.58 0.82 -0.747 0.56 [0.11, 2.81] 
gastric antrum   0.08 0.24 0.729 1.09 [0.67, 1.77] 







A.3 Hazards Ratio supplemental plots 
HNSC 
 
Cox proportional hazards forest plot illustrating effects of smoke in HNSC. When adding 
interaction of smoke, infection status of HPV and Rothia mucilaginosa have a detrimental effect 
on overall survival. However wide confidence intervals prevent accurate interpretation based on 












Cox proportional hazards forest plot illustrating effects of smoke in LIHC. When controlling for 
interaction terms of age, race and sex significant hazards remain for males at intermediate 












Cox proportional hazards forest plot for STAD controlling for interaction terms. After controlling 
for the interaction of sex and race, effects of bacterial diversity is no longer significant, while the 
effects of race and infection status remain. Among Asian patients who have on average lower 
diversity indices have significant lower risk compared to White counterparts (HR=0.13, 









Diagnostic plots for Cox proportional hazards assumptions. Plots were created with survminer’s 
ggcoxdiagnostic function. All plots include interaction terms.  
HNSC diagnostic plots 
 
HNSC after correcting for proportional hazards violation by applying interaction terms of smoke, 
sex and race.  
LIHC diagnostic plots 
 
LIHC diagnostic plots after correcting proportional hazards violation by applying interaction 






STAD diagnostic plots  
 
Diagnostic plots for STAD after correcting for assumption violations with interaction terms of 












B. Data Management  
B.1 Data Management Plan  
This study was based on data generated from level 1 (original raw data) sample sequences 
from the TCGA consortium. As such a data management plan (DMP) was developed as part of 
the approval process. Original management plan is presented below. DMP has undergone 4 
revisions to add additional researchers and additional datasets not related to this study.  
____________________________________________________________________________ 
TCGA Controlled-Access Data Management Plan 
 
Protocol: Divergent Bacteria Associations with Cancer Pathogenesis across Tumor Types 
DMP Version: 1.0 







Vance C Mizuba 
Rebecca M Rodriguez 
Reviewed by: 
Leonard Gouveia, Institutional Signing Official  








This Data Management Plan (DMP) outlines policies and procedures related to data security as well as study 
database design and structure for our study (Project ID 14778) as it relates to the GDC Commons (dbGaP) data 
download and local storage of NIH Controlled-Access Data (phs000178.v9.p8). 
This DMP is prepared by the Bioinformatics Core team in collaboration with the JABSOM IT Department. This 
DMP will be updated as necessary throughout the course of the study. Editorial changes and clarifications may be 
made without consultations. Once a change has been approved, the revised document will be made available with a 
new date and version number and implementation date if applicable. This plan will be reviewed on an annual basis. 
A copy will be maintained in the study regulatory folder. 
Roles and responsibilities:  
General protocol roles and responsibilities will apply. In brief, principal investigator (PI) is responsible for the 
procurement of NIH Controlled-Access Data used in this study, the protection of data confidentiality and of 
providing annual progress reports as delineated in the Data Use Certification (DUC). The Bioinformatics Core 
located at UH Manoa JABSOM Campus, is responsible for the management of the data. Institutional Signing 
Official (SO) and Information Technology (IT) Director are responsible for proper use and security of the data 
downloaded. As per dbGaP Security Best Practices, IT Director may not function as PI, SO or collaborating 
scientist. The following study key personnel and collaborators will have authorized access to the data in order to 
achieve the project’s objectives:  
Personnel Project’s objective 
Youping Deng, 
Principal Investigator 
-Procurement of controlled access-data 
-Management of data integrity assurance 
-Preparation of process data for analysis, creation and execution of analytical 
programing 
-Annual Progress Report 
Brenda Y Hernandez, 
Study Collaborator 
 
-Procurement of controlled access-data 
-Validation of study findings 
-Annual Progress Report 
Mark Menor, 
Data Configuration and 
Programmer 
-Abstract raw data from NCI Genomic Data Commons 
-Preparation of process data for analysis, creation and execution of analytical 
programing 
-Management of data integrity assurance 
Vedbar Khadka  
Data Configuration and 
Management 
-Preparation of processed data for analysis, creation and execution of analytical 
programing 
-Management of raw/processed data integrity assurance 
Rebecca Rodriguez, 
Research Coordinator  
-Overall study coordination 
-Preparation of processed data for analysis, creation and execution of analytical 
programing 
Vance C Mizuba 
IT Director 
-Management of requested data set according to NIH expectations and Best Practices 
for Controlled-Access Data and UH Policies and Security Requirements 
-Develop and execute CAPA procedures in the event of data security incidents 
 
-Least Privileged Access. In order to access, process and analyze data the personnel listed above are granted access 
according to their roles to accomplish project’s objectives. All personnel follows strict UH guidelines and policies to 
set unique user account and passwords. 
-Personnel Training. All study staff are required to take appropriate training in information security awareness.  




This DMP is primarily for the download, processing, storage and security of TCGA human genomic Level 1 
sequencing data. The data here referenced are whole genome DNA sequence binary alignment files (BAM), 
throughout this document described as “raw data” or “controlled-access data”. These data are provided de-
identified and will be used to create microbial profiles. 
Clinical data, biospecimen data and pathology reports data are described in this document as “clinical data”. 
Clinical data are being requested and will be downloaded from Level 1 (.xml) files. These data includes basic 
demographic information, treatment and survival data as well as details about of sample processing and pathology 
reports. These data are provided de-identified and will be used to correlate microbial profiles to clinical outcomes.  
Human DNA sequences will be filtered out from raw data. Reads will be subsequently filtered, trimmed and 
compiled using validated pipeline as described (section 1). Remaining operational taxonomic units (mostly 
microbial DNA) will be aligned against reference genomes, throughout this document described as “process(ed) 
data” 
1. Data Management Milestones 
 Due to the ongoing nature of this project, milestones relating to project completion and data lock are not included. 
-Pipeline Design. Previously validated pipelines are being used with few modification to fit the needs of the project. 
-Pipeline Validation. Pipeline specifications and programming were checked against open-access exome 
sequencing data for 9 gastrointestinal stromal tumors and normal matched pairs.  
-Controlled Access Data Download. Request to controlled-data have been submitted via dbGaP (Project ID 
14778). After data access approval notification, PI will grant access to key personnel according to their roles through 
dbGaP Portal. Download should commence within 5 business days upon granting access to key personnel. 
-Data Queries. Data queries will be run once a month to ensure data integrity is maintained. Data configuration 
staff and the research coordinator will be responsible for resolving data queries. 
-Pilot Audit. A pilot audit will be completed immediately following initial TCGA data download for the first 10 
BAM files.  This will ensure system is working as intended and files are downloading appropriately. 
2. Data Collection Instruments 
Raw data will be downloaded directly from NCI Genomics Data Commons in BAM files, processed and transcribed 
(processed data) into spreadsheets after the filtering process. This task will be completed by data configuration 
and/or programmers. Clinical data, as described in definitions sections, will be extracted from .xml files onto 
spreadsheets (when available). This task will be completed by the PI and/or research coordinator. Only project 
specific data will be retained as specified in the approved protocol, all other will be discarded as per UH Policies and 
Procedures HRS 487R. Raw data will be retained according to DUC Agreement for TCGA data and Institution data 
retention policies. 
3. Collection Schedule 
NIH Controlled-Access Data (TCGA, phs000178.v9.p8) and clinical data will be downloaded at once upon access 
approval and token authentication. PI will ensure key personnel is granted access to project data prior to requesting 
token authentication. Tokens are valid for thirty (30) days. It is estimated complete data download will take in 
excess of 30 business days and will depend on size of BAM files and speed of access. New tokens will be requested 
as needed per GDC Data User’s Guide.  
4. Data Flow 
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Data Source  Data Transfer  Data Management 
1. NIH Controlled-access data will be downloaded from GDC Data Commons into Bioinformatics server and 
network storage system.  
2. Data will be cleaned and transferred to study database for processing within the Bioinformatics servers. 
3. Data will be stored and analyzed according to protocol to answer study aims. 
5. Pipeline Design and Testing/Validation 
The study pipeline and database will be setup and tested by the data configuration and programming team prior to 
approval for production use.  All changes made to the pipeline structure/programming after final approval are to be 
documented in a change control log and included in an updated version of the project data management plan. 
BAM to fastq  PathoQC  PathoMap  MegaBLAST filter  PathoID  PathoReport  taxize 
 
6. Data Security 
Protection of the privacy and confidentiality of the participants whom information is derived is our number one 
priority. Data security measures and appropriate safeguards will be employed to ensure compliance with standards 
as per UH policy, DUC Agreement and dbGaP Approved User Code of Conduct. 
-Primary Work Locations (PWLs). The PWLs for this project are identified as: 
UH Bioinformatics Core 
Biosciences Building, UH JABSOM Campus 
651 Ilalo Street 
Honolulu, HI 96813 
MEB Server Room 
Medical Education Bldg, UH JABSOM Campus 
651 Ilalo Street 
Honolulu, HI 96813 
 
Workstations and study staff reside at the UH Bioinformatics Core work location. The servers reside at the MEB 
Server Room location. 
-Physical Access Controls. Access to the Biosciences building is restricted by key card access and manned 24/7 by 
security guards at the front desk. Access to the MEB server room is restricted by key card and biometric fingerprint 
access. Audit logs for ingress access are available as needed for both PWLs. 
-Environmental Protection. The MEB server room has a FM-200 fire suppression system; UPS and generator 
power backup in cases of long-term power failures; and active monitoring for temperature range and water leakage. 
-Data Storage. The server is the primary data storage location and houses the raw data and processed data sets. 
Study staff workstations may store copies of the processed data set as needed for daily workflows. All servers, 
workstations, and removable media that store data are encrypted-at-rest with full disk encryption enabled. The 
encryption uses 128-bit AES encryption cipher or better. 
-Data Transfer. All data transfers over a network use end-to-end encryption methods, such as SSH or sFTP. All 
data transfer of processed data is made via password protected CD or encrypted transfer such as encrypted email or 







Media Formats of Data Safeguards 
☒ Data stored on servers and workstations 
--Raw and processed data 
Full disk encryption is implemented on the hard 
drive of all devices that will house NIH 
controlled-access data or a copy there of. 
Workstations are prohibited from storing raw 
data. 
 
☒ Data on removable media (CD, DVD, 
portable hard drives, USB drives, etc.) 
--Processed data 
 
All data on removable media storage will be 
encrypted with full disk encryption 
 
☒ Data in printed format 
--Processed data for use in publications, 
presentations 
Facility entrance is restricted. Physical 
precautions policies are in place to protect data in 
printed format to prevent unauthorized access. 
 
 
-Encryption Key Management. All encryption keys for encrypted files and disks is stored either on a separate 
computer system not involved in this project or kept as hard copies in a locked secured file cabinet that only can be 
accessed by data management staff. 
-Remote Access. Remote access away from PWLs is authorized through VPN secure connection. As per UH Policy, 
End-to-End encryption will be utilized on Secure Socket Layer (SSL) or Virtual Private Network (VPN) connections 
for transferring data. Only de-identified cleaned data (processed data) will be authorized remote access. 
-Computer Network Technical Controls and Safeguards. The JABSOM Office of Information Technology (OIT) 
manages the network firewall, workstation firewalls, workstation group policy, and network intrusion 
prevention/detection system. Host based firewalls are required per UH policy on all workstations that store copies of 
the data. 
Our computer Operating System (OS) are current with latest patches and security updates in accordance with the 
JABSOM OIT patch management policy. In brief, all Windows-based workstations are joined to the domain and 
receive security patches and updates automatically on a monthly basis. Per UH Policy, anti-virus/ anti-spyware 
software are deployed throughout the network on workstations and servers and are periodically updated. 
Practices and policies are in place to safeguard servers and workstations during periods of inactivity. These include 
auto-logoff after 30 minutes of inactivity and screensaver lock after 15 minutes of inactivity for all workstations.  
Security audit controls are implemented which record and examine user activities on the workstations where 
controlled-access data is processed. All logging attempts are tracked and auditable. 
Vulnerability scans will be executed on a quarterly schedule. Remediation of all threats rated ‘high’ will be resolved 
in 7 days. Remediation of all threats rated ‘medium’ or ‘low’ will be resolved in 30 days.  
In the event of a security incident, the PI and JABSOM OIT will be notified immediately. Steps to initiate corrective 
action or other remediation and mitigation to determine the data loss and prevent recurrence of the breach will be 
implemented immediately. The UH System Security Officer will also be notified. 
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-Data Storage and Document Archiving. Raw and processed data will be housed in a Network Attached Storage 
(NAS) server in a folder accessible only to the study team.  No copies of the raw data will ever be made into any 
workstations. A study database will be compiled from the processed data (microbial and clinical data combined) for 
analyses. Study team will maintain copies of the study database on the bioinformatics core for at least one (1) year 
after analysis and according to UH record retention policies and according to DUC Agreement, section 6- Data 
Security and Release Reporting. After study completion and publication study files will be retained or discarded as 
per UH Policies and Procedures HRS 487R. Reports will be archived indefinitely as read-only files. 
-Backup. Data backup will be conducted at least once a month at regular intervals by the data management study 
team. Backups are written to encrypted disks and maintained at PWL. 
DMP Change Control Log  
Date  Version Author Revision 
 
 
   
 
 
   
 
 
   
 
References: 
E2.210: Use and Management of Information Technology Resources Policy 
E2.214: Security and Protection of Sensitive Information 
E2.215: UH Institutional Data Governance Policy 
HRS 487R: Destruction of Personal Information Records 
NCI Genomic Data Commons (GDC) Data User’s Guide 
NCI Genomic Data Commons (GDC) Data Transfer Tool User’s Guide 
The Cancer Genome Atlas (TCGA) Data Use Certification Agreement, version 20.AUG.2014 
NIH Genome Wide Association Studies (GWAS) Data Sharing Policy   
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D. R-Package tools 
D.1 R script (Microbial differential abundance-main) 
#####################################################################################









#Part I. Build phyloseq object####################################################### 
##################################################################################### 
#A. Load and arrange data needed to build phyloseq object 
#1. otu_table and taxa_table 
##IMPORTANT: before loading the file with the otu counts we should have cleaned the file## 
##meaning: 
##should not contain any records of patients without bacterial reads. Leaving them will## 
##change the results as it will erroneously have all bacteria present in as significant##  
##number of records## 
 
otucount <- read.csv('XXXX_bacteria_counts.csv', row.names = 1)+1 #before running 
#script ensure to change "XXXX for the name of the cancer type i.e STAD" 
#Note: addition of 1 is important to avoid errors with log of zero 




#remove microbial reads that are not present in both tumor and normal across all# 
#samples…should not be different if adding 1. If running for creation of relative# 
#abundances, DO NOT add 1####### 
raw <- rowSums(otucount) 
otucountC <- otucount[raw != 0,] 
dim(otucountC)  
 
taxdata<- read.csv("XXXX_taxa_table.csv",sep=',', header = T, row.names = 1)#before 
runing script ensure to change "XXXX for the name of the cancer type i.e STAD" 




#2. sample metadata 
sampledata<- read.csv("XXXX_sample_meta.csv", sep=',', header= T, row.names= 1) 






#3. merge initial phyloseq object (otu and taxa) to create rooted tree 
OTU <- otu_table(otucountC, taxa_are_rows = TRUE) 




XXXXphyloseq <- phyloseq(OTU, TAX) #before runing script ensure to change "XXXX for 
the name of the cancer type i.e STAD" 
XXXXphyloseq #before runing script ensure to change "XXXX for the name of the cancer 
type i.e STAD" 
 
 
#4. rooted tree 
XXXXtree <- rtree(ntaxa(XXXXphyloseq), rooted=TRUE, 
tip.label=taxa_names(XXXXphyloseq), br= runif(1))#before runing script ensure to 




#B. Build phyloseq object summarized experiemnt with all components 
XXXXpseq <- merge_phyloseq(XXXXphyloseq, sampledata, XXXXtree)#before runing script 
ensure to change "XXXX for the name of the cancer type i.e STAD" 
XXXXpseq 
##################################################################################### 
#Part II. Use phyloseq object to obtain microbial densities with microbiome R-package 
##################################################################################### 
#####load any mising dependencies##### 
 
#A. create relative abundance table from pseq object and save file for future analyses 
#remember to change XXXX for the cancer type before running the script# 
XXXXpseq.compositional <- transform(XXXXpseq, "compositional") 
XXXX_relabund<-XXXXpseq.compositional@otu_table 
write.csv(XXXX_relabund, file = "XXXX_ra_from_pseq_object.csv")#double check no 
samples get dropped.  
#microbiome package will drop to make table with even number of samples. 
 
#B. Identify core taxa. May have to change the detection and prevalence levels until# 
#dataframe produces values.  
####OTU abundance data must have non-zero dimensions.################################ 
#####################################################################################  
#if receiving above error message change the prevalence reducing 10%ges at the time# 
#until error dissapears############################################################## 
#Core taxa ideally is Taxa with over 50% prevalence at .2% or .5 % relative #abundance.# 
#Viral study (Cantalupo et al. Virology. 2018; 513:208-216) included any and all virus# 
#in at least 5% of the population without defining true core. Our internal process# 
#includes any taxa with 20% prevalence in either tissue type as determined by read 
#counts with a relative abundance of min# #.2% in at least 50% of those positive for# 
#the microbe therefore there is room to play around to determine core taxa for each# 




#1. core taxa by relative abundance (compositional transformation) 
XXXXcore <- core(XXXXpseq.compositional, detection = .2/100, prevalence = 




#before running script ensure to change "XXXX for the name of the cancer type i.e STAD" 
XXXX_p <- plot_core(transform(XXXXcore, "compositional"),  
               plot.type = "heatmap",  
               colours = gray(seq(0,1,length=5)), 
               prevalences = seq(.05, 1, .05),  
               detections = 10^seq(log10(1e-3), log10(.2), length = 10),  
               horizontal = TRUE) + 
  xlab("Detection Threshold (Relative Abundance (%))")  
print(XXXX_p)     
 
#2. collect the tids of the taxa resulted from the core plot  
#3. plot core taxa relative abundance in the population 
#before running script ensure to change "XXXX for the name of the cancer type i.e STAD" 
plot_composition(transform(XXXXcore, "compositional"),  
                 plot.type = "barplot", sample.sort = "neatmap")  
      
#C. Ordinate data using the phyloseq object and microbiome R-package 
#remember to set the seed. we are using the seed "4235421" and the Bray method per 
#microbiome package tutorial 
 
#1. set seed 
set.seed(4235421) 
ord <- ordinate(XXXXpseq, "MDS", "bray")#remember to change XXXX to the cancer type 
before running the script 
 
#2. by Sample type 
plot_ordination(XXXXpseq, ord, color = "Sample.Type") + 
  geom_point(size = 5) 
   
#3. may copy above sentence code with different variables as needed 
 
#4. canonnical (CCA) ordination may be more informative when looking a % explained by 
racial differences for example or taxa variations 
#4a. by race 
XXXXpseq.cca <- ordinate(XXXXpseq, "CCA") 
p <- plot_ordination(XXXXpseq, XXXXpseq.cca, 
                     type = "Sample.Type", color = "Race") 
p <- p + geom_point(size = 4) 
print(p) 
 
#4b. by taxonomy 
p <- plot_ordination(XXXXpseq, XXXXpseq.cca, 
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                     type = "taxa", color = "phylum") 
p <- p + geom_point(size = 4) 
print(p) 
   
#5. if interested may plot density of the core taxa or of the significant taxa 
individually 
#using the tid or the name according to how it was recorded in the otu table 
#5a for absolute (observed abundance) 
plot_density(XXXXpseq, "XXXXxx") +ggtitle("Absolute abundance of 'enter name of taxa' 
")   
##remeber to change XXXX for the cancer type, XXXXxx for the tid and to enter the name 
of the taxa in the title 
##before running the script 
 
#5b for relative abundances 
x <- microbiome::transform(XXXXpseq, "compositional") 
tax <- "XXXXxx" 
plot_density(x, tax, log10 = TRUE) + 
  ggtitle("Relative abundance 'enter name of taxon' ") + 
  xlab("Relative abundance (%)") 
##################################################################################### 
#Part III. Diversity Metrics using vegan package 
##################################################################################### 
#A. load data in from counts table with bacteria counts only  
##table must be flipped with taxa in columns (taxa=columns) may use the transpose 
function t() 
##it may also be necessary to load a separate sample metadata or annotation file for 
plotting 
 
#1. load data 
XXXX_meta<-read.csv("XXXX_sample_meta.csv") 
XXXX_bac.counts<-read.csv("XXXX_bacteria_counts_flip.csv", row.names = 1)#analyses 
#require data be supplied as taxa=columns 
str(XXXX_bac.counts)# can use to check if ny are not integers that may need adjusting 
if so may use ceiling function 
 
XXXX_bac.counts<-ceiling(XXXX_bac.counts) #remember to change the XXXX for the cancer 
type 
 
XXXX_bac.anno<-read.csv("XXXX_bacteria_annotation.csv")#may use sample meta or 
specific bacteria annotation if sample size is different 
 
#2. bind by column the counts and the annotation 
XXXX_data<-cbind.data.frame(XXXX_bac.counts, XXXX_bac.anno)#ensure samples were sorted 
correctly 
 
#3. Calculate Diversity indeces, Shannon, Simpson, invSimp etc. and get the stast 
##remember to change XXXX for the cancer type before running the script 
XXXX.Simpson<-diversity(XXXX_bac.counts, index = "simpson") 
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summary(XXXX.Simpson)#provides the statistics for the samples 
 
XXXX.Shannon<-diversity(XXXX_bac.counts, index = "shannon") 










#5. Run a pairwise with all diversity metrics including fisher alpha 
pairs(cbind(XXXX.Shannon,XXXX.Simpson, XXXX.invSimp, XXXX.unbSimp, XXXX.Fisher), 
pch="o", col="dodgerblue")#only include Fisher if non-NANs produced 
 
#6. Determine speies counts by number of reads and richness (S) 
XXXX.sr<-rowSums(XXXX_bac.counts)#total short reads per sample that are assigned to 
individual taxa output is species count 
#may save output as a csv to add column in the metadata or print to screen with quotes 
to copy and paste 
 
reads<-as.data.frame(XXXX.sr) 
print(reads, quote = TRUE)# copy and paste output to excel file or add to metadata 
 
#7. Determine richness and evenness save file for metadata addition 
XXXX.S<-specnumber(XXXX_bac.counts)#richness "S" where S is the number of species 
 
XXXX.eH<-XXXX.Shannon/log(XXXX.S)# evenness defined by Shannon's index (H) 
#it may be important to compare simpson's and shannon's measures 
 
#8. Calculate Beta diversity as defined by gamma/alpha-1 
#remember to change XXXX to the cancer type before running script 
XXXX.alpha<-with(XXXX_bac.anno, tapply(specnumber(XXXX_bac.counts), Sample.Type, 
mean)) 
XXXX.gamma<-with(XXXX_bac.anno, specnumber(XXXX_bac.counts, Sample.Type)) 
XXXXBeta<-XXXX.gamma/XXXX.alpha-1 
XXXXBeta #provides mean beta diversity per sample type, for indiv. change samp.type 
#for sample ID 
XXXX.alpha 
XXXX.gamma #compare gamma with data from pivots, should be same composition# 
 
#print the beta diversity by primary tumor and solid normal 
#9. plot histograms and boxplots of the diversity indices to observe the breakdown 
hist(XXXX.Simpson, col="dodgerblue", main = "XXXX.Simpson" ) 
hist(XXXX.Shannon,col = "orange", main= "XXXX.Shannon") 
 




boxplot(XXXX.Shannon~ XXXX_bac.anno$Sample.Type, main="XXXX Shannon Diversity Index", 
xlab="Sample Type", ylab="Diversity Index") 
boxplot(XXXX.Simpson~ XXXX_bac.anno$Sample.Type, main="XXXX Simpson Diversity Index", 
xlab="Sample Type", ylab="Diversity Index") 
boxplot(XXXX.invSimp~ XXXX_bac.anno$Sample.Type, main="XXXX invSimp Diversity Index", 
xlab="Sample Type", ylab="Diversity Index") 
boxplot(XXXX.unbSimp~ XXXX_bac.anno$Sample.Type, main="XXXX unbSimp Diversity Index", 
xlab="Sample Type", ylab="Diversity Index") 
boxplot(XXXX.Fisher~ XXXX_bac.anno$Sample.Type, main="XXXX Fisher's alpha", 
xlab="Sample Type", ylab="Diversity Index") 
#it may be that only simpson and shannon are needed  
 
#10. save files of diversity indices to include with metadata for future analyses 
 
XXXX_diversity_indeces<-cbind(XXXX.Shannon, XXXX.Simpson, XXXX.invSimp, XXXX.unbSimp, 
XXXX.Fisher, XXXX.sr, XXXX.S, XXXX.eH) 
write.csv(XXXX_diversity_indeces, file= "XXXX_diversity_indeces.csv") 
 
#Part IV Differential abundance by wilcox() test 
#testing will be completed for each tissue separately and then combined. It is IMPORTANT 
to ensure data is sorted# 
#when loading data for each tissue type ensure only samples with bacterial data are 
included and that the aggregate at species # 
#level data is being loaded# 
#remeber to change XXXX for the cancer type before running script 
 
#load data 
tumorRA<-read.csv("XXXX_tumor_bacteria_relabund.csv", row.names = 1) 
head(tumorRA) 
normalRA<-read.csv("XXXX_normal_bacteria_relabund.csv", row.names = 1) 
head(normalRA) 
 
#A. Tumor relative abundance testing 
#1. mean and sd measures 
T_mean_RA<-apply(tumorRA, 1, mean) 
T_sdRA<-apply(tumorRA, 1, sd) 
measure<-cbind(T_mean_RA, T_sdRA) 
 
write.csv(measure, file = "XXXX_tumor_bacteria_aggregate_mean_sd.csv") 
 
#plot histogram with log 10 of abundace to observe distribution 
hist(log10(apply(tumorRA, 1, var)), 
     xlab="log10(variance)", breaks=50, 
     main="Log Transformed OTUs Relative Abundance Variance- Tumor Bacteria") 
 
#2. wilcoxon one sample test 
colnames(tumorRA)#verify column names 




pval<-tumorRA$pval <- apply(tumorRA, 1, function(x) wilcox.test(as.numeric(x[idx_1]), 
paired = F, exact=F)$p.value) 
#paired test should be set to false for one sample test, exact=F to handle zeros 
 
padj<-p.adjust(pval, method = "fdr")#we are using fdr correction although it may be 






write.csv(tumorBACsigtab, file = 
"Results_XXXX_tumor_bac_only_RA_wilcox_sigtab_pval_padj.csv")#remember to change XXXX 
#for cancer type 
 
#B. Normal relative abundance testing 
#1. mean and sd measures 
N_mean_RA<-apply(normalRA, 1, mean) 
N_sdRA<-apply(normalRA, 1, sd) 
measure2<-cbind(N_mean_RA, N_sdRA) 
 
write.csv(measure2, file = "XXXX_normal_bacteria_aggregate_mean_sd.csv") 
 
#plot histogram of normal tissue 
hist(log10(apply(normalRA, 1, var)), 
     xlab="log10(variance)", breaks=50, 
     main="Log Transformed OTUs Relative Abundance Variance- Adjacent Normal Bacteria") 
   
#2. wilcoxon one sample test  
colnames(normalRA)#verify column names 
idx_11 <- grepl('.*\\.11', colnames(normalRA)) ## ensure all 
 
pval<-normalRA$pval <- apply(normalRA, 1, function(x) 
wilcox.test(as.numeric(x[idx_11]), paired = F, exact=F)$p.value) 






write.csv(normalBACsigtab, file = 
"XXXX_normal_bac_only_RA_wilcox_sigtab_pval_padj.csv")#remember to change XXXX for 
cancer type 
 
#C. Combined differential abundance testing using wilcoxon paired test 
#1. load data; ensure data is sorted! dataset should include all samples even empty 
columns, meaning all paired 
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#samples with at least one microbe in one tissue type should include both pairs. if 
#both pairs have no microbes (tumor and normal) DO NOT INCLUDE!# 
 
XXXX_RA_data <- read.csv('XXXX_overall_bacteria_relabund.csv', header= TRUE,row.names 
= 1) + 0.0001 #arbitrary number to manage log of zero, change according to data set 
#to the lowest abundance present within the file. Addition of arbitrary number will 
#affect lof2fc incrementally. Run with and without compare true values. 
XXXX_RA_data <- data.frame(XXXX_RA_data)#data should be in dataframe format 
colnames(XXXX_RA_data )#verify column names 
 
XXXX_RA_data <- XXXX_RA_data[, sort(colnames(XXXX_RA_data )) ]#sort  
colnames(XXXX_RA_data )#double check column names 
tail(XXXX_RA_data) 
XXXX_RA_data1=XXXX_RA_data # correct format  
 
#get variables with grepl function 
idx_01  <- grepl('.*\\.01', colnames(XXXX_RA_data )) 
idx_11  <- grepl('.*\\.11', colnames(XXXX_RA_data )) 
 
cbind(colnames(XXXX_RA_data )[idx_01],colnames(XXXX_RA_data )[idx_11])#pair the 
##sample columns with cbind and check again matching is correct 
 
#2.run test 
#set pair to TRUE for paired testing, exact=FALSE to handle zeros 
 
XXXX_RA_data1$mean_T <- apply(XXXX_RA_data , 1,function(x) mean(as.numeric(x[idx_01]))) 
XXXX_RA_data1$mean_N <- apply(XXXX_RA_data , 1,function(x) mean(as.numeric(x[idx_11]))) 
 
XXXX_RA_data1$sd_T <- apply(XXXX_RA_data , 1,function(x) sd(as.numeric(x[idx_01]))) 
XXXX_RA_data1$sd_N <- apply(XXXX_RA_data , 1,function(x) sd(as.numeric(x[idx_11]))) 
 
XXXX_RA_data1$log2fc <- apply(XXXX_RA_data , 1, function(x) log2(mean(as.numeric(x[idx_01]))) - 
log2(mean(as.numeric(x[idx_11])))) 
 
XXXX_RA_data1$pval <- apply(XXXX_RA_data , 1, function(x) 
wilcox.test(as.numeric(x[idx_01]), as.numeric(x[idx_11]), paired = T, exact = 
F)$p.value) 
 




#3. visualize results with log fold change chart (edited from joey711 phyloseq 
#tutorial) 
#load taxa table as dataframe 
XXXX_taxa<-read.csv("XXXX_taxa_table.csv", row.names = 1) 
XXXX_taxa<-data.frame(XXXX_taxa)#convert to dataframe 
 
#call results from wilcoxon paired test comparing tumor vs normal 





alpha <- 0.05 
sigtab <- sigtab[(sigtab$pval < alpha), ] 
sigtab<- sigtab[order(sigtab$pval),]# sorted by the pvalues fdr values usually all 
























D.2 Complete list and session info of R-packages used for this project 
Session info ------------------------------------------------------------- --
------------------ 
 setting  value                        
 version  R version 3.5.1 (2018-07-02) 
 os       Windows >= 8 x64             
 system   x86_64, mingw32              
 ui       RStudio                      
 language (EN)                         
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 collate  English_United States.1252   
 ctype    English_United States.1252   
 tz       Pacific/Honolulu             




 ! package              * version       date       lib source                 
   abind                  1.4-5         2016-07-21 [1] CRAN (R 3.5.2)         
   acepack                1.4.1         2016-10-29 [1] CRAN (R 3.5.1)         
   ade4                 * 1.7-13        2018-08-31 [1] CRAN (R 3.5.1)         
   annotate               1.60.0        2018-10-30 [1] Bioconductor           
   AnnotationDbi          1.44.0        2018-10-30 [1] Bioconductor           
   ape                  * 5.2           2018-09-24 [1] CRAN (R 3.5.1)         
   assertthat           * 0.2.0         2017-04-11 [1] CRAN (R 3.5.1)         
   backports            * 1.1.3         2018-12-14 [1] CRAN (R 3.5.2)         
   base64enc              0.1-3         2015-07-28 [1] CRAN (R 3.5.0)         
   BiasedUrn            * 1.07          2015-12-28 [1] CRAN (R 3.5.0)         
   bindr                * 0.1.1         2018-03-13 [1] CRAN (R 3.5.1)         
   bindrcpp             * 0.2.2         2018-03-29 [1] CRAN (R 3.5.1)         
   Biobase              * 2.42.0        2018-10-30 [1] Bioconductor           
   BiocGenerics         * 0.28.0        2018-10-30 [1] Bioconductor           
   BiocInstaller        * 1.32.1        2018-11-01 [1] Bioconductor           
   BiocManager          * 1.30.4        2018-11-13 [1] CRAN (R 3.5.1)         
   BiocParallel         * 1.16.5        2019-01-03 [1] Bioconductor           
   BiocStyle              2.10.0        2018-10-30 [1] Bioconductor           
   biomformat             1.10.1        2019-01-04 [1] Bioconductor           
   Biostrings             2.50.2        2019-01-03 [1] Bioconductor           
   bit                    1.1-14        2018-05-29 [1] CRAN (R 3.5.0)         
   bit64                  0.9-7         2017-05-08 [1] CRAN (R 3.5.0)         
   bitops               * 1.0-6         2013-08-17 [1] CRAN (R 3.5.0)         
   blob                   1.1.1         2018-03-25 [1] CRAN (R 3.5.1)         
   boot                 * 1.3-20        2017-08-06 [2] CRAN (R 3.5.1)         
   broom                * 0.5.1         2018-12-05 [1] CRAN (R 3.5.1)         
   callr                  3.1.1         2018-12-21 [1] CRAN (R 3.5.2)         
   car                  * 3.0-2         2018-08-23 [1] CRAN (R 3.5.2)         
   carData              * 3.0-2         2018-09-30 [1] CRAN (R 3.5.2)         
   caTools                1.17.1.2      2019-03-06 [1] CRAN (R 3.5.2)         
   cellranger           * 1.1.0         2016-07-27 [1] CRAN (R 3.5.1)         
   checkmate            * 1.9.1         2019-01-15 [1] CRAN (R 3.5.2)         
   class                  7.3-15        2019-01-01 [2] CRAN (R 3.5.2)         
   cli                  * 1.0.1         2018-09-25 [1] CRAN (R 3.5.1)         
   cluster              * 2.0.7-1       2018-04-13 [2] CRAN (R 3.5.1)         
   cmprsk                 2.2-7         2014-06-17 [1] CRAN (R 3.5.2)         
   coda                   0.19-2        2018-10-08 [1] CRAN (R 3.5.2)         
   codetools              0.2-16        2018-12-24 [2] CRAN (R 3.5.2)         
   colorspace             1.4-0         2019-01-13 [1] CRAN (R 3.5.2)         
   corpcor                1.6.9         2017-04-01 [1] CRAN (R 3.5.0)         
   cowplot              * 0.9.4         2019-01-08 [1] CRAN (R 3.5.2)         
   crayon               * 1.3.4         2017-09-16 [1] CRAN (R 3.5.1)         
   curl                   3.3           2019-01-10 [1] CRAN (R 3.5.2)         
   data.table           * 1.12.0        2019-01-13 [1] CRAN (R 3.5.2)         
   DBI                    1.0.0         2018-05-02 [1] CRAN (R 3.5.1)         
   dbplyr               * 1.3.0         2019-01-09 [1] CRAN (R 3.5.2)         
   DelayedArray         * 0.8.0         2018-10-30 [1] Bioconductor           
   desc                   1.2.0         2018-05-01 [1] CRAN (R 3.5.1)         
   DESeq2               * 1.22.2        2019-01-04 [1] Bioconductor           
   devtools             * 2.0.1         2018-10-26 [1] CRAN (R 3.5.1)         
   digest               * 0.6.18        2018-10-10 [1] CRAN (R 3.5.1)         
   dplyr                * 0.8.0.1       2019-02-15 [1] CRAN (R 3.5.2)         
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   DT                     0.5           2018-11-05 [1] CRAN (R 3.5.1)         
   e1071                * 1.7-0.1       2019-01-21 [1] CRAN (R 3.5.2)         
   edgeR                * 3.24.3        2019-01-02 [1] Bioconductor           
   epiR                 * 0.9-99        2018-11-06 [1] CRAN (R 3.5.1)         
   evaluate             * 0.13          2019-02-12 [1] CRAN (R 3.5.2)         
   fansi                  0.4.0         2018-10-05 [1] CRAN (R 3.5.1)         
   forcats              * 0.4.0         2019-02-17 [1] CRAN (R 3.5.2)         
   foreach              * 1.4.4         2017-12-12 [1] CRAN (R 3.5.1)         
   foreign              * 0.8-71        2018-07-20 [2] CRAN (R 3.5.1)         
   forestplot           * 1.7.2         2017-09-16 [1] CRAN (R 3.5.2)         
   formatR                1.6           2019-03-05 [1] CRAN (R 3.5.2)         
   Formula              * 1.2-3         2018-05-03 [1] CRAN (R 3.5.0)         
   fs                     1.2.6         2018-08-23 [1] CRAN (R 3.5.1)         
   futile.logger        * 1.4.3         2016-07-10 [1] CRAN (R 3.5.1)         
   futile.options         1.0.1         2018-04-20 [1] CRAN (R 3.5.0)         
   gdata                  2.18.0        2017-06-06 [1] CRAN (R 3.5.1)         
   genefilter           * 1.64.0        2018-10-30 [1] Bioconductor           
   geneplotter            1.60.0        2018-10-30 [1] Bioconductor           
   generics             * 0.0.2         2018-11-29 [1] CRAN (R 3.5.1)         
   GenomeInfoDb         * 1.18.1        2018-11-12 [1] Bioconductor           
   GenomeInfoDbData       1.2.0         2018-10-11 [1] Bioconductor           
   GenomicRanges        * 1.34.0        2018-10-30 [1] Bioconductor           
   GGally               * 1.4.0         2018-05-17 [1] CRAN (R 3.5.2)         
   ggcorrplot           * 0.1.2         2018-09-11 [1] CRAN (R 3.5.2)         
   ggfortify            * 0.4.5         2018-05-26 [1] CRAN (R 3.5.2)         
   ggnetwork            * 0.5.1         2016-03-25 [1] CRAN (R 3.5.2)         
   ggplot2              * 3.1.0         2018-10-25 [1] CRAN (R 3.5.1)         
   ggpubr               * 0.2           2018-11-15 [1] CRAN (R 3.5.2)         
   ggrepel              * 0.8.0         2018-05-09 [1] CRAN (R 3.5.2)         
   ggsci                * 2.9           2018-05-14 [1] CRAN (R 3.5.2)         
   ggsignif             * 0.5.0         2019-02-20 [1] CRAN (R 3.5.2)         
   ggthemes             * 4.1.0         2019-02-19 [1] CRAN (R 3.5.2)         
   gld                  * 2.4.1         2016-12-05 [1] CRAN (R 3.5.2)         
   glmnet                 2.0-16        2018-04-02 [1] CRAN (R 3.5.1)         
   glue                 * 1.3.0         2018-07-17 [1] CRAN (R 3.5.2)         
   gmodels                2.18.1        2018-06-25 [1] CRAN (R 3.5.1)         
   gower                * 0.2.0         2019-03-07 [1] CRAN (R 3.5.2)         
   gplots                 3.0.1.1       2019-01-27 [1] CRAN (R 3.5.2)         
   gridExtra              2.3           2017-09-09 [1] CRAN (R 3.5.1)         
   gtable                 0.2.0         2016-02-26 [1] CRAN (R 3.5.1)         
   gtools                 3.8.1         2018-06-26 [1] CRAN (R 3.5.0)         
   GUniFrac             * 1.1           2018-02-12 [1] CRAN (R 3.5.1)         
   haven                  2.1.0         2019-02-19 [1] CRAN (R 3.5.2)         
   Hmisc                * 4.2-0         2019-01-26 [1] CRAN (R 3.5.2)         
   hms                    0.4.2         2018-03-10 [1] CRAN (R 3.5.1)         
   htmlTable              1.13.1        2019-01-07 [1] CRAN (R 3.5.2)         
   htmltools            * 0.3.6         2017-04-28 [1] CRAN (R 3.5.1)         
   htmlwidgets            1.3           2018-09-30 [1] CRAN (R 3.5.1)         
   httpuv                 1.4.5.1       2018-12-18 [1] CRAN (R 3.5.2)         
   httr                 * 1.4.0         2018-12-11 [1] CRAN (R 3.5.2)         
   igraph               * 1.2.4         2019-02-13 [1] CRAN (R 3.5.2)         
   infer                * 0.4.0         2018-11-15 [1] CRAN (R 3.5.1)         
   inline                 0.3.15        2018-05-18 [1] CRAN (R 3.5.2)         
   IRanges              * 2.16.0        2018-10-30 [1] Bioconductor           
   iterators            * 1.0.10        2018-07-13 [1] CRAN (R 3.5.1)         
   jsonlite               1.6           2018-12-07 [1] CRAN (R 3.5.1)         
   KernSmooth             2.23-15       2015-06-29 [2] CRAN (R 3.5.1)         
   km.ci                  0.5-2         2009-08-30 [1] CRAN (R 3.5.2)         
   KMsurv                 0.1-5         2012-12-03 [1] CRAN (R 3.5.2)         
   knitr                * 1.22          2019-03-08 [1] CRAN (R 3.5.3)         
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   labeling             * 0.3           2014-08-23 [1] CRAN (R 3.5.0)         
   lambda.r               1.2.3         2018-05-17 [1] CRAN (R 3.5.1)         
   later                  0.8.0         2019-02-11 [1] CRAN (R 3.5.2)         
   lattice              * 0.20-38       2018-11-04 [1] CRAN (R 3.5.1)         
   latticeExtra           0.6-28        2016-02-09 [1] CRAN (R 3.5.1)         
   lazyeval             * 0.2.1         2017-10-29 [1] CRAN (R 3.5.1)         
   lda                    1.4.2         2015-11-22 [1] CRAN (R 3.5.2)         
   limma                * 3.38.3        2018-12-02 [1] Bioconductor           
   lme4                   1.1-21        2019-03-05 [1] CRAN (R 3.5.2)         
   lmom                   2.7           2019-03-10 [1] CRAN (R 3.5.3)         
   lmtest               * 0.9-36        2018-04-04 [1] CRAN (R 3.5.1)         
   locfit                 1.5-9.1       2013-04-20 [1] CRAN (R 3.5.1)         
   loo                    2.0.0         2018-04-11 [1] CRAN (R 3.5.2)         
   lubridate            * 1.7.4         2018-04-11 [1] CRAN (R 3.5.1)         
   magrittr             * 1.5           2014-11-22 [1] CRAN (R 3.5.1)         
   markdown             * 0.9           2018-12-07 [1] CRAN (R 3.5.2)         
   MASS                   7.3-51.1      2018-11-01 [1] CRAN (R 3.5.1)         
   Matrix                 1.2-16        2019-03-08 [2] CRAN (R 3.5.3)         
   matrixStats          * 0.54.0        2018-07-23 [1] CRAN (R 3.5.1)         
   memoise                1.1.0         2017-04-21 [1] CRAN (R 3.5.1)         
   mgcv                 * 1.8-27        2019-02-06 [1] CRAN (R 3.5.2)         
   microbiome           * 1.4.2         2018-12-01 [1] Bioconductor           
   mime                   0.6           2018-10-05 [1] CRAN (R 3.5.1)         
   minqa                  1.2.4         2014-10-09 [1] CRAN (R 3.5.1)         
   modelr               * 0.1.4         2019-02-18 [1] CRAN (R 3.5.2)         
   multtest             * 2.38.0        2018-10-30 [1] Bioconductor           
   munsell              * 0.5.0         2018-06-12 [1] CRAN (R 3.5.1)         
   network                1.14-377      2019-03-06 [1] CRAN (R 3.5.2)         
   nlme                 * 3.1-137       2018-04-07 [2] CRAN (R 3.5.1)         
   nloptr                 1.2.1         2018-10-03 [1] CRAN (R 3.5.1)         
   nnet                   7.3-12        2016-02-02 [2] CRAN (R 3.5.1)         
   openxlsx               4.1.0         2018-05-26 [1] CRAN (R 3.5.2)         
   PathoStat            * 1.8.4         2018-12-02 [1] Bioconductor           
   permute              * 0.9-5         2019-03-12 [1] CRAN (R 3.5.1)         
   phyloseq             * 1.26.1        2019-01-04 [1] Bioconductor           
   pillar               * 1.3.1         2018-12-15 [1] CRAN (R 3.5.2)         
   pkgbuild               1.0.2         2018-10-16 [1] CRAN (R 3.5.1)         
   pkgconfig              2.0.2         2018-08-16 [1] CRAN (R 3.5.1)         
   pkgload                1.0.2         2018-10-29 [1] CRAN (R 3.5.1)         
   plotly               * 4.8.0         2018-07-20 [1] CRAN (R 3.5.1)         
   plyr                 * 1.8.4         2016-06-08 [1] CRAN (R 3.5.1)         
   prettyunits            1.0.2         2015-07-13 [1] CRAN (R 3.5.1)         
   pROC                 * 1.13.0        2018-09-24 [1] CRAN (R 3.5.2)         
   processx               3.3.0         2019-03-10 [1] CRAN (R 3.5.3)         
   promises               1.0.1         2018-04-13 [1] CRAN (R 3.5.1)         
   ps                     1.3.0         2018-12-21 [1] CRAN (R 3.5.2)         
   purrr                * 0.3.1         2019-03-03 [1] CRAN (R 3.5.2)         
   R6                     2.4.0         2019-02-14 [1] CRAN (R 3.5.1)         
   RColorBrewer           1.1-2         2014-12-07 [1] CRAN (R 3.5.0)         
   Rcpp                 * 1.0.0         2018-11-07 [1] CRAN (R 3.5.1)         
   RCurl                * 1.95-4.12     2019-03-04 [1] CRAN (R 3.5.2)         
   readr                * 1.3.1         2018-12-21 [1] CRAN (R 3.5.2)         
   readxl               * 1.3.0         2019-02-15 [1] CRAN (R 3.5.2)         
   remotes                2.0.2         2018-10-30 [1] CRAN (R 3.5.1)         
   rentrez                1.2.1         2018-03-05 [1] CRAN (R 3.5.1)         
   reshape              * 0.8.8         2018-10-23 [1] CRAN (R 3.5.2)         
   reshape2               1.4.3         2017-12-11 [1] CRAN (R 3.5.1)         
   rhdf5                * 2.26.2        2019-01-02 [1] Bioconductor           
   Rhdf5lib               1.4.2         2018-12-03 [1] Bioconductor           
   rio                    0.5.16        2018-11-26 [1] CRAN (R 3.5.2)         
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   rlang                * 0.3.1         2019-01-08 [1] CRAN (R 3.5.2)         
   rmarkdown            * 1.11          2018-12-08 [1] CRAN (R 3.5.2)         
   ROCR                   1.0-7         2015-03-26 [1] CRAN (R 3.5.1)         
   rpart                  4.1-13        2018-02-23 [2] CRAN (R 3.5.1)         
   rprojroot              1.3-2         2018-01-03 [1] CRAN (R 3.5.1)         
   RSQLite                2.1.1         2018-05-06 [1] CRAN (R 3.5.1)         
   rstan                  2.18.2        2018-11-07 [1] CRAN (R 3.5.2)         
   rstudioapi             0.9.0         2019-01-09 [1] CRAN (R 3.5.2)         
   RTCGA                * 1.12.1        2019-01-04 [1] Bioconductor (R 3.5.2) 
   RTCGA.clinical       * 20151101.12.0 2018-11-01 [1] Bioconductor (R 3.5.1) 
   rvest                  0.3.2         2016-06-17 [1] CRAN (R 3.5.1)         
   S4Vectors            * 0.20.1        2018-11-09 [1] Bioconductor           
   scales               * 1.0.0         2018-08-09 [1] CRAN (R 3.5.1)         
   sessioninfo            1.1.1         2018-11-05 [1] CRAN (R 3.5.1)         
   shiny                * 1.2.0         2018-11-02 [1] CRAN (R 3.5.2)         
   shinyjs                1.0           2018-01-08 [1] CRAN (R 3.5.1)         
   sna                    2.4           2016-08-08 [1] CRAN (R 3.5.2)         
   StanHeaders            2.18.1        2019-01-28 [1] CRAN (R 3.5.2)         
   stargazer            * 5.2.2         2018-05-30 [1] CRAN (R 3.5.2)         
   statnet.common         4.2.0         2019-01-08 [1] CRAN (R 3.5.2)         
   stringi              * 1.3.1         2019-02-13 [1] CRAN (R 3.5.2)         
   stringr              * 1.4.0         2019-02-10 [1] CRAN (R 3.5.2)         
   SummarizedExperiment * 1.12.0        2018-10-30 [1] Bioconductor           
   survey                 3.35-1        2019-01-29 [1] CRAN (R 3.5.2)         
 R survival             * 2.43-3        <NA>       [2] <NA>                   
   survminer            * 0.4.3         2018-08-04 [1] CRAN (R 3.5.2)         
   survMisc               0.5.5         2018-07-05 [1] CRAN (R 3.5.2)         
   sva                  * 3.30.1        2019-01-04 [1] Bioconductor           
   table1               * 1.1           2018-07-19 [1] CRAN (R 3.5.2)         
   tableone             * 0.10.0        2019-02-17 [1] CRAN (R 3.5.2)         
   themetagenomics      * 0.1.0         2017-06-06 [1] CRAN (R 3.5.2)         
   tibble               * 2.0.1         2019-01-12 [1] CRAN (R 3.5.2)         
   tidyr                  0.8.3         2019-03-01 [1] CRAN (R 3.5.2)         
   tidyselect             0.2.5         2018-10-11 [1] CRAN (R 3.5.1)         
   UpSetR               * 1.3.3         2017-03-21 [1] CRAN (R 3.5.2)         
   usethis              * 1.4.0         2018-08-14 [1] CRAN (R 3.5.1)         
   utf8                   1.1.4         2018-05-24 [1] CRAN (R 3.5.1)         
   vcd                  * 1.4-4         2017-12-06 [1] CRAN (R 3.5.1)         
   vegan                * 2.5-4         2019-02-04 [1] CRAN (R 3.5.2)         
   VennDiagram          * 1.6.20        2018-03-28 [1] CRAN (R 3.5.1)         
   viridis                0.5.1         2018-03-29 [1] CRAN (R 3.5.1)         
   viridisLite            0.3.0         2018-02-01 [1] CRAN (R 3.5.1)         
   webshot                0.5.1         2018-09-28 [1] CRAN (R 3.5.1)         
   withr                * 2.1.2         2018-03-15 [1] CRAN (R 3.5.1)         
   xfun                 * 0.5           2019-02-20 [1] CRAN (R 3.5.1)         
   XML                    3.98-1.19     2019-03-06 [1] CRAN (R 3.5.2)         
   xml2                 * 1.2.0         2018-01-24 [1] CRAN (R 3.5.1)         
   xtable                 1.8-3         2018-08-29 [1] CRAN (R 3.5.1)         
   XVector              * 0.22.0        2018-10-30 [1] Bioconductor           
   yaml                   2.2.0         2018-07-25 [1] CRAN (R 3.5.1)         
   zip                    2.0.0         2019-02-25 [1] CRAN (R 3.5.2)         
   zlibbioc               1.28.0        2018-10-30 [1] Bioconductor           
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